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It can be said that now is the best time for everyone infected to become aware of their 
own HIV status. The state of the art in HIV management progressively reveals that 
antiretroviral treatment can prevent transmission, as well as chronic damage in the 
human body, if started early.  Unfortunately, antiretrovirals are not widely available in 
many places, especially in developing countries.  In these parts of the world, diagnosis 
of HIV infection must be kept in the agenda as a priority, in order to understand specific 
details of local epidemics and as an effort to interrupt the chain of HIV transmission.
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As of 2010, an estimated 34 million individuals (ranging from 31,6 to 35,2 million) are 
living with HIV according to UNAIDS. There were also 2,7 million new HIV infections 
in the last year (2,4 to 2,9 million) and 1,8 million (1,6 to 1,9 million) individuals died 
during last year. It is also estimated that as many as 97% of infections occur in 
countries of low and median income. Especially vulnerable are women and children in 
developing countries. Almost 48% of new infections occurred among women and 42% 
among young people from 15 to 24 years of age. 
HIV testing is entering a new era with important considerations for maintaining health 
and reducing the spreading of the virus. HIV-infected individuals not aware of the 
infection are not able to take advantage of the therapies that can keep them healthy 
and extend their lives, nor do they have the knowledge to protect their offspring, and 
sex or drug-use partners from becoming infected. Knowing whether one is positive or 
negative for HIV confers great benefits in health decision-making. 
The biomedical interventions towards the decrease of HIV-1 transmission have greatly 
improved in the recent years. One of the factors for decreasing new HIV infections is 
more effective antiretroviral therapy. In developing world, the effective treatment of 
HIV infected pregnant women has rendered achievable the virtual elimination of 
pediatric HIV disease. It has also been demonstrated that HIV treatment of HIV-1 
infected individuals can decrease the HIV transmission among discordant couples,1 
meaning that widespread antiretroviral treatment can greatly decrease the HIV-1 
transmission in the world,2 thus configuring the so called “test and treat era”.  This 
rationale has become one of the pillars of earlier initiation of antiretroviral therapy in 
more recent guidelines in Europe and United States, such as the European AIDS 
Guidelines, the IAS-USA guidelines and the DHHS guidelines.  In the absence of an 
effective HIV vaccine and the lack of adherence to the use of condoms, biomedical 
interventions, such as male circumcision, have also been advocated as a possible tool 
for decreasing HIV incidence.3  Nonetheless, being aware of HIV-1 status is the central 
pillar of HIV prevention and interruption of HIV-1 transmission chains.   
In this book, some original work is presented adding important information on 
epidemiology of HIV in developing countries vis a vis the diagnosis of HIV infection. 
X Preface 
 
Also presented are reviews on the state-of-the-art diagnosis of HIV infection, as well as 
modern tools that can be used currently and in the future. 
 
Ricardo Sobhie Diaz 
Infectious Diseases Division of the Paulista School of Medicine  
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Diagnosis and Monitoring 
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In the test and treat era of HIV-1 epidemics, it is becoming extremely urgent to detected 
HIV-1 infected individuals. It is well known that HIV-1 testing enables health care 
professions to strategize interventions towards interruption of HIV-1 transmission chains, 
and to implement antiretroviral therapy. Expanding the number of persons treated with 
antiretroviral potentially decrease the number of new infections.[1] It is very well 
determined that the available antibodies based assays are very effective in the majority of 
cases to detect and confirm HIV-1 infection. However, some exceptions do apply. Diagnosis 
of HIV-1 infection during the so-called immunologic window period, which is the time 
between the acquisition of HIV infection and the HIV antibody detection, may be of 
fundamental importance in some specific cases. It has been debated that effective 
antiretroviral treatment instituted during acute infection period, which occurs during the 
immunologic window period, may contribute to a better restructuration of the host immune 
system, thus allowing to a better long term virologic control or to slower pace of disease 
progression.[2] Detection of infections during the immunologic window period is also a 
necessity in order to increase the safety of the blood supply. Furthermore, detection of HIV-
1 infection is not specific enough in the cases where the passive transfer of antibodies occurs, 
such as among infants born from HIV infected mothers. For all these above applications, the 
direct identification of the pathogen can be an extremely helpful tool, which can be 
performed using molecular biology based techniques. It is important to bear in mind that 
passive transfer of antibodies do not occur exclusively among infant born from HIV positive 
mothers. In one case, a blood recipient from a seropositive unit did not get infected by HIV, 
but received antibodies that made anti HIV-EIA and Western-blot positive for a period up to 
six month, being the western blot profile identical to the one found in the infected blood 
donor.[3] Other case also showed the immediate detection of donors anti-HIV antibodies 
following a health care work accident, where a broken blood collection tube injured a 
nurse.[4]   
Molecular based techniques area also present in the HIV monitoring tools in tests known as 
viral load assays. Viral load monitoring can classically predict the pace of HIV-1 disease 
progression[5] and the effectiveness of antiretroviral treatment. Those tests are still evolving 
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and becoming more sensitive, since detection of low level residual replication is becoming 
increasingly important in the management of HIV-1 infected individuals. Furthermore, 
molecular biology has been applied as a valuable tool in detection of HIV strains resistant to 
antiretrovirals. It is no longer acceptable empirical change in antiretroviral treatment since 
resistance testing can increase the odds of a successful salvage therapy.[6, 7]  As treatment 
evolves, laboratory tests emerge to make any kind of treatment more effective, safe and 
predictable. It is the pharmacogenomics playing its role, and again, based in molecular 
biology techniques. This chapter will describe the challenges related to HIV diagnosis and 
monitoring, and the contribution of molecular tests in this field. 
2. Nucleic acid testing and diagnosis of primary HIV infection 
a. Early stages of HIV Infection 
After an exposure to HIV-1, and in spite of the exposition route, a dendritic cell will capture 
the virus and conduct it to the regional lymphonode with the intention of constructing the 
adaptative immune response.[8]  Odds of becoming HIV infected relates to the viral load of 
the donor of the infection in spite of the rout of HIV transmission. Studies show that there is 
a threshold level of viral load bellow which heteroseuxual transmission is unlikely to 
occur.[9, 10]  The level of viremia in a blood donor at the time of the donation is the primary 
factor influencing the probability of the infection.[11] A similar relationship between viral 
load and HIV transmission has been proposed for perinatal and[12] needlestick 
exposures.[13, 14] Interestingly however, HIV-1 transmission is considered to be clonal in 
the large majority of the cases, since 76% start from a single transmitted HIV strains and in 
24% of the cases, transmission is seeded by two to five HIV strains.[15]  The burst of viremia 
will start after the dendritic cells reach the regional lymphonode, which takes from 5 to 14 
days.[16]   Dendridic cells do not get infected by HIV, and after attachment to the DC-SIGN, 
these cells captures the virus and bring it trapped in its surface or even protected by 
endocitosis in its way to the regional lymphonode (the dendritic cell present in the genital 
mucosa is the Langherhan cell). The time elapsed between HIV exposure and the burst of 
viremia is denominated eclipse period.[17]   
When viral replication starts, HIV-1 viral load tends to be exceedingly high, usually with the 
detection of more than 1 million of HIV RNA copies/mL.[17]  Once host immune specific 
humoral and cellular immunity starts to emerge, viral load tends to decrease to basal values 
which tend to be constant for the rest for life, and usually affected only by antiretroviral 
treatment.  
Third generation HIV EIA tests can detected HIV as early as 1 month after exposure, and 
time elapsed between the exposure to HIV and detection of specific antibodies are described 
as the immunologic window period (Figure 1). The first HIV marker that can be detected is 
the RNA of virions, which occurs after 17 days (13 to 28), followed by the proviral DNA at 
the 20th day (18 to 34), followed by the detection of the p24 antigen, which occurs at day 22 
(18 to 34).[17]  All those markers can be readily used to shorten up the period to detect HIV-
1 infection after the exposure event. 
b. Nucleic acid testing during the immunologic window period. 
The diagnosis of HIV infection is challenging in individuals with recent exposure or 
symptomatic primary infection, and or the detection of HIV infection from mother to child 
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Fig. 1. Approximately sequence and time course of virological and serological events during 
primary HIV-1 infection. Plasma HIV-1 RNA is detected by commercial viral load assays, 
whereas HIV DNA in PBMCs is detected by home brew PCE assays.[17]   
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after vertical exposure. Either of the above mentioned tests, the virion RNA, proviral DNA 
and p24 antigen can be of utility in the detection of HIV infection after the eclipse period 
and before fully HIV-1 seroconversion. Especially challenging is the diagnosis among 
children born from infected mothers. All those children will receive a passive transfer of 
maternal antibodies which can make anti HIV results positive for up t 18 month after 
delivery.[18] It is known that the great majority of exposed children will not become HIV 
infected. Without any sort of antiretroviral prophylaxis, which include the treatment of the 
mother and use of anitretrovirals by the exposed children for a limited time period, only 20 
to 30% of exposed children will become infected.[19] Incident infections will follow to 7% 
with the use of zidovudine monotherapy by the mothers,[18] being even 50% more 
efficacious with the use of single doses nevirapine by the time of delivery[20] and to 
virtually zero if highly active antiretroviral therapy is successfully used, and maintaining 
maternal viral loads bellow detection limits. Therefore, efforts to overcome the problem of 
low specificity in diagnosing HIV infection in newborns have been made targeting the direct 
identification of the virus. The first attempts to overcome this diagnostic problem have been 
made with the use of co-culture to detected HIV among newborns,[21] which is 
cumbersome, expensive, takes longer time, and requires well equipped laboratories that 
cannot be used in large scale in the clinical setting. Therefore, detection of HIV DNA and 
RNA seems to be more appropriate to detect the vertical transmission of HIV-1. 
Timing of vertical HIV transmission is also important in the strategy to test children born 
from infected mothers. A smaller and variable zproportion of HIV transmission will occur 
intra-uterus (around 30%), and in these cases, newborns will likely be viremic by the time of 
birth.[22]  In the peripartum transmission, however, the presence of viruses will occur in 
general around two weeks after birth.[23]  Other feature that needs to be taken into account 
relates to the viral dynamics of HIV- replication among children infected by the vertical 
route. Whereas among adults, viral load in general reaches the set point by 6 month after 
HIV infection,[24] and mean basal viral load is inferior to 100,000 RNA copies/mL, children 
will take much longer to show a week control of viremia after primary infection.[25]  In the 
case of infants, viral loads will be in general above 100,000 RNA copies/mL for a period that 
is superior to 24 month.[25]  
The use of RNA rather than proviral DNA for detection of primary infection has the 
advantage of providing a shorter window period between HIV acquisition and the first 
detectable virologic marker, as seen in Figure 1. False positive results with qualitative DNA 
PCR or quantitative RNA methodologies have been reported in the literature.[26-28]  
Usually the false positive result can be attributed to the Polymerase Chain reaction (PCR) 
carry over, decreasing specificity to as low as 96%.[26]  As an interesting example, transient 
HIV-1 infection has been proposed based on the detection of a positive PCR among children 
who seroreverted (HIV uninfected children born from HIV positive mothers who loose 
antibodies after 18 month of life).[29]  In these cases, detection of human HIV-1 on only one 
or a few occasions in these infants has been interpreted to indicate that infection may be 
transient rather than persistent. However, genetic analysis of viruses revealed that either 
specimens were mistakenly attributed to an infant, or phylogenetic analysis failed to 
demonstrate the expected linkage between the infant's and the mother's virus,[30] being 
PCR carry-over the likely explanation for these mistakes.  
PCR-carry over, which is a feature of molecular based tests that amplify nucleic acid targets, 
can be more difficult to be detected in qualitative rather than quantitative assays. In this 
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sense, viral load assays for detecting primary infection has the advantage of potentially 
discriminating false positive results due to PCR carry over from true positive results since it 
is expected a high viral load in these situations, being this particularly true for children born 
from infected mother. In other words, a qualitative assay gives a “yes” or “no” result, 
whereas the viral load assays can potentially discriminate false positive results since it is 
expected a very high viral load during primary HIV infection or in infection among children 
with less than two years old. It has to be taken into account that PCR carry over will always 
provide a considerable low viral load, which usually is low than 1,000 RNA copies/mL. 
Therefore, as discussed above, better tests to detect HIV infection in these target populations 
are assays that targets RNA rather than DNA, and have the quantitative nature rather than 
qualitative, those tests being the RNA viral load assays. When those tests are performed in 
children using samples collected after 3 weeks of deliver, the sensitivity, specificity, positive 
and negative predictive value can be all 100%.[23]   
c. HIV-1 RNA quantitation for HIV-1 infection monitoring (ultra-sensitive) 
It has been defined since the beginning of the HIV epidemics that HIV-1 viral replication 
relates well with disease progression and response to treatment.[5]  The guidelines for HIV 
treatment recommend that viral load should be kept as low as possible, preferable bellow 
detection levels. However, questions have been always related to how sensitive should be a 
viral load assays. It has been demonstrated that viral replication will occur in spite of the 
apparently complete HIV suppression using antiretrovirals. One cohort of 130 treated 
patients kept of HIV-1 RNA viral load bellow 75 copies/mL revealed that 80% of 
individuals will still present detectable viremia when more sensitive viral load strategies 
were used (1 RNA copies/mL of plasma) being the median viral load equal 3.1 
copies/mL.[31, 32]  Other study showed that this low level viremia is likely to be shed by 
the gastrointestinal tract sanctuary.[33] It has been described that this low level (and 
sometimes unrecognized) viral replication may lead to a CD4 and CD8+ T cell activation 
which relates to relates to apoptosis and disease progression.[34, 35]  This cell activation can 
be also detected among elite suppressors, which are individuals that naturally control 
viremia thus preventing the CD4+ T cell decline, and this cell activation may relate to 
deleterious aspects among those individuals.[36, 37] 
The risk of selecting HIV-1 antiretroviral resistant strains also relates to the level of viral 
replication, and the pace of emergence of resistant related mutations may be somewhat 
predictable. Indeed, the number of new mutations relates to the residual viral replication, 
being directly proportional to the viral load of individuals in virologic failure.[38] 
d. HIV-1 antiretrovirals resistance testing  
It has been recognized that HIV resistance testing is of benefit in the performance of salvage 
therapy[7, 31, 39-41] and survival rates.[42]  Furthermore, resistant testing exerts great 
influence in medical decision regarding choice of antiretrovirals in salvage therapy.[43]  The 
current available resistance testing are the so called genotypic resistance tests. Those are 
indirect measures of resistance, where HIV RNA is obtained, reverse transcribed and cDNA 
is sequenced to detect the antiretroviral related mutations. Interpretation algorithms are 
applied to infer the activity of diverse antiretroviral agents. The direct measure of resistance 
is provided by the phenotypic assays. In these assays, RNA form HIV is also purified and 
recombinant viruses that have the pol gene of patient´s HIV and the backbone of a 
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will take much longer to show a week control of viremia after primary infection.[25]  In the 
case of infants, viral loads will be in general above 100,000 RNA copies/mL for a period that 
is superior to 24 month.[25]  
The use of RNA rather than proviral DNA for detection of primary infection has the 
advantage of providing a shorter window period between HIV acquisition and the first 
detectable virologic marker, as seen in Figure 1. False positive results with qualitative DNA 
PCR or quantitative RNA methodologies have been reported in the literature.[26-28]  
Usually the false positive result can be attributed to the Polymerase Chain reaction (PCR) 
carry over, decreasing specificity to as low as 96%.[26]  As an interesting example, transient 
HIV-1 infection has been proposed based on the detection of a positive PCR among children 
who seroreverted (HIV uninfected children born from HIV positive mothers who loose 
antibodies after 18 month of life).[29]  In these cases, detection of human HIV-1 on only one 
or a few occasions in these infants has been interpreted to indicate that infection may be 
transient rather than persistent. However, genetic analysis of viruses revealed that either 
specimens were mistakenly attributed to an infant, or phylogenetic analysis failed to 
demonstrate the expected linkage between the infant's and the mother's virus,[30] being 
PCR carry-over the likely explanation for these mistakes.  
PCR-carry over, which is a feature of molecular based tests that amplify nucleic acid targets, 
can be more difficult to be detected in qualitative rather than quantitative assays. In this 
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sense, viral load assays for detecting primary infection has the advantage of potentially 
discriminating false positive results due to PCR carry over from true positive results since it 
is expected a high viral load in these situations, being this particularly true for children born 
from infected mother. In other words, a qualitative assay gives a “yes” or “no” result, 
whereas the viral load assays can potentially discriminate false positive results since it is 
expected a very high viral load during primary HIV infection or in infection among children 
with less than two years old. It has to be taken into account that PCR carry over will always 
provide a considerable low viral load, which usually is low than 1,000 RNA copies/mL. 
Therefore, as discussed above, better tests to detect HIV infection in these target populations 
are assays that targets RNA rather than DNA, and have the quantitative nature rather than 
qualitative, those tests being the RNA viral load assays. When those tests are performed in 
children using samples collected after 3 weeks of deliver, the sensitivity, specificity, positive 
and negative predictive value can be all 100%.[23]   
c. HIV-1 RNA quantitation for HIV-1 infection monitoring (ultra-sensitive) 
It has been defined since the beginning of the HIV epidemics that HIV-1 viral replication 
relates well with disease progression and response to treatment.[5]  The guidelines for HIV 
treatment recommend that viral load should be kept as low as possible, preferable bellow 
detection levels. However, questions have been always related to how sensitive should be a 
viral load assays. It has been demonstrated that viral replication will occur in spite of the 
apparently complete HIV suppression using antiretrovirals. One cohort of 130 treated 
patients kept of HIV-1 RNA viral load bellow 75 copies/mL revealed that 80% of 
individuals will still present detectable viremia when more sensitive viral load strategies 
were used (1 RNA copies/mL of plasma) being the median viral load equal 3.1 
copies/mL.[31, 32]  Other study showed that this low level viremia is likely to be shed by 
the gastrointestinal tract sanctuary.[33] It has been described that this low level (and 
sometimes unrecognized) viral replication may lead to a CD4 and CD8+ T cell activation 
which relates to relates to apoptosis and disease progression.[34, 35]  This cell activation can 
be also detected among elite suppressors, which are individuals that naturally control 
viremia thus preventing the CD4+ T cell decline, and this cell activation may relate to 
deleterious aspects among those individuals.[36, 37] 
The risk of selecting HIV-1 antiretroviral resistant strains also relates to the level of viral 
replication, and the pace of emergence of resistant related mutations may be somewhat 
predictable. Indeed, the number of new mutations relates to the residual viral replication, 
being directly proportional to the viral load of individuals in virologic failure.[38] 
d. HIV-1 antiretrovirals resistance testing  
It has been recognized that HIV resistance testing is of benefit in the performance of salvage 
therapy[7, 31, 39-41] and survival rates.[42]  Furthermore, resistant testing exerts great 
influence in medical decision regarding choice of antiretrovirals in salvage therapy.[43]  The 
current available resistance testing are the so called genotypic resistance tests. Those are 
indirect measures of resistance, where HIV RNA is obtained, reverse transcribed and cDNA 
is sequenced to detect the antiretroviral related mutations. Interpretation algorithms are 
applied to infer the activity of diverse antiretroviral agents. The direct measure of resistance 
is provided by the phenotypic assays. In these assays, RNA form HIV is also purified and 
recombinant viruses that have the pol gene of patient´s HIV and the backbone of a 
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laboratory virus are produced in vitro. These pseudoviruses are cultured with different 
concentrations of different antiretrovirals and the resistant related fold change is 
determined. Fold changes always refer to the amount of drug used to inhibit the patient´s 
HIV compared to the wild type laboratory strain. Biological and clinical cut-offs are used to 
infer the probability of response to specific antiretrovirals. Genotypic tests are easier to 
perform, more available and less expensive than phenotypic based assays. They also are 
more sensitive in detecting resistance when mixtures of mutant and wild type viruses are 
present, since it is likely that resistant strains will be overwhelmed by the more fit wild type 
strains in the initial culture producing the pseudoviruses.[44]  The quantitative nature of 
phenotypic based assays may be of utility in analyzing the highly resistance strains. 
Phenotypic tests are also advantageous for new antiretrovirals with poorly defined 
resistance profile and perhaps for non-B strains, where resistance pathways and mutations 
may not be yet available. Furthermore, the presence of fold change and clinical cut-off 
increase the confidence of physicians in the choice of salvage therapy.[43]  There is also the 
virtual phenotype test, which is in fact a genotypic based assays. In these tests, HIV-1 pol 
sequences are submitted to a specific database, which will infer the phenotypic profile of 
viruses providing fold changes and clinical cut-offs. In fact, performance of virtual 
phenotype has been comparable or better than the performance found using phenotype for 
salvage therapy.[41, 45] The likely explanation for the alleged better performance of virtual 
phenotype as compared to the “real” phenotype relies in the fact that virtual phenotype will 
be less likely to underestimate resistance since mixtures of wild type and resistant strains 
found in the sequencing process will be considered as resistant. Conversely, as explained 
above, mixtures of wild type/resistant will facilitate overgrow of wild type strains in cell 
culture.  
e. HIV-1 Tropism 
The practical issue of HIV-1 tropism emerged with the development of CCR5 antagonists 
as antiretrovirals. Nonetheless, HIV tropism has been studied for a long time in the 
attempt to correlate the HIV-1 correceptor use with cytopathycity. In summary, HIV may 
use CCR5 and CXCR4 chemokine receptors for entry, and viruses that exclusively use the 
CCR5 are denominated R5, viruses that use CXCR4 are X4, whereas viruses able to use 
both coreceptors are dual tropic (reviewed by Moore et al).[16]  Infection usually starts 
with R5 viruses and as HIV-1 quasispecies evolves, CXCR4 using strains may emerge. 
There is also the association between the emergence of CXCR4 using strains and rapid 
HIV-1 disease progression.[46] Therefore, it is conceivable that the determination and 
monitoring HIV-1 tropism over time may be of use in the decision of introduction of 
antiretroviral treatment or more frequent evaluation of CD4+ T cell levels in the infected 
patient.  
The main utility of tropism determination relates to the decision of use of CCR5 
antagonists such as maraviroc, since this specific class of antiretrovirals will lose activity 
in the presence of detectable X4 or dual tropic viruses.[47]  Therefore, a tropism test 
before treatment with these drugs is required; gold standard tropism tests being the 
phenotypic based tests. One phenotypic tropism test constructs pseudoviruses containing 
the gp160 of patient’s viruses and a backbone of HIV-1 laboratory virus plus the luciferase 
gene.[48] Two lineages of cells containing either the CCR5 or the CXCR4 coreceptors are 
used in two distinct lab reactions. Once infected, light will be generated from cells due the 
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presence of the luciferase gene, and HIV can be detected in the culture either inside cells 
harboring CCR5 and/or CXCR4 coreceptors. If HIV is detected only in the culture of cells 
harboring CCR5 coreceptor, viruses will be classified as R5, whereas X4 viruses will 
appear only in the culture of cells harboring CXCR4 coreceptors. In the case viruses are 
detected in both cultures, it is reported that dual mixed and/or mixtures of R5 and X4 are 
present. Alternatively, genotropism tests can be used. These tests detect substitutions at 
the V3 region of gp120 HIV-1 gene in order to predict the CXCR4 use by viruses present 
in the patient’s quaispecie. Although phenotypic and genotypic tests do not fully agree 
with each other, genotypic tests are probably equally able to predict virologic treatment 
failure in maraviroc containing antiretroviral schemes[47] and have been advocate as 
preferential in some guidelines.[49] 
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infer the probability of response to specific antiretrovirals. Genotypic tests are easier to 
perform, more available and less expensive than phenotypic based assays. They also are 
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present, since it is likely that resistant strains will be overwhelmed by the more fit wild type 
strains in the initial culture producing the pseudoviruses.[44]  The quantitative nature of 
phenotypic based assays may be of utility in analyzing the highly resistance strains. 
Phenotypic tests are also advantageous for new antiretrovirals with poorly defined 
resistance profile and perhaps for non-B strains, where resistance pathways and mutations 
may not be yet available. Furthermore, the presence of fold change and clinical cut-off 
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1. Introduction 
1.1 Discovery of HIV-2: A story of antibody reactivity 
Two years after the isolation of the first AIDS virus in 1983 (Barre-Sinoussi et al. 1983), a 
simian virus inducing a similar pathology was described in rhesus monkeys in captivity 
(Letvin et al. 1985). Apparently healthy individuals living in Senegal had antibodies that 
reacted better with the antigens of the simian virus than with those from the human virus 
(Barin et al. 1985). At the same period, two patients originating from West Africa were 
hospitalized in France and in Portugal with typical symptoms of AIDS, whereas their 
serology was negative for the human virus now called HIV-1. The second virus causing 
AIDS was isolated in 1986 (Clavel et al. 1986). It was then described in various countries of 
West Africa, and was later called Human immunodeficiency virus type 2 (HIV-2) (Brun-
Vezinet et al. 1987; Clavel et al. 1987). It is classified in the Retroviridae family within the 
lentivirus genus. Among the lentiviruses, the two HIV are phylogenetically closer to simian 
lentiviruses than those infecting other animal species, explaining the antibody cross-
reactivity observed at first (Chakrabarti et al. 1987). The HIV-2 genome is closest to SIVsm 
infecting sooty mangabeys (Hirsch et al. 1989), whereas HIV-1 is closest to SIVcpz infecting 
chimpanzees (Huet et al. 1990). 
1.2 Clinical outcome 
HIV-2 differs from HIV-1 in its lower rate of disease progression and infectivity (Jaffar et al. 
2004). The routes of transmission are identical to those described for HIV-1, but with lower 
rates for both horizontal and vertical transmissions, and correlate with the mean lower viral 
load in HIV-2 infected patients (O'Donovan et al. 2000). The majority of them are long-term 
non-progressors (LTNP), meaning that they don’t develop symptoms and that the infection 
does not significantly affect their survival (Rowland-Jones & Whittle 2007). Nevertheless, 
patients experiencing disease progression and AIDS share the same likelihood of morbidity 
and mortality as seen in HIV-1 infection (Schim van der Loeff et al. 2002), and will be 
eligible for antiretroviral therapy. AIDS-defining events are comparable in both types of 
infections (Martinez-Steele et al. 2007). The distinction between LTNP, patients who remain 
asymptomatic for at least 8 years while CD4 counts are above 500 cells/ul, and controllers, 
who control HIV replication without therapy, was recently analysed in the French ANRS 
cohort; they represented respectively 6.1% and 9.1% (Thiébaut et al. 2011). Although those 
low percentages contrast with previous publications, it remains clear that LTNP in HIV-2 
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are far most frequent compared to HIV-1 cohorts, and that low viral load is the main feature 
of non-progression. Cellular immunity and the maintenance of early-differentiated CD8+ T-
cells contribute to low immune activation and low viral replication (Leligdowicz et al. 2010). 
Understanding the mechanisms underlying HIV-2 biology and the immune response, as a 
model for attenuated-HIV disease, are important in the concept of HIV vaccines 
(Leligdowicz &  Rowland-Jones 2008). 
1.3 Sensitivity to ARV drugs  
HIV-2 is naturally resistant to non-nucleosidic reverse transcriptase inhibitors, including those 
of second generation, and to the fusion inhibitor enfuvirtide (Witvrouw et al. 2004; Andries et 
al. 2004; Poveda et al. 2004). The sensitivity to some protease inhibitors is reduced: amprenavir 
and its prodrug are not active, and contradictory results were published for atazanavir and 
tipranavir (Desbois et al. 2008; Brower et al. 2008). Moreover, the genetic barrier to resistance is 
reduced for several NRTIs and PIs (Smith et al. 2009). In the context of that reduced 
therapeutic arsenal, recent drug classes represent welcome options.  
Theoretically, CCR-5 antagonists can be used to treat HIV-2 infection, but two main issues 
need to be solved: no tropism assay is currently available for clinical routine, and the 
possible impact of the broader co-receptor usage compared to HIV-1 is not known (Calado 
et al. 2010). Nevertheless some experimental case studies showed treatment success 
(Armstrong-James et al. 2010).  
Integrase inhibitors are active on HIV-2; several in vitro studies on patient isolates and case 
series showed good activity (Roquebert et al. 2008; Damond et al. 2008a): raltegravir is 
therefore an option in case of failure or intolerability to other drugs (Francisci et al. 2011), 
but long-term data are lacking at this point (Gottlieb et al. 2011). No randomized clinical 
trials were performed to investigate response to treatment in HIV-2 patients (Gottlieb et al. 
2008a). Data on treatment efficacy are obtained through cohort analysis, case series or 
collaborative networking between cohorts: a double-NRTI backbone combined to a boosted-
PI is the preferred first-line regimen (Benard et al. 2011). Therapy limitations underline the 
importance of an accurate diagnosis of HIV-2 infection, particularly in countries where drug 
classes availability is limited (Peterson et al. 2011).  
1.4 Epidemiology  
The evaluation of the total number of case varies between 1 and 2 million infected people 
worldwide, the majority living in West African countries (Gottlieb et al. 2008a). The highest 
prevalence was noticed in Guinea-Bissau around 1990, where 17% of blood donors were 
positive (Poulsen et al. 1993; Naucler et al. 1989). Since then, the HIV-2 prevalence has 
declined, and is nowadays lower than 1% in the global population in most countries, with 
the exceptions of the Gambia, Guinea-Bissau and Côte d’Ivoire (da Silva et al. 2008; Sangare 
et al. 1998). The prevalence of HIV-1 infection has increased during the last two decades in 
West Africa, and has now exceeds that of type 2 (van Tienen et al. 2010). Although 
declining, HIV-2 remains of concern particularly in urban areas. The prevalence is more 
important in older groups, above 45 years of age (van Tienen et al. 2010).  Outside West 
Africa, the virus is present in European countries, essentially in Portugal and France who 
share colonial histories with endemic regions (Valadas et al. 2009; Barin et al. 2007). Sporadic 
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cases are found in other African and European countries, in Brazil, in the Middle East, in 
Japan, Korea and in India. The majority of patients in these countries were born in or had a 
possible transmission link with West Africa (Campbell-Yesufu & Gandhi 2011). The virus is 
very rare in North America (Torian et al. 2010; Centers for Disease Control 2011).  
1.5 Diversity of HIV-2: Origins and impact on laboratory assays 
Eight groups of HIV-2 have been described, named A to H (Damond et al. 2004). Each of 
those phylogenetically distinct groups corresponds to a cross-species transmission from 
monkey to man (Sharp et al. 2001). Only groups A and B spread in the human population 
while other groups seem epidemic dead-ends possibly because of weak adaptation to the 
human organism (Gao et al. 1994). A/B recombinant forms appeared (Yamaguchi et al. 
2008) and disseminated outside West Africa (Ibe et al. 2010). Based on HIV-2 sequences with 
available sampling dates, the date of the most recent common ancestor was inferred by 
phylogeny: group A and B strains appeared respectively around 1940 and 1945 (Lemey et al. 
2003). Molecular clock analysis favours the hypothesis of a zoonotic transmission during the 
first half of the 20th century, followed by an epidemic dissemination during the 1960s. The 
independence war of Guinea-Bissau between 1963 and 1974 offered the circumstances 
favouring human transmissions (Poulsen et al. 2000; Gomes et al. 2003). Genetic variability 
between HIV-2 groups, and between strains of the same group is important. The most 
conserved genomic regions are the LTRs, followed by the gag and pol genes (Kanki 1991). 
Several examples in the next paragraphs will illustrate the impact of viral diversity on 
laboratory assays: the use of conserved epitopes can lead to cross-reactivity between HIV 
types in serology. On the opposite, if an assay targets particularly variable regions, the 
probability of a false negative result or an underestimated quantification will rise. 
Serological screening and confirmatory assays, as well as nucleic acid tests (NAT) used for 
diagnosis or clinical follow-up, must thus take into account HIV-2 diversity from design 
through field validation. 
2. Diagnosis of HIV-2 infection 
2.1 Screening assays 
The diagnosis of HIV-1 or -2 infection is based on serology, mostly using enzyme 
immunoassays (EIA). As antibodies appear in the serum several weeks post-infection, 
antibody detection was progressively improved in order to reduce the window period 
between infection and test positivity. Sensitive assays detecting IgM and IgG are positive a 
mean of 3 weeks after transmission. Fourth generation assays sensitive to both HIV-antigen 
and anti-HIV antibodies, also called “combo-tests”, are able to detect an acute infection as 
early as 2 weeks after the transmission event, when the viral replication level is extremely 
high (review in Branson 2010). The duration of the window period was established for HIV-
1 infections and is largely unknown for HIV-2. A study on recent seroconverters showed 
that viral loads are on average 28-fold times lower compared to HIV-1 (Andersson et al. 
2000). As replication capacity is lower and viral turnover slower, there exists the possibility 
that the time between HIV-2 infection and seropositivity is longer. 
Initially designed for the detection of HIV-1 group M, most commercial tests are nowadays 
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progression is on the mean slower in HIV-2 and that the majority of patients are 
asymptomatic, we can expect to underdiagnose HIV-2 infection in countries or regions 
where HIV screening assays do not recognize anti-HIV-2 antibodies. It is therefore 
recommended to opt for tests sensitive to anti-HIV-1 and -2. For antigen detection, fourth 
generation assays reacting with HIV-1 p24 Ag have no specific component to detect HIV-2 
antigens. However, because of conserved regions in the Gag capsid protein and its epitopes, 
p24-sensitive antigen assays can detect the HIV-2 related antigen, the p26. We cannot 
exclude a difference of sensitivity for HIV-2 antigen detection in HIV combo assays. That 
difference has probably a negligible impact in clinical practice, because the probability to 
test a patient in early acute HIV-2 infection is very low. Nevertheless, as for HIV-1 infection, 
in the presence of an HIV negative test and clinical signs or seroconversion illness, the 
patient should be retested 2 to 4 weeks later (Poljak et al. 2009). If a risky behaviour is 
suspected in an HIV-2 prevalent area, a period of 3 months is recommended to ascertain the 
negativity. 
Several rapid tests using immunoprecipitation techniques for antibody detection are 
approved for clinical use, using serum, whole blood or saliva. As the result can be obtained 
in 20 minutes, it may be appropriate for the screening of individuals who may not return for 
the results in conventional settings. They require a minimum of reagents and infrastructure: 
their use is widespread in resource-constrained countries, in point-of-care facilities, or in 
centres for voluntary testing. Rapid assays of four generation are currently developed, such 
as Alere Determine HIV1/2 combo assay (Inverness Medical, UK). Although its 
performance for antibody detection is comparable to reference EIA, the assay’s antigen 
sensitivity is weaker than references and is unable to detect HIV-2 antigens (Beelaert & 
Fransen 2010).  
Antibody screening assays relying on other methods than EIA or immunoprecipitation are 
currently in development, with the goal to enhance specificity and to have a higher 
throughput (Talha et al. 2011). 
Present day screening assays have an excellent sensitivity close to 100%, and a specificity 
higher than 99%. Their negative predictive value is very high, but the positive predictive 
value is low, depending on the local prevalence. False positive results are thus common in 
practice, and a second independent test should be used to confirm the initial result. As the 
first-line assays give a positive signal in screening whether due to anti-HIV-1 or anti-HIV-2 
antibodies, confirmatory tests used in clinical settings should be able to discriminate the 
type of virus and arrive to the final diagnosis of HIV-2 infection. 
2.2 Discrimination of anti-HIV-2 antibodies 
Three types of assays are widespread in clinical laboratories for the discrimination of HIV 
type by serology: Western Blots, line immunoassays, and rapid tests. Commercial Western 
blot registered for diagnostics such as New LAV Blot II (Bio-Rad, CA) or HIV Blot 1.2 WB 
(Genelabs, CA) use immobilised HIV antigens to detect specific IgG antibodies to different 
viral proteins.  A result is interpreted as positive if bands reveal a reaction with two or more 
of the following HIV antigens: p24, gp41, or gp120/160.  The result is considered as 
indeterminate if bands are present, but fewer than two reacting with the antigens cited 
above. Western blot has several pitfalls. It can overestimate HIV-2 infection, particularly in 
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regions with very low prevalence, because of frequent cross-reactions (Qiu et al. 2009; 
McKellar et al. 2008). Moreover, the turnaround time is higher compared to line 
immunoassay or rapid tests, it needs more laboratory material, and generates more waste.  
The use of a commercial line peptide assay such as Inno-Lia (InnoGenetics, Belgium) 
engineered with synthetic peptides, allows more standardised results and gives less 
significant cross reactivity for the discrimination between type 1 and 2 infections (Amor et 
al. 2009).  
The rapid test Genie HIV-1/HIV-2 (Bio-Rad, CA) is a test based on the 
immunochromatography principle for the specific detection and differentiation of HIV-1 
and HIV-2 antibodies. In several West African countries, national algorithms are based on 
rapid tests including Genie I/II (Kania et al. 2010). Double reactive samples as defined in 
Burkina Faso were retested with line peptide assay: only 59% of dually reactive serums had 
concordant results. Among dual positive samples, 15 % had a detectable HIV-2 plasma viral 
load while 60% of HIV-2 seropositive patients had a detectable viraemia (Ruelle et al. 2007).  
Double HIV-1/HIV-2 infections are thus largely overestimated. Double-reactive samples in 
serology tested with specific qualitative PCRs confirmed only 32% of double infections 
(Ciccaglione et al. 2010). The group of HIV-2 may also influence serological cross-reactivity: 
a strong reaction was described between group B and HIV-1 env antigen, mostly in the gp 
transmembrane glycoprotein (Damond et al. 2001a).  
2.3 Nucleic acid tests (NAT) 
Molecular tests are available for the quantitative detection of HIV-1 plasma RNA, beside 
commercial plasma viral load assays. No commercial qualitative or quantitative test is 
available for HIV-2. Several in-house methods have been published and validated (Schutten 
et al. 2000; Ruelle et al. 2004; Damond et al. 2001b; Ferns & Garson 2006), but are restricted 
to specialised laboratory. As many HIV-2 patients has very low plasma viral load, without 
any ARV therapy, RNA counts will often fall under the PCR limit of detection. As a 
consequence, the viraemia can often not be considered as a diagnostic marker.  
However, proviral DNA can be theoretically detected in all HIV-2 seropositive patients, at 
least if the PCR is sensitive enough, and if the primers target a sufficiently conserved region. 
The amount of DNA present in PBMC was thought to be similar to that in HIV-1 infection. It 
seems to be the case in patients experiencing low CD4 counts, but can be lower for 
controllers (Gueudin et al. 2008; Gottlieb, Hawes et al. 2008). Globally the ratio plasma 
RNA/proviral DNA is lower in HIV-2 infection, due to putative differences in the 
replicative cycle. It is estimated that HIV proviral DNA is present in 1 cell out of 10,000 
PBMC. Laboratory NAT protocols should therefore use a sufficient number of cells to avoid 
false negative PCR results: to detect 10 HIV DNA copies, we should introduce in the PCR 
reaction a DNA volume corresponding to the extraction of a minimum of 100,000 cells. 
2.4 Proposed HIV-2 testing algorithm 
A decisional algorithm is shown in Figure 1; it avoids the shortcomings of Western Blot 
detailed above, allows differentiating HIV-2 from HIV-1 upon confirmation, and reduces the 
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regions with very low prevalence, because of frequent cross-reactions (Qiu et al. 2009; 
McKellar et al. 2008). Moreover, the turnaround time is higher compared to line 
immunoassay or rapid tests, it needs more laboratory material, and generates more waste.  
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engineered with synthetic peptides, allows more standardised results and gives less 
significant cross reactivity for the discrimination between type 1 and 2 infections (Amor et 
al. 2009).  
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immunochromatography principle for the specific detection and differentiation of HIV-1 
and HIV-2 antibodies. In several West African countries, national algorithms are based on 
rapid tests including Genie I/II (Kania et al. 2010). Double reactive samples as defined in 
Burkina Faso were retested with line peptide assay: only 59% of dually reactive serums had 
concordant results. Among dual positive samples, 15 % had a detectable HIV-2 plasma viral 
load while 60% of HIV-2 seropositive patients had a detectable viraemia (Ruelle et al. 2007).  
Double HIV-1/HIV-2 infections are thus largely overestimated. Double-reactive samples in 
serology tested with specific qualitative PCRs confirmed only 32% of double infections 
(Ciccaglione et al. 2010). The group of HIV-2 may also influence serological cross-reactivity: 
a strong reaction was described between group B and HIV-1 env antigen, mostly in the gp 
transmembrane glycoprotein (Damond et al. 2001a).  
2.3 Nucleic acid tests (NAT) 
Molecular tests are available for the quantitative detection of HIV-1 plasma RNA, beside 
commercial plasma viral load assays. No commercial qualitative or quantitative test is 
available for HIV-2. Several in-house methods have been published and validated (Schutten 
et al. 2000; Ruelle et al. 2004; Damond et al. 2001b; Ferns & Garson 2006), but are restricted 
to specialised laboratory. As many HIV-2 patients has very low plasma viral load, without 
any ARV therapy, RNA counts will often fall under the PCR limit of detection. As a 
consequence, the viraemia can often not be considered as a diagnostic marker.  
However, proviral DNA can be theoretically detected in all HIV-2 seropositive patients, at 
least if the PCR is sensitive enough, and if the primers target a sufficiently conserved region. 
The amount of DNA present in PBMC was thought to be similar to that in HIV-1 infection. It 
seems to be the case in patients experiencing low CD4 counts, but can be lower for 
controllers (Gueudin et al. 2008; Gottlieb, Hawes et al. 2008). Globally the ratio plasma 
RNA/proviral DNA is lower in HIV-2 infection, due to putative differences in the 
replicative cycle. It is estimated that HIV proviral DNA is present in 1 cell out of 10,000 
PBMC. Laboratory NAT protocols should therefore use a sufficient number of cells to avoid 
false negative PCR results: to detect 10 HIV DNA copies, we should introduce in the PCR 
reaction a DNA volume corresponding to the extraction of a minimum of 100,000 cells. 
2.4 Proposed HIV-2 testing algorithm 
A decisional algorithm is shown in Figure 1; it avoids the shortcomings of Western Blot 
detailed above, allows differentiating HIV-2 from HIV-1 upon confirmation, and reduces the 






* Alternatively one single test if high HIV prevalence 
** Alternatively a rapid test discriminant for HIV type 
*** If not available, retest a new sample 2 to 4 weeks later. Not informative about HIV type in case of 
positivity 
Fig. 1. Algorithm for HIV-2 confirmation 
result, we should consider a NAT amplifying specifically HIV-2 proviral DNA. A single or 
dual-infection result will strongly influence the therapeutic management, as recommended 
first-line therapies are based on NNRTI in most countries. Although no study is available, 
the proviral DNA approach in case of dual-reactivity should be cost-effective by avoiding 
therapeutic failures. 
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2.5 Children born to HIV-2 seropositive mothers 
Vertical transmission occurs rarely, reported rates vary between 0.1 and 2% (Burgard et al. 
2010; Padua et al. 2009). Undetectable viral load during the third trimester of pregnancy and 
at delivery is a good predictor of prevention success. Due to passive transfer of maternal 
antibodies, the diagnosis of a mother-to-child HIV transmission is based on viral genome 
amplification. In addition to the issues of low DNA amount and primer mismatches 
discussed above for provirus detection, viral turnover is lower in HIV-2 infection and we 
have virtually no data on what occurs after the child’s infection. Plasma RNA should be 
amplified in parallel with proviral DNA, or alternatively different sets of primers should be 
used to amplify the same DNA sample. As viral genetic variability can be responsible of 
PCR failure (Padua et al. 2009), some authors recommend amplifying one sample from the 
mother, with the same sets of primers, as a positive control. Ideally, the follow-up of the 
baby should include the search for proviral DNA: if viral genome is not detected at the age 
of 3 months, vertical transmission did not occur. In countries where NATs are not available, 
prevention with antiretroviral therapy including PIs will considerably reduce the chances of 
transmission. 
3. Plasma viral load 
3.1 Available assays and standardisation  
Plasma viral load correspond to the number of RNA genomes present in the patient’s blood, 
expressed in copies per millilitre (ml) of plasma or in log copies/ml. It is a predictor of 
disease progression: viral replication will enhance CD4 count drop (Gottlieb et al. 2002). 
RNA quantification also allows the identification of HIV-2 controllers. 
No commercial assay was approved for HIV-2 viral load monitoring in clinical settings. 
Some companies developed PCR primers sets, other offer a biochemical assay based on 
reverse transcriptase activity, but no major HIV-1 viral load platform has a version 
dedicated to HIV-2. Some studies described the use of the Nuclisens HIV-1 assay 
(Biomérieux, France), an isothermal RNA amplifiction method, applied to HIV-2 group A 
(Rodes et al. 2007). When compared to in-house RT-PCR assays, sensitivity was not optimal 
(Damond et al. 2008b).  
Plasma viral load assays are mainly restricted to some reference laboratories across Europe, 
and in some African centres. Real-time PCR is by far the most common technology used by 
those laboratories. If the coverage is sufficient for the HIV-2 cohorts in Europe, most West 
African countries lack reliable assays to monitor their patients.   
RNA quantification is ensured by an external standard curve in PCR. Several methods were 
published using an electron microscopy counted reference strain. The main advantages of 
such standard is that the process of extraction and amplification is exactly the same as a 
sample, avoiding extraction yield discrepancies, and that one quantified stock conserved in 
aliquots at -80°C can be used for a long period of time. As a drawback, the viral load is 
expressed in RNA genomes per ml and not in viral particles: some non-infectious virions 
present in a viral stock do not contain nucleic acid and can therefore bias the result. As an 
example, if 1000 viral particles contain less than the 2000 supposed genome copies, the 
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is the use of nucleic acids quantified by spectrophotometry as standards. The count of RNA 
standards is more close to the real number of genome copies than counted particles, but 
RNAs are less stable and can easily be degraded by environmental RNAse or by too long 
conservation periods. Moreover, a supplementary control on the extraction step must be 
added to the assay, and traces of parental DNA serving as template for RNA synthesis can 
also bias the RNA quantification. 
The quality and reproducibility of HIV-2 viral load assays was evaluated across Europe and 
in the Gambia through the AcHIeV2e collaborative network (Damond et al. 2008b). A first 
round showed that most of the assays gave reproducible results, but important 
discrepancies were seen for absolute quantifications. As those were possibly linked to the 
use of different standards, a second round of controls was sent around together with one 
aliquot of counted particles. Inter-laboratory homogeneity was then better, and primer 
mismatches were suspected as the origin of result variability (Damond et al. 2011). A good 
correlation of results was obtained for HIV-2 group A samples, but quantification of group B 
strains is extremely variable between laboratories. The latter evaluations underscore the 
need of a common standard if multi-centric assessments using viral load as a parameter are 
foreseen, and the need for an enhanced quality for HIV-2 group B quantifications. Two 
reference standards are now available, made respectively from strains ROD and CAM, 
belonging to group A. Their titres are expressed in international units (IU), which raises the 
unsolved issue about the use of IU vs. RNA copies in HIV clinical practice.  
3.2 Indications and interpretation 
Plasma viral load is indicated to monitor the absence or degree of viral replication during 
antiretroviral therapy. If we hypothesise that HIV-2 patients in need of therapy have the 
same likelihood to progress as compared to HIV-1, we can assume that recommendations 
for the follow-up are the same: viral load measurement at therapy initiation, one month 
after and then every 3 months, with the goal of achieving durable suppression. In resource-
constraint settings, clinical monitoring alone should be used to expand antiretroviral 
therapy, although it is not the optimal solution (Laurent et al. 2011). Given the mean slower 
disease progression and the high proportion of non-progressors, the monitoring of HIV-2 
viral load could be spaced for untreated patients from 6 months to 1 year, but no study 
support clearly that recommendation until now. In case CD4 counts drop or if disease 
progresses despite an undetectable viral load, the plasma should be retested with an 
alternative assay to avoid a possible problem of genetic variability (Gilleece et al. 2010). 
4. Resistance testing 
4.1 Genotypic assays 
To determine the sensitivity of an HIV-1 isolate to antiretroviral drugs, genotypic assays are 
the most widespread in clinical laboratories by sequencing the viral gene coding for the 
drug target (protease, reverse transcriptase, integrase and envelope glycoproteins). The 
translated amino acid sequence is compared to that of a reference strain to establish a list of 
mutations. From that list, sensitivity to each drug is inferred by interpretation rules. 
Although some phenotypic assays can be used in the clinic, their use is restricted by much 
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higher costs, the need for a biosafety level 3 laboratory, and higher turnaround times; they 
are usually developed for research purposes. Alternatively, virtual HIV-1 phenotypes are 
available, translating genotypic data into IC50 fold changes and activity cut-offs (review in 
Schutten 2006). Clinically relevant cut-offs were inferred using clinical trials and cohort data 
(Winters et al. 2008).  
None of the commercial assays available for HIV-1 resistance testing can be used for HIV-2: 
resistance assays are restricted to some reference laboratories, mostly in Europe, and rely on 
home-brew protocols. Classically Sanger sequencing is performed after RT-PCR 
amplification from plasma RNA: sensitive PCR protocols are needed, as HIV-2 viral loads 
are low. Next-generation sequencing allowing detection of more variants in quasi-species 
would help to understand HIV-2 specific viral dynamics and resistance pathways.  
4.2 Interpretation rules 
Even if the two types of HIV share some major resistance mutations, the genetic barrier, the 
pathways leading to resistance and the frequency of mutations differ (Ntemgwa et al. 2009; 
Smith et al. 2009). Therefore the interpretation rules developed to determine HIV-1 
resistance do not apply to HIV-2. Some natural polymorphisms in the HIV-2 pol gene 
correspond to resistance mutations in HIV-1 algorithms (Bercoff et al. 2010; Rodes et al. 
2006; Colson et al. 2005). Compared to HIV-1, the RT multi-drug resistance mutation Q151M 
is far more frequent after therapy failure, as the K65R mutation (Descamps et al. 2004). Two 
sets of HIV-2 specific interpretation rules have been published so far: the ANRS (Agence 
Nationale de Recherche sur le SIDA et les Hépatites, Paris, France) and the Rega (Rega 
Institute, KULeuven, Belgium) rules. The latest versions of those algorithms are available on 
line (ANRS-AC11 2011; Gomes et al. 2009). The first one is more specific, as the list includes 
only mutations for which the impact was clearly demonstrated in several publications:  
K65R, Q151M, M184V and S215 changes in the RT (Damond et al. 2005), as well as 
mutations at positions 143, 148 and 155 in the integrase (Charpentier et al. 2011). The second 
algorithm is probably more sensitive as the list includes other minor mutations for which an 
impact has been described, as well as primary protease mutations absent from the ANRS 
list. Nevertheless, in the absence of large clinical studies on HIV-2 treatment failures, the 
evidence related to some mutations is based on small case series. Moreover the lists of 
mutations refer to the strain ROD from HIV-2 group A: it may skew the interpretation for 
group B, as some mutations are natural polymorphisms with no known effect on drug 
sensitivity in B strains. Besides the analysis of clinical samples related to virological failures, 
more studies depicting the phenotypic impact of mutations on isolates in vitro are 
warranted.  
4.3 Indications 
HIV-2 resistance tests are indicated in case of virological failure, i.e. presence of viral 
replication (detectable plasma viral load) under therapy. European guidelines for the clinical 
use of resistance tests recommend genotypic assays (Vandamme et al. 2011). As genetic 
barrier to resistance is low and therapeutic options limited, a resistance test should not be 
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In antiretroviral-naïve patients, HIV-2 resistance tests are not indicated in clinical practice. 
Even though some studies demonstrated the transmission of drug-resistant strains in West 
Africa and in Europe (Ruelle et al. 2007; Ruelle et al. 2008; Jallow et al. 2009), no data 
support the cost-effectiveness of such indication for HIV-2. 
4.4 Tropism testing 
No HIV-2 tropism assay suitable for clinical use has been currently developed. Besides the 
lack of phenotypic or genotypic assay, the guidelines on the clinical management of HIV-1 
tropism (Vandekerckhove et al. 2011) do not apply to HIV-2 for the following reasons: the 
clinical outcome of CCR-5 antagonists containing regimen is unknown, few studies 
correlating the gp120 coding sequences and the phenotype are published and thus no 
genotypic interpretation rules exist (Dimonte et al. 2011), and the viral tropism extends to 
broader chemokine receptors for which the clinical relevance is controversial (Calado et al. 
2010; Blaak et al. 2005). 
5. Conclusions 
Several challenges related to the diagnosis and the follow-up of HIV-2 infections need to be 
addressed:  
 Although most HIV screening assays now detect antibodies directed against type 1 and 
2 viruses, fourth generation tests have poorer sensitivity to HIV-2 antigens. 
 The algorithms defining the number and which tests to use for HIV-2 diagnosis differ 
widely. This is related to varying prevalences between countries or continents, but is 
also related to the availability of tests, particularly nucleic acid tests. Those decision 
trees should be harmonised to ensure an accurate diagnosis: misidentification of HIV 
type has hazardous consequences for the clinical management.   
 Reference standards for plasma viral load quantification will facilitate multi-centric 
collaborations, as a lack of consistency between assays has been observed. Although 
standards are now available for group A, quantification of other groups remains 
problematic. No commercial HIV-1 viral load platform is up to now applicable for HIV-
2 in clinical settings.  
 No clinically validated tropism assay is available, preventing the use of CCR-5 
antagonists for HIV-2 treatment. 
 The apparent reduced genetic barrier to antiretroviral resistance imposes a careful 
choice of drugs and a fine-tuning of genotypic interpretation rules. 
 The majority of patients are long-term non-progressors or controllers; prediction of 
evolution and applying different follow-up patterns to controllers or progressors would 
rationalise the use of resources. 
We have to keep in mind that the majority of HIV-2 patients live in countries where the 
diagnostics tools discussed here are not all available. More field evaluations in endemic 
regions, monitoring the impact of new laboratory tools, defining the best antiretroviral 
regimen, evaluating the prevalence of resistance and understanding better the pathways 
leading to treatment failure would supplement expert opinion rules with evidence-based 
data.   
 




Amor, A., A. Simon, M. Salgado, B. Rodes, V. Soriano, and C. Toro. 2009. Lack of significant 
cross-reactivity for HIV-2 immunoblots in HIV-1-infected patients. J Acquir Immune 
Defic Syndr 50 (3):339-40. 
Andersson, S., H. Norrgren, Z. da Silva, A. Biague, S. Bamba, S. Kwok, C. Christopherson, 
G. Biberfeld, and J. Albert. 2000. Plasma viral load in HIV-1 and HIV-2 singly and 
dually infected individuals in Guinea-Bissau, West Africa: significantly lower 
plasma virus set point in HIV-2 infection than in HIV-1 infection. Arch Intern Med 
160 (21):3286-93. 
Andries, K., H. Azijn, T. Thielemans, D. Ludovici, M. Kukla, J. Heeres, P. Janssen, B. De 
Corte, J. Vingerhoets, R. Pauwels, and M. P. de Bethune. 2004. TMC125, a novel 
next-generation nonnucleoside reverse transcriptase inhibitor active against 
nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency 
virus type 1. Antimicrob Agents Chemother 48 (12):4680-6. 
ANRS-AC11. Genotype interpretation for HIV-2, www.hivfrenchresistance.org  2011. Consulted  
2011 Aug 18. 
Armstrong-James, D., J. Stebbing, A. Scourfield, E. Smit, B. Ferns, D. Pillay, and M. Nelson. 
2010. Clinical outcome in resistant HIV-2 infection treated with raltegravir and 
maraviroc. Antiviral Res 86 (2):224-6. 
Barin, F., S. M'Boup, F. Denis, P. Kanki, J. S. Allan, T. H. Lee, and M. Essex. 1985. Serological 
evidence for virus related to simian T-lymphotropic retrovirus III in residents of 
west Africa. Lancet 2 (8469-70):1387-9. 
Barin, F., F. Cazein, F. Lot, J. Pillonel, S. Brunet, D. Thierry, F. Damond, F. Brun-Vezinet, J. C. 
Desenclos, and C. Semaille. 2007. Prevalence of HIV-2 and HIV-1 group O 
infections among new HIV diagnoses in France: 2003-2006. AIDS 21 (17):2351-3. 
Barre-Sinoussi, F., J. C. Chermann, F. Rey, M. T. Nugeyre, S. Chamaret, J. Gruest, C. 
Dauguet, C. Axler-Blin, F. Vezinet-Brun, C. Rouzioux, W. Rozenbaum, and L. 
Montagnier. 1983. Isolation of a T-lymphotropic retrovirus from a patient at risk for 
acquired immune deficiency syndrome (AIDS). Science 220 (4599):868-71. 
Beelaert, G., and K. Fransen. 2010. Evaluation of a rapid and simple fourth-generation HIV 
screening assay for qualitative detection of HIV p24 antigen and/or antibodies to 
HIV-1 and HIV-2. J Virol Methods 168 (1-2):218-22. 
Benard, A., A. van Sighem, A. Taieb, E. Valadas, J. Ruelle, V. Soriano, A. Calmy, C. Balotta, 
F. Damond, F. Brun-Vezinet, G. Chene, and S. Matheron. 2011. Immunovirological 
response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted 
protease inhibitors in treatment-naive HIV-2-infected patients: The ACHIEV2E 
Collaboration Study Group. Clin Infect Dis 52 (10):1257-66. 
Bercoff, D. P., P. Triqueneaux, C. Lambert, A. A. Oumar, A. M. Ternes, S. Dao, P. Goubau, J. 
C. Schmit, and J. Ruelle. 2010. Polymorphisms of HIV-2 integrase and selection of 
resistance to raltegravir. Retrovirology 7:98. 
Blaak, H., P. H. Boers, R. A. Gruters, H. Schuitemaker, M. E. van der Ende, and A. D. 
Osterhaus. 2005. CCR5, GPR15, and CXCR6 are major coreceptors of human 
immunodeficiency virus type 2 variants isolated from individuals with and 
without plasma viremia. J Virol 79 (3):1686-700. 






In antiretroviral-naïve patients, HIV-2 resistance tests are not indicated in clinical practice. 
Even though some studies demonstrated the transmission of drug-resistant strains in West 
Africa and in Europe (Ruelle et al. 2007; Ruelle et al. 2008; Jallow et al. 2009), no data 
support the cost-effectiveness of such indication for HIV-2. 
4.4 Tropism testing 
No HIV-2 tropism assay suitable for clinical use has been currently developed. Besides the 
lack of phenotypic or genotypic assay, the guidelines on the clinical management of HIV-1 
tropism (Vandekerckhove et al. 2011) do not apply to HIV-2 for the following reasons: the 
clinical outcome of CCR-5 antagonists containing regimen is unknown, few studies 
correlating the gp120 coding sequences and the phenotype are published and thus no 
genotypic interpretation rules exist (Dimonte et al. 2011), and the viral tropism extends to 
broader chemokine receptors for which the clinical relevance is controversial (Calado et al. 
2010; Blaak et al. 2005). 
5. Conclusions 
Several challenges related to the diagnosis and the follow-up of HIV-2 infections need to be 
addressed:  
 Although most HIV screening assays now detect antibodies directed against type 1 and 
2 viruses, fourth generation tests have poorer sensitivity to HIV-2 antigens. 
 The algorithms defining the number and which tests to use for HIV-2 diagnosis differ 
widely. This is related to varying prevalences between countries or continents, but is 
also related to the availability of tests, particularly nucleic acid tests. Those decision 
trees should be harmonised to ensure an accurate diagnosis: misidentification of HIV 
type has hazardous consequences for the clinical management.   
 Reference standards for plasma viral load quantification will facilitate multi-centric 
collaborations, as a lack of consistency between assays has been observed. Although 
standards are now available for group A, quantification of other groups remains 
problematic. No commercial HIV-1 viral load platform is up to now applicable for HIV-
2 in clinical settings.  
 No clinically validated tropism assay is available, preventing the use of CCR-5 
antagonists for HIV-2 treatment. 
 The apparent reduced genetic barrier to antiretroviral resistance imposes a careful 
choice of drugs and a fine-tuning of genotypic interpretation rules. 
 The majority of patients are long-term non-progressors or controllers; prediction of 
evolution and applying different follow-up patterns to controllers or progressors would 
rationalise the use of resources. 
We have to keep in mind that the majority of HIV-2 patients live in countries where the 
diagnostics tools discussed here are not all available. More field evaluations in endemic 
regions, monitoring the impact of new laboratory tools, defining the best antiretroviral 
regimen, evaluating the prevalence of resistance and understanding better the pathways 
leading to treatment failure would supplement expert opinion rules with evidence-based 
data.   
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1. Introduction  
Globally, since the AIDS epidemic began, nearly 60 million individuals have contracted HIV 
with 25 million having died from causes related to the infection (World Health Organization 
[WHO], 2009). In 2009, it was estimated that 33.4 million people world-wide were living 
with HIV (WHO, 2009). The Centers for Disease Control and Prevention (CDC) estimates 
that over one million individuals in the United States are living with HIV, and since the 
1990s, the annual rate of individuals newly infected with HIV has remained relatively stable 
at about 56, 300 (CDC, 2010).  
While the number of individuals reporting ever having been tested for HIV has been 
increasing steadily over time (Kaiser Family Foundation, 2006), a fifth (21%) of the HIV-
infected population is unaware they are infected. This is an alarming statistic that continues 
to hamper efforts to substantially reduce the spread of the disease and improve the health of 
the public (CDC, 2010). Further, according to the CDC, among individuals appearing to a 
CDC-funded HIV-testing site in 2000, only 31% of those who tested positive for HIV ever 
returned to receive the results of the test (CDC, 2003).   
Advances in medicine have proven effective in improving the quality of life of those who 
are HIV-positive. However, these improvements are more fully realized when HIV-positive 
status is identified early on. Early identification of HIV-positive status can be important in 
reducing morbidity and mortality (CDC, 2006), and studies have shown that individuals 
who are aware that they are HIV-positive will modify their behavior in an effort to prevent 
transmission of the virus (Marks et al., 2005).    
The public health benefits of increased rates of HIV testing and awareness of HIV-positive 
status are clear. Consequently, strategies to increase HIV-testing, awareness of positive 
status, and motivation to obtain medical care are important in the effort to reduce the 
negative impact of HIV/AIDS. Today’s technologies have the potential to substantially 
impact the AIDS epidemic by providing innovative and cost-effective means by which to 
reach more individuals and increase HIV-testing rates, awareness and motivation to change 
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Researchers and clinicians working to influence and promote health behavior have only just 
begun to scratch the surface with regard to the uses of technologies in prevention and 
intervention programs. Examples that utilize technology to influence and promote health 
behavior include, but are not limited to, sending text messages to remind individuals of 
health care appointments, creating websites that provide specific health-related information 
and motivate individuals to seek health care services, and using tablet PCs or other mobile 
technologies to reach hidden populations and to administer assessments and interventions 
electronically. The potential for integrating and utilizing technology into health programs to 
influence and promote behavior is great and will continue to grow at a rapid pace. It is 
possible that as society continues to become more reliant on such technologies, health 
programs not utilizing or incorporating technologies will become less effective in 
comparison to technology-based health programs.  
2. Advantages to using technology with HIV-positive and at-risk populations 
The availability of, and advances in, personal computers, mobile phones and the Internet 
have grown exponentially over the last several years and growth continues at a staggering 
pace. As such, the use of these technologies is far reaching—impacting society in multiple 
ways. While the use of technology is pervasive in many ways, its application and potential 
benefit in raising awareness of and changing health behavior is much less pervasive, and 
thus potentially severely underutilized. To understand how technologies such as mobile 
phones, computers and the Internet can potentially positively impact the fight against 
HIV/AIDS, a general overview of the advantages of using or incorporating technology into 
programs created to change health behavior follows.  
The use of technology to raise awareness of health concerns such as HIV-positive status and 
facilitate health behavior change is a relatively new and substantially understudied area. 
Given the apparent advantages to utilizing and incorporating technologies to impact the 
health outcomes of the public, including underserved populations, this line of research is 
likely to grow significantly over the next several years. The use and integration of 
technologies to influence and promote health behavior has several potential advantages (c.f., 
Bull, 2011). Below we reiterate and expand on the advantages of using technologies to 
influence and promote health as originally described by Bull (2011). 
Reach. Perhaps the most significant and fundamental contribution technologies such as 
computers, mobile phones and the Internet have on promoting and changing health 
behavior is that of reach. Bull (2011) argues that the Internet offers an unprecedented 
opportunity to reach untold numbers of individuals. Likewise, the growing use and 
affordability of portable computers and mobile phones extends opportunities to connect 
with greater numbers of individuals. As a result, the effort to positively influence the health 
of the public can expand past traditional means of contact and interaction, thus reaching 
and impacting far more individuals than was previously thought possible. The use of the 
Internet, computers and mobile phones to promote and change health behavior has the 
potential to overcome many of the barriers that limit or preclude access to health programs 
(e.g., transportation and/or child care, inflexible work schedules of patients) (see, for 
example, DeLeon, Wakefield, & Hagglund, 2003; Nordal, Copans, & Stamm, 2003; 
Organista, Munoz, & Gonzalez, 1994; Stamm, 2003). This is especially true for women and 
minority individuals who are preferentially impacted by these barriers (Connell, Sanders, & 
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Markie-Dadds, 1997; National Institute of Mental Health, 2003; US Census Bureau, 2002; 
Weismann & Jensen, 2002). Highlighting the need to discover ways to overcome barriers, 
authors have noted that while a health program may be found efficacious, it may not 
necessarily have a substantial impact if it cannot reach the target population and engage that 
population over time for sustained effects (see Thyrian & Ulrich, 2007; Glasgow, Klesges, 
Dzewaltowski, Estabrooks, & Vogt, 2006; Klesges, Estabrooks, Dzewaltowski, Bull, & 
Glasgow, 2007).  
Tailored Content. Technology can allow for health programs and interventions to be tailored 
to address patient factors (e.g., language barriers, low self-efficacy) and cushion provider 
bias (e.g. cognitive bias) and real-world system constraints (e.g., second/third-shift 
workers). Disadvantaged individuals tend to be more severely impacted by these factors 
and recent studies have shown that interactive multimedia computer programs can lessen 
these impacts (Jerant, Sohler, Fiscella, Franks, & Franks, 2010). Studies also indicate that 
information tailored to an individual becomes more relevant to the individual and thus is 
more likely to be read, comprehended and stored (Kreuter, Farrell, Olevitch, & Brennan, 
2000; Stretcher, 1999). For instance, a computer-based health program designed to educate 
about the dangers of drug use can be programmed to discuss only issues related to drugs 
with which the respondent has indicated experience. A video-based health program would 
play through the dangers of all drugs, regardless of a drug’s relevance to the respondent. As 
a result, respondents may become uninterested in the health program and fatigued by it 
because of what may be considered irrelevant information.  
Feasibility. The use of technology in health programs and interventions can make the 
adoption, implementation and utilization of programs more feasible for community 
agencies. Glasgow, Lichtenstein, and Marcus (2003) argue that in order to reach some 
populations and have an impact on those populations, health programs must be made easy 
for community agencies to adopt, implement and utilize. Preliminary studies utilizing 
technology to promote health have shown that technology integration has promising 
potential to provide the means by which community agencies can easily implement and 
utilize proven health programs (Leeman-Castillo, Beaty, Raghunath, Steiner, & Bull, 2010; 
Cullen & Thompson, 2008; Skinner, Rivette, & Bloomberg, 2007). In short, utilizing a 
computer-based health program or intervention is often easier to implement and less 
expensive than hiring and training staff to deliver the same intervention.  
Cost-Effectiveness. Technologies have the potential to lower costs associated with 
implementing and sustaining health programs and interventions. For example, the 
portability of computers, mobile phones and the Internet increases reach and reduces 
reliance on physical locations that require maintenance and which are often limited by size 
(see, for example, Booth, Nowson, & Matters, 2008; Brendryen & Kraft, 2008; Rainie, 
Horrigan, Wellman, & Boase, 2006). Home care programs can use camera phones to monitor 
patient wounds (estimated at 25% of home health admissions), thereby increasing the 
appropriate use of specialist services and decreasing associated costs (Sugrue & Riggs, 
2005). Video phones used with patients receiving palliative care and antenatal home care 
have been shown to decrease isolation, save travel time and allow care team members to 
meet at a distance (Miyazaki, Stuart, Liu, Tell, & Stewart, 2003).  
Standardization. Using technologies such as the Internet, mobile phones and computers, 
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Standardization helps ensure that each participant in the health program or intervention 
gets the content of the program exactly as it was intended. Further, standardization reduces 
variability, especially with regard to interactions with counselors or other content deliverers, 
and can substantially increase adherence to program curricula. 
Interactive. Health programs can be technologically-enhanced to allow for a higher degree of 
interactivity than past means of health information delivery, such as video recordings and 
simple text-based or audio-assisted computer applications. For example, computers, mobile 
phones and the Internet can deliver health program content in multiple formats, including 
video-game formats. Similarly, health programs can be designed to mimic real-life 
interactivity with a counselor or other health care professional through the use of human 
simulation and artificial intelligence programs. Further, given that younger individuals are 
substantially more tech-savvy and reliant on technology, these individuals may, in fact, 
prefer interacting through computers, mobile phones and the Internet.  
Anonymity & Confidentiality. While some caveats apply, technologies more readily offer 
anonymity to recipients of health programs and interventions. For example, through the use 
of a computer or mobile phone with Internet access, individuals can access and receive 
health program information and interventions without ever being personally identified. 
Likewise, technologies can store respondent information confidentially by generating 
unique identification codes or using biometric identification such as fingerprints, which can 
link several sources of data without identifying respondents.  
Autonomy. Using technologies such as mobile phones, computers and the Internet, 
individuals can move through programs and interventions at their own pace. Further, 
individuals can be afforded the flexibility of accessing programs and interventions at times 
that are most convenient to them. For example, individuals who have work schedules that 
vary from week to week may not be able to readily access treatment or intervention services 
or may have trouble keeping appointments can benefit from the flexibility of accessing 
programs and services online at times and from locations convenient to their schedule. 
Portability. Increasingly, over the past several years technologies have become more 
portable. Likewise, Internet access, especially free access, has become increasingly more 
common. Together, portability and Internet access allow individuals to easily access online 
content. Advances in mobile phone technologies (e.g., “smartphones”) allow for the 
potential to create health prevention and intervention programs using software programs 
(“Apps”) that can be downloaded to a smartphone and accessed anytime and anywhere, 
often without needing access to the Internet. 
Storage & Backup. Technologies provide relatively easy and inexpensive storage and backup 
of information and can range from basic hard-drives or portable drives (e.g., flash drive, 
external hard drive) to more sophisticated devices such as secured networked drives with 
automatic and redundant backup. Further, electronic storage and backup can safeguard 
against information loss due to theft or disaster. For example, automatic backup and storage 
to a remote off-site location can protect information that might otherwise be destroyed in an 
on-site fire or other similar disaster.  
The aforementioned discussion of the use of technology to influence and promote health 
behavior, including HIV-related testing and behavior, highlights the many potential 
advantages of using technology. Perhaps most importantly, technologies afford community  
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Reach  Access to the Internet through free Wi-Fi is increasing. 
 Mobile phones (“smartphones”) that can access the Internet have 
become more affordable. 
 Smart phones are able to run computer programs (“Apps”). 
 Internet-, computer- and mobile phone-delivered programs have 
the potential to always be on—allowing access at any time. 
Tailored Content  Programs can be tailored to the individual characteristics of the 
participant (e.g., an African-American female counselor can appear 
in a video for an African-American female client). 
 Content can be tailored based on the responses of the participant.  
Feasibility  Programs or interventions can be implemented with little or no 
training of staff, thus reducing potential costs to the agency. 
 An agency with limited staff may be able to provide additional 
services by utilizing technologies.  
Cost-Effective  Technologies can be utilized in place of more expensive program 
staff. 
 Technologies can reduce costs of training staff to conduct 
programming that can be done by a computer or other technology. 
 Technologies can be utilized off-site and have the ability to reach 
more individuals. 
Standardization  Content can be delivered exactly the same way each time. 
 Technologies can increase program fidelity. 
 Technologies can reduce the variability associated with individual 
differences of those delivering program content.  
Interactive  Technologies allow for interaction with computers, which may be 
more comforting for some participants, especially younger 
participants. 
 Content can be delivered using an approach that utilizes multiple 
forms of media (e.g., video, audio, games).  
Anonymity & 
Confidentiality 
 Participants can provide information or interact with a program 
anonymously through the Internet.  
 Participants can provide information or interact with programs on-
site without revealing personally identifying information.  
 Technologies reduce the risk of breach of confidentiality because 
there are no hardcopy or paper formats of participant information. 
Autonomy  Participants can proceed through curricula or programming at 
their own pace without significant disruption to other participants 
or program staff. 
Portability  Technologies can be mobile and thus can remain in contact with 




 Participant information can be safely stored and backed-up to 
safeguard against theft or disaster. 
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agencies that serve at-risk HIV populations more options in which to provide services within 
limited and often shrinking operating budgets. For instance, as a result of federal and state cuts 
in funding for services, including services for minority populations (Zeanah, Stafford, & 
Zeanah, 2005), there have been calls to support the adoption of interventions that can be 
delivered in nontraditional and innovative ways that overcome traditional barriers to treatment 
provision and utilization (Hollon et al., 2002; National Institute of Mental Health, 2003).  
Affordability of technology makes it increasingly possible for community agencies even in 
the poorest of neighborhoods, to utilize technology and technology-based services. As a 
result, technologies or technology-enhanced services can be more readily adopted, 
implemented and maintained allowing greater penetration into populations that are at risk 
for HIV. Additionally, the use of technology and technology-enhanced services allows 
agencies to expand evidence-based practices (EBPs) with minimal strain to limited staff and 
resources that are already stretched thin in many community agencies. Thus, technologies 
and technology-enhanced services can provide feasible real-world and evidence-based 
solutions that can reach even the most remote and underserved populations of individuals 
at risk for or living with HIV/AIDS. 
3. Emerging literature 
The emerging body of literature on computer-based interventions (including delivery via 
local computer or Internet, smart phone and social media) as applied to HIV testing, 
awareness and prevention shows great promise. Researchers point out that technological 
applications are especially important because significant investments have been made in the 
development of HIV prevention and behavioral interventions; however, there remain 
barriers to widespread use. These barriers include, but are not limited to, the cost of delivery 
(that is, requiring a human facilitator), maintenance to fidelity of interventions and 
distribution to remote or rural areas.  
Noar (2011) presents a review of computer technology-based interventions in HIV 
prevention including interventions that are group-targeted, individually tailored and apply 
interactive video. The author presents a series of intriguing research questions regarding the 
use of technologies along the lines of reach (who are the appropriate audiences?), efficacy 
(what kinds of effects are possible?), adoption (who uses the technology?), implementation 
(what are the process issues?) and maintenance (how can the use of technology be sustained 
over time?). This work provides a framework for analyzing the newly emerging studies on 
the use of technology to promote HIV prevention. 
Seeking health information online has become routine for most Americans. As such, it is no 
surprise that the Internet has been shown to be a source of sexual health information. 
Lesbian, gay, bisexual and transgender (LGBT) youth report that they use the Internet to 
seek sexual health information, particularly to avoid the stigma associated with asking 
questions of health care providers (Magee, Bigelow, DeHann, & Mustanski, 2011). Hightow-
Weidman et. al (2011) developed a theory-based HIV/STI website for young, Black men 
who have sex with men (MSM) based on the Institute of Medicine’s integrated model of 
behavior change and with input from young Black MSM focus group participants. Their 
interactive web site design uses live chats, quizzes, personalized health and “hook up/sex” 
journals. Clients reported high satisfaction with the approach, particularly due to its high 
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cultural relevance. Therefore, websites present the opportunity to tailor health information 
in a way that can be continuously updated, as opposed to brochures in print. 
Most studies of the Internet and HIV prevention have focused on gay, bisexual, and MSM 
who seek sexual partners online. These interventions have sought to promote HIV testing. A 
community-based participatory research (CBPR) partnership developed and piloted 
CyBER/testing, an intervention using Internet chat rooms set up to promote HIV testing 
among MSM “chatters” (MSM who use the chat room). The intervention showed a 
significant increase in self-reported testing for the chatters overall (Rhodes, et. al, 2011). This 
result was also supported by a study promoting testing via an online community for high-
risk clients in North Carolina (Feldacker, et. al, 2010). Holt et. al (2011) in Australia  found 
that the Internet is an important way to promote HIV testing among MSM.  In particular, 
this study found that Internet social networks present the opportunity to engage never-
tested clients in chat rooms which leads to increased motivation for testing. Bowen et. al 
(2008) examined the use of the Internet to conduct HIV prevention outreach to rural MSM. 
Overall, their findings suggest that web-based interventions may make rural outreach more 
feasible.  
Clearly, Internet and social networking holds promise for reaching adolescent populations, 
given the documented high use of technology among this age group. Bull et. al (2007) 
developed a theoretically-based online HIV/STD and pregnancy prevention  intervention 
aimed at 15-25 year old participants. The youth in this study felt that role model-delivered 
messages about HIV/STD and pregnancy risk, attitudes about condoms, norms and self-
efficacy for negotiation would have a high impact. The youth preferred highly interactive 
websites such as chat rooms and message boards. The participants also felt that effective 
websites would give facts and real stories; however, they felt that reading should be short 
and to the point.  
An interesting target population is that of homeless adolescents. A recent study (Young and 
Rice, 2011) found that in a sample of 201 homeless youth in Los Angeles, 79% reported using 
MySpace and/or Facebook almost every week. The adolescents used the Internet sites to 
communicate with others about drinking, drugs, parties, sex, being homeless and school 
experiences. The authors found that online social networks can be associated with both 
potential increases and potential decreases in HIV/STD risk among homeless youth. As an 
example of potential increases in HIV/STD risk, some homeless youth reported that they 
used social network sites to sell sex. Overall, however, online social network use was 
associated with increased knowledge and HIV/STD prevention behaviors among homeless 
youth. The authors conclude that homeless youth need more access to the Internet, since 
access may facilitate contact with family and home-based peers. This contact was found to 
be associated with decreased risk and increased testing. However, the authors caution that 
online environments need to be carefully monitored to prevent youth from soliciting sex 
online. 
Using the Internet to reach high-risk individuals is a strategy being used in HIV prevention 
globally. Blas et. al (2007) used an Internet intervention in Peru to access high risk MSM. In 
this context, the authors describe how Peruvian MSM are shifting from physical to virtual 
places, not only to look for sexual partners but also to look for HIV-related health 
information. The study concluded that attracting high-risk MSM not tested for HIV to an 
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Brief computerized interventions to reduce risk and increase HIV testing have been found to 
be effective. Alemagno et. al (2009) developed and implemented a computerized, self-
administered HIV/STD risk screen using the “brief negotiation interviewing” (BNI) 
approach. Participants were able to answer a set of risk questions via computer, receive 
immediate risk feedback and work through a plan to increase motivation for testing. The 
participants in the computerized BNI intervention group were more likely to obtain an HIV 
test by the 3-month follow-up interview as compared to the controls. Grimley and Hook 
(2009) also found that a 15-minute interactive, computerized condom use intervention 
increased condom use. The intervention was conducted in a clinical setting and self-
administered by the participants. The authors concluded that the intervention held 
considerable promise in that there was no additional burden on clinicians or staff.  
Another promising technology for HIV prevention is the use of mobile phones. A recent 
study finds that riskier youth (in terms of HIV/STI risk behavior) are online and using cell 
phones frequently (Whiteley et. al, 2011). This study of over 1,500 African American 
adolescents found that over 90% of adolescents used their cell phones every day and 60% 
used social networking sites. The authors conclude that mobile phone interventions may be 
promising to reducing risks by providing health information. 
Text messaging is an application that is emerging to reach target populations. A pilot 
program aimed at young Black men using a 12-week text message program found that the 
intervention group showed a trend toward increased monogamy at follow-up compared to 
controls (Juzang, Fortune, Black, Wright, & Bull, 2011). The intervention group also had 
higher awareness of sexual health compared to the controls. Another study found that 
young persons have positive attitudes toward text messages as appointment or medication 
reminders or for health information related to HIV (Person, Blain, Jiang, Rasmussen, & 
Stout, 2011). Receiving a text message was perceived as more acceptable than having to 
answer the phone. A message could be saved for viewing at a later time. One drawback of 
using text messages is that target populations must have sufficient literacy and there is the 
obvious cost associated with a mobile phone with text capabilities. This study also points 
out that less frequent, targeted reminders are most acceptable so the frequency is an 
important consideration.  
4. Cautions in using technologies  
While the use of technologies such as computers, mobile phones and the Internet show 
significant promise, careful consideration should be given to address any potential concerns. 
Below we discuss several potential issues that could arise when utilizing technologies in 
health-promoting programs for populations living with or at risk for HIV/AIDS. As more 
research emerges on the topic of technology-based health promotion, so should solutions to 
these potential issues. 
Literacy. Even though it is possible to program computers to read text to participants, the use 
of health education websites or the use of health messages sent by text message requires 
participants to have the ability to read and understand the content. Few studies have 
examined the impact of literacy on mobile device use.  
Confidentiality. There are confidentiality concerns regarding information that is disclosed on 
Internet sites and mobile devices, including risks related to self-disclosure and risks related 
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to unintended persons viewing information transmitted to mobile devices. While providers 
may feel assured that they are transmitting information to the correct person based on a 
mobile number, there is no control over who is reading the information once delivered to 
the device. Participants in chat rooms or using social media that is not properly secured and 
protected may have a false sense that their identities are not available to other participants. 
Adverse Use. Several studies have voiced concerns that participants engaged in interventions 
may use computers for alternative purposes. For example, online interventions using chat 
rooms have been used by participants to solicit sex. This is especially concerning for 
interventions targeted at adolescents.  
Cost to Participants. Not all intervention programs can afford to provide participants with 
necessary intervention technologies (e.g., mobile phones, Internet). As such, participants  
 
Concerns Example 
Literacy  Use of websites and text messaging requires a basic level of 
computer literacy and reading level. 
 Participants may not understand health information and take 
adverse actions based on misunderstanding. 
 Participants who take online risk screening may have a false sense 
of safety regarding their risks. 
Confidentiality  Confidential health information cannot be transmitted on the 
Internet in some settings. 
 Other persons may gain access to a mobile device and read text 
messages with sensitive information. 
 Participants may disclose personal information on the Internet. 
Adverse Use 
 
 Participants may misuse online chat rooms or social media sites for 
soliciting sex, selling drugs or other illegal trade. 
 Adolescents may engage in inappropriate activities or be solicited. 
Cost to 
Participants 
 While mobile devices may be inexpensive, services required (e.g., 
Internet access, mobile cell service providers) to use such devices is 
still relatively costly. 
 Mobile devices are transitional; participants change providers and 





 Providers may need to invest considerable costs in the development 
of web-based interventions or other content (“Apps”). 





 The impact of substituting a computer for a person conducting an 
intervention is unknown; removing the human factor from the 
intervention may not be effective in all settings or for all participants.  
Digital Divide  While the use of computer, Internet and mobile phones is increasing 
for all populations, there remains a considerably large number of 
individuals within target populations for HIV prevention and 
testing who do not have access to these technologies.  
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may need to pay for monthly mobile phone or Internet access in order to remain a 
participant in the intervention. Well-intended participants may withdraw from an 
intervention solely because they cannot afford the required technology, thus continuous 
contact with participants may become challenging for intervention providers. 
Cost of Technology and Application Development. While there are savings associated with the 
use or incorporation of technologies, there are also costs related to the purchase of 
computers, design of websites, and programming of software applications. Further, there 
may also be costs associated with the training needs of staff using or implementing the 
technologies. Some uses of technologies may require the need for additional staff. For 
instance, additional staff may be needed to monitor chat rooms and social media sites.  
Replacement of the Human Factor. The vast majority of evidence-based interventions to reduce 
HIV risk and increase testing have been designed to be delivered by human interventionists. 
Much is yet to be learned about the efficacy of replacing humans with technology-based 
intervention platforms. Future research is clearly needed to examine what benefits or 
shortfalls emerge when an intervention is delivered solely by a computer or mobile device 
devoid of personal contact.   
Digital Divide. Despite the growing use of and reliance on technologies by society, some 
populations do not have access to it. This is especially notable among the very poorest 
populations (National Telecommunications and Information Administration and US 
Department of Commerce, 1999). Interventions targeting such populations will need to be 
provided to participants or available to participants in convenient locations. 
5. Future directions 
It will be important for future research to address research questions related to the use of 
technologies to increase HIV testing and reduce HIV/AIDS in at-risk populations. The 
majority of work to date has been on MSM; little is known about how interventions should be 
developed differently across populations or for those who lack computer skills. Further, few 
studies have examined the lasting impact of technology-based interventions or the ability to 
maintain contact with clients over time when interventions utilize these technologies.  
Our review of the literature for this chapter did not reveal any “bundled” HIV intervention 
approaches that examine the efficacy of combining in-person and computer-based 
interaction in an intervention. Measuring the efficacy of the technology-based interventions 
as compared to traditional in-person approaches is in early stages, and rarely have studies 
been conducted comparing human-administered intervention to the same content delivered 
by a computer or a mobile phone. There may well be target populations for whom such 
technology-based approaches are not appropriate.  
One thing is for certain, the technologies available for use in HIV-related interventions 
increases daily. There are new mobile devices with new “Apps” emerging all the time and 
the use statistics indicate that virtually everyone will eventually have some access to 
computers and/or mobile devices, even in remote countries around the world. The ability to 
examine such interventions with different target populations in different cultural contexts 
opens a new world for health education and interventions. There is a need for information 
regarding the barriers and facilitators to adoption of technologies for HIV-specific programs. 
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There is also a need for more information on the capacity of organizations to implement 
technologies in place of more traditional approaches. In this new era of technology-based 
interventions for HIV prevention, the only thing that remains certain is that opportunities to 
apply these technologies will grow much more quickly than our ability to understand all of 
the implications.  
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may need to pay for monthly mobile phone or Internet access in order to remain a 
participant in the intervention. Well-intended participants may withdraw from an 
intervention solely because they cannot afford the required technology, thus continuous 
contact with participants may become challenging for intervention providers. 
Cost of Technology and Application Development. While there are savings associated with the 
use or incorporation of technologies, there are also costs related to the purchase of 
computers, design of websites, and programming of software applications. Further, there 
may also be costs associated with the training needs of staff using or implementing the 
technologies. Some uses of technologies may require the need for additional staff. For 
instance, additional staff may be needed to monitor chat rooms and social media sites.  
Replacement of the Human Factor. The vast majority of evidence-based interventions to reduce 
HIV risk and increase testing have been designed to be delivered by human interventionists. 
Much is yet to be learned about the efficacy of replacing humans with technology-based 
intervention platforms. Future research is clearly needed to examine what benefits or 
shortfalls emerge when an intervention is delivered solely by a computer or mobile device 
devoid of personal contact.   
Digital Divide. Despite the growing use of and reliance on technologies by society, some 
populations do not have access to it. This is especially notable among the very poorest 
populations (National Telecommunications and Information Administration and US 
Department of Commerce, 1999). Interventions targeting such populations will need to be 
provided to participants or available to participants in convenient locations. 
5. Future directions 
It will be important for future research to address research questions related to the use of 
technologies to increase HIV testing and reduce HIV/AIDS in at-risk populations. The 
majority of work to date has been on MSM; little is known about how interventions should be 
developed differently across populations or for those who lack computer skills. Further, few 
studies have examined the lasting impact of technology-based interventions or the ability to 
maintain contact with clients over time when interventions utilize these technologies.  
Our review of the literature for this chapter did not reveal any “bundled” HIV intervention 
approaches that examine the efficacy of combining in-person and computer-based 
interaction in an intervention. Measuring the efficacy of the technology-based interventions 
as compared to traditional in-person approaches is in early stages, and rarely have studies 
been conducted comparing human-administered intervention to the same content delivered 
by a computer or a mobile phone. There may well be target populations for whom such 
technology-based approaches are not appropriate.  
One thing is for certain, the technologies available for use in HIV-related interventions 
increases daily. There are new mobile devices with new “Apps” emerging all the time and 
the use statistics indicate that virtually everyone will eventually have some access to 
computers and/or mobile devices, even in remote countries around the world. The ability to 
examine such interventions with different target populations in different cultural contexts 
opens a new world for health education and interventions. There is a need for information 
regarding the barriers and facilitators to adoption of technologies for HIV-specific programs. 
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There is also a need for more information on the capacity of organizations to implement 
technologies in place of more traditional approaches. In this new era of technology-based 
interventions for HIV prevention, the only thing that remains certain is that opportunities to 
apply these technologies will grow much more quickly than our ability to understand all of 
the implications.  
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1.1 Health disparities related to HIV  
HIV-related health disparities are differences in the incidence, prevalence, mortality, 
and/or burden of HIV and related adverse health conditions that exist among specific 
population groups. Health disparities exist within the impoverished or low-income 
housed population in Puerto Rico with respect to HIV. Formative research findings with 
women who live in public housing revealed a three percent self-reported HIV positive 
serostatus (Norman, et. al., 2008). However, due to the stigma associated with HIV in 
Puerto Rico, especially within the residents of public housing, this figure is likely to be an 
underestimation of the real seroprevalence (Norman, et. al., 2009). The vast majority is 
unemployed (95%) and has no visible means of monetary support. As such, they qualify 
for “Reform, as the local Puerto Rico Health Reform program (Reforma de Salud de Puerto 
Rico in Spanish), is called. This is a government-run program which provides medical and 
healthcare services to indigent and impoverished citizens of Puerto Rico. It is run by 
means of contracting services of private health insurance companies, as opposed to the 
traditional system of government-owned hospitals and emergency centers. The Reform is 
administered by the Puerto Rico Health Insurance Administration and, as of December 31, 
2005, provides healthcare coverage to over 1.5 million Puerto Ricans, which equals to 
37.5% of the island population (PR Department of Health, 2010). While these persons 
qualify for Reform, many of them have no means of accessing needed health care due to 
the costs of or lack of transportation.   
The course of HIV disease varies among individuals, with complications such as 
opportunistic infections (OIs) emerging at different times throughout the trajectory of the 
illness. The goal of healthcare is to keep the individual as healthy as possible through 
health-promoting behaviors.  When examining the quality of life among PR residents, one 
study found that older women, persons with less education or lower income, persons unable 
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to work, and those who were overweight or who had diabetes or high blood pressure 
reported more days for which they were physically or mentally unhealthy during the 30 
days preceding the survey (CDC, 2002). Health-promoting behaviors include good nutrition 
and ongoing risk reduction, as well as making persons aware of their HIV status. Ensuring 
that people know their HIV status and receive adequate care if infected can improve clinical 
outcomes and reduce the transmission of HIV. However, researchers estimate that 21 
percent of persons infected with HIV are unaware that they have the disease (IOM 2011). 
Once persons are made aware of their positive status, they can be offered treatment and 
appropriate care, which can help decrease HIV-related disparities associated with morbidity 
and mortality.  
1.2 Why impoverished females in Puerto Rico are considered disproportionately 
affected by HIV/AIDS  
As of September 2011, 43,648 cases of AIDS have been reported in the island (PR 
Department of Health, 2011). Women constitute 20% of the total number of prevalent cases. 
Heterosexual transmission accounts for 61% of the cases among women, followed by 
injecting drug use (IDU) (PR Department of Health, 2011).  
Puerto Rico has one of the highest incidence rates of AIDS in the Americas (CDC, 2010). In 
the year 2009, rates of HIV diagnoses among female adults and adolescents ages 13 years 
and older in Puerto Rico had then 5th highest rates among 40 states and five US territories, 
with a rate of 15.4 cases per 100,000 population (CDC, 2010). Prevalence rates of adult and 
adolescent females living with a diagnosis of HIV infection, year-end 2008, revealed that 
Puerto Rico was the 3rdn highest, with 349.7 cases per 100,000 population. Lastly, in terms 
of rates of AIDS diagnosis among adult and adolescent females in 2009, Puerto Rico 
reported the 5th highest rate with 13.2 cases per 100,000 population being reported. 
The estimated HIV prevalence was calculated for women and girls living in Puerto Rico 
using the data described above and the population of Puerto Rico residents, which includes 
approximately 3.8 million, of which approximately 1.6 million are female aged 13 years and 
older (US Census Bureau, 2011). At the end of 2008, the estimated prevalence among women 
and girls ages 13 years and older living in Puerto Rico was 69 cases per 10,000 women (0.69 
per 100) (CDC, 2010). While this prevalence rate may seem to be low, self-reported data 
collected from 1,138 women during the formative phase of Proyecto MUCHAS revealed a 
rate more than four times that estimate, with three percent self-reporting their HIV status as 
positive (Norman, et. al., 2008). This rate does not include those women who refused to 
disclose their status on the survey. If we include assume they are positive and include them, 
the rate goes up to 3.9 per 100. As the percentage of AIDS cases among women continues to 
increase in Puerto Rico, it becomes imperative that research and prevention efforts target 
additional groups of women who may be at increased risk of HIV. 
1.3 Social and cultural factors that exacerbate HIV risk for impoverished women  
HIV risks are exacerbated for impoverished women by a number of social and cultural 
factors. Poverty is a major factor that contributes to the increased risk of HIV for women. 
Many experts believe poverty, unemployment, and a lack of education are helping to drive 
the growing HIV problem among women. Women living in inner-city poor neighborhoods 
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are often in poor health and without access to healthcare for prevention or treatment 
(Women’s Health, 2011). While risky behaviors in these communities directly spread HIV, 
urban poverty is clearly playing an important role because it is directly related to lack of or 
low education, poor housing conditions, and other factors associated to low self-esteem, and 
lack of knowledge about health issues. Previous research has examined the relationship 
between socioeconomic status and HIV risk and identifying significant associations between 
the two, such as persons who are considered low-income are more likely to be HIV positive 
than are their higher income peers (CDC, 2011; Johns, Bauermeister, & Zimmerman, 2010; 
Dinkelman, Lam & Leibbrandt, 2007). The findings from these studies suggest that 
impoverished persons are at increased risk for HIV infection because of the heightened risk 
that stems from the increased HIV prevalence within their social/sexual networks. 
Furthermore, the physical, psychological, and social circumstances in which their poverty 
places them may also increase their risk of HIV exposure.  
In addition to the risk that poverty imposes on impoverished women, another social issue 
contributing to increased risk for women and girls has to do with gender socialization 
(Carovano, 1992). Gender refers to the widely shared expectations and norms held by a 
society with regard to appropriate male and female behavior, characteristics, and roles. It is 
a social and cultural construct that differentiates women from men and defines the ways in 
which women and men interact with each other (Carovano, 1992). With respect to women’s 
vulnerability, in many societies, there is a culture of silence surrounding sex that dictates 
that “good” women are expected to be ignorant about sex and passive in sexual interactions, 
making it difficult for women to be well informed about risk reduction or, even when 
informed, making it difficult for them to be proactive in negotiating safer sex with their male 
partners (Carovano, 1992). The women in the above mentioned study sample of Puerto 
Rican residents are members of just such a society. Another issue related to this culture in 
many societies is the belief that variety in sexual partners is essential to men’s nature as 
men, and that men need to seek multiple partners for sexual release; the manifestations of 
traditional notions of masculinity are strongly associated with a wide range of risk-taking 
behaviors among men that affect both men and women (Courtney, 1998).  
Research with impoverished minority women suggests that these women who live in male-
dominated societies are at a significant risk of HIV due to increased levels of drug use, risky 
sexual practices, and intimate partner violence, among other factors; in addition, there may 
be significant levels of interaction with members of concentrated groups (Fuller, et. al., 2005; 
Brown-Peterside, et. al., 2002; Kalichman, et. al., 1998; Soler, et. al., 2000)  While current 
research findings can be used to hypothesize increased HIV risk, data on impoverished 
Latina women in Puerto Rico are scarce, so it is difficult to estimate either the levels of HIV 
risk or the factors contributing to such risk for this population. Unique cultural and social 
factors may exist, which contribute significantly to the exacerbation of HIV and STIs risk for 
impoverished Latina women living in public housing developments of Puerto Rico.  
As is frequently the case in Latino societies, children born into the Puerto Rican culture find 
themselves subjected to attitudes, mores, and customs that promote very strong gender 
differences. From birth on, these differences are inherent in every aspect of sexual 
expression and male-female interaction (Raffaelli, 2004). The outward manifestation of the 
principle illustrated by these differences is called machismo, which is the belief that males are 
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pervasive attitude, women are relegated to the role of being sexual objects with the sole aim 
of fulfilling men’s desires and needs (Montesinos & Preciado, 2001). Furthermore, in Puerto 
Rico, these ideas are prevalent among members of the low-income population, who tend to 
agree with the more traditional values as related to gender (Pico, 1998). These factors need 
to be considered if one is to develop culturally appropriate, effective interventions to 
decrease HIV/STI risk-related behaviors among these women.  
Therefore, research into HIV-prevention efforts needs to explore the mechanisms by which 
various social and cultural constructs increase women’s vulnerability to HIV. By developing 
an understanding of these constructions, one can begin to develop and implement 
appropriate and effective strategies to improve women’s situations. Given the patterns and 
inequalities in the roles of women and men, it is not surprising that women are at high risk 
for HIV transmission, especially those who live in societies that are impoverished and that 
support male dominance over women as well as gender inequality. Furthermore, 
considering these additional cultural and social factors present in Puerto Rico, impoverished 
women who live in a male dominated society may be at a significantly higher risk for HIV 
than are their peers who do not live in such a society.  
1.4 Importance of HIV testing 
Public HIV antibody testing started in 1985 and two years later, was expanded. This 
expansion included the development of voluntary counseling and testing (VCT) guidelines, 
due to the new treatment discovery (i.e., Retrovir [AZT, Zidovudine]), which was approved 
by the FDA and offered to those individuals who tested positive for HIV (Cichocki, 2010). 
As such, since treatment has become available, it is standard procedure to offer VCT to any 
person seeking HIV testing. This allows for persons testing positive for HIV to learn how to 
modify their behavior to reduce the risk of HIV transmission to others; as well as providing 
the linkage medical care and services that further reduce morbidity, mortality, and improve 
quality of life. Today, HIV testing is almost standard operating procedure in all of the 
following: urgent care clinics, inpatient services, substance abuse treatment clinics, public 
health clinics, community clinics, correctional health-care facilities, and primary care 
settings. Conventional tests such as the ELISA antibody test take up to a week to complete, 
which lessens the likelihood that patients return for the results. In addition to the lengthy 
process for awaiting results, other barriers include fear of the testing results, denial that they 
have been exposed to HIV, an assumption that they are HIV-negative, the ramifications of 
an HIV-positive result, ignorance about treatment, fear of discrimination, and perceived 
stigma (Galvin et al., 2000).  
1.5 Introduction to rapid HIV testing 
Initially, conventional tests such as the ELISA and Western Blot tests were the gold standard 
of HIV testing. Conventional tests still play a vital role in HIV testing but current rapid HIV 
testing provides a less intrusive modality for determining a person’s HIV status. However, it 
is recommended that a positive rapid HIV test result be followed up  with confirmatory 
testing, such as the ELISA and Western Blot as described above because it is believed that 
confirmatory blood testing with more sophisticated testing algorithms are more accurate. 
Recommendations for HIV testing in health care settings, published by the Centers for 
Disease Control and Prevention (CDC), have led to increased rapid HIV testing in a variety 
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of settings including emergency departments (Haukoos et al., 2011). In 2003, CDC 
introduced an initiative to reduce barriers to early diagnosis of HIV infection and increase 
access to treatment and prevention services entitled, “Advancing HIV Prevention: New 
Strategies for a Changing Epidemic” (AHP). The initiative placed an emphasis on offering 
routine HIV testing as part of the medical visit. It also highlighted the importance of using 
rapid HIV tests to facilitate access to early diagnosis in high prevalence areas (CDC, 2003; 
Greenwald et al., 2006). The initiative promotes four strategies: (1) make HIV testing a 
routine part of medical care; (2) prevent new infections by working with persons diagnosed 
with HIV and their partners; (3) further decrease mother-to-child HIV transmission; and, (4) 
implement new models for diagnosing HIV infections outside medical settings. In 
particular, the latter strategy funded new demonstration projects using OraQuick® to 
increase access to early diagnosis and referral for treatment and prevention services in high-
HIV prevalence settings. It created new prospects for expanding HIV testing to identify and 
treat HIV-infected persons earlier in the progression of the disease than ever before.  
Rapid HIV tests can provide results in as little as 10 minutes, depending on the test. Persons 
receiving reactive test results from the initial testing visit are left with information indicative 
that they are highly likely to be seropositive compared with receiving no test information at 
the end of the visit where a conventional HIV test specimen was collected (Greenwald et al., 
2006). The five FDA-approved rapid HIV tests include OraQuick Advance Rapid HIV-1/2 
Antibody Test (finger prick; venipuncture whole blood, serum, plasma; oral fluid); Reveal 
Rapid HIV-1 Antibody Test (serum, plasma); Uni-Gold Recombigen HIV Test (serum, 
plasma, venipuncture whole blood); Multispot HIV-1/HIV-2 Rapid Test (serum, plasma) 
(Kaiser Foundation, 2005) and Clearview 1/2 Stat-Pak and Clearview Complete HIV ½ 
(Whole blood, serum/plasma) (Pacific AIDS Education and Training Center, 2009). 
Similar to conventional HIV tests, reactive rapid HIV tests require confirmation. Among all 
rapid HIV tests, the commonalities include the process in which the tests functions (i.e., 
visual interpretation, lack of instrumentation, and affixation of HIV antigens to the test strip 
or membrane), the periodic use of external controls (i.e., known HIV-positive and -negative 
specimens), the use of product information sheets that are provided to the patients, and 
confirmation by a more specific assay (Western Blot or immunofluorescent assay) for 
reactive results (Greenwald et al., 2006). 
1.6 Participant satisfaction with rapid HIV testing 
There are tremendous advantages to using rapid HIV testing, as discussed earlier, compared 
to conventional HIV tests. Patient satisfaction has played an integral role to sustaining the 
implementation of CDC’s recommended HIV screening for patients in all health care 
settings. It enhances that: (1) patients with newly identified infection learn the importance of 
seeking immediate care; and (2) patients at high risk of infection continue to be open to 
appropriate retesting (Donnell-Fink et al., 2011). Thus, a number of studies have been 
conducted to determine patient satisfaction with rapid HIV testing in a variety of settings 
and programs.  
One of the earliest studies was conducted by Spielberg et al. (2003). A survey of elicited 
testing motivators, barriers, and preferences for new strategies was administered to a 
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HIV prevalence settings. It created new prospects for expanding HIV testing to identify and 
treat HIV-infected persons earlier in the progression of the disease than ever before.  
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receiving reactive test results from the initial testing visit are left with information indicative 
that they are highly likely to be seropositive compared with receiving no test information at 
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confirmation by a more specific assay (Western Blot or immunofluorescent assay) for 
reactive results (Greenwald et al., 2006). 
1.6 Participant satisfaction with rapid HIV testing 
There are tremendous advantages to using rapid HIV testing, as discussed earlier, compared 
to conventional HIV tests. Patient satisfaction has played an integral role to sustaining the 
implementation of CDC’s recommended HIV screening for patients in all health care 
settings. It enhances that: (1) patients with newly identified infection learn the importance of 
seeking immediate care; and (2) patients at high risk of infection continue to be open to 
appropriate retesting (Donnell-Fink et al., 2011). Thus, a number of studies have been 
conducted to determine patient satisfaction with rapid HIV testing in a variety of settings 
and programs.  
One of the earliest studies was conducted by Spielberg et al. (2003). A survey of elicited 
testing motivators, barriers, and preferences for new strategies was administered to a 





who have sex with men, and a sexually transmitted disease clinic. It was found that most of 
the participants preferred rapid testing strategies (clinic-based and home self-testing). 
Two years later, Spielberg et al. (2005) did further research to show that rapid HIV testing is 
overwhelmingly preferred by people seeking to know their status. In a randomized study 
involving the selection of alternative HIV counseling and testing approaches based on the 
results of focus groups and interviews, a preference survey administered to clients at the 
three study sites in Seattle (i.e., a needle exchange program and two bathhouses frequented 
by MSM), found that in outreach settings, alternative HIV counseling and testing strategies 
help to maximize the number of clients who learn their HIV test results. Furthermore, it was 
found that traditional HIV testing with standard counseling was least effective at providing 
clients with knowledge of their HIV status. Significantly more participants chose to learn 
their HIV serostatus based on a variety of advantages that included offering a combination 
of rapid oral fluid testing with written pretest materials. This proved the best way to 
increase the number of persons who learn their HIV status.  
Antonio-Gaddy (2006) initiated a study at 61 HIV testing sites in New York State, comparing 
HIV test use during the first 6 months of rapid testing in 2003 with the same time period in 
2002. Surveys were administered to clients at each site during the first 30 days of rapid 
testing and to counselors before and after training--and after 12 weeks of using rapid tests in 
the field. It was found that participants preferred finger-stick blood rapid tests (96.5%) over 
conventional HIV testing by drawing blood intravenously primarily because of the ability to 
get same-day results and a dislike of needles. Additionally, counselors reported increased 
self-efficacy or the perceived ability to administer the rapid test, and a heightened level of 
comfortableness in administering rapid HIV testing.  
Donnell-Fink et al. (2011) surveyed 1,616 participants in the Universal Screening for HIV 
Infection in the Emergency Room (USHER) randomized controlled trial on patient 
satisfaction. The survey questions focused on overall satisfaction with emergency 
department (ED) visit, time spent on primary medical problem, time spent on HIV testing, 
and test provider’s ability to answer HIV-related questions using a four-point Likert scale, 
ranging from very dissatisfied to very satisfied (defined as optimal satisfaction). It was 
found that, overall, 1,478 (91.5%) were very satisfied. These were the factors associated with 
less optimal satisfaction: reactive test result, aged 60 years or older, black race, 
Hispanic/Latino ethnicity, and testing by ED provider instead of HIV counselor.  
Collectively, the abovementioned studies show that rapid HIV testing is in sync with CDC’s 
recommendation for routine HIV screening and contributes to an increase in routine testing 
in health care settings around the world. The factors associated with patient satisfaction are 
important.  
1.7 Challenges of rapid HIV testing 
Essentially, rapid HIV tests are screening tests that require confirmation by Western Blot or 
Immunofluorescence antibody, which are more specific assays. Consequently, a reactive or 
positive test result is considered a preliminary positive. Though highly unlikely ( 2%), false-
positives do occur with rapid HIV testing, at slightly higher rates than the confirmatory 
testing, mainly as a result of medical conditions such as Hepatitis A and B viruses 
(Greenwald et al., 2006). 
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Over the past few years, several studies have been done to examine sensitivity and 
specificity issues associated with rapid HIV tests. Tests that require the use of oral fluid, 
such as OraQuick, have been found to be most at risk of false positives. Delaney et al., (2006) 
compared the accuracy of the rapid test performed on whole blood and oral fluid specimens 
with the results of conventional HIV tests by using four separate studies, in which all 
participants were provided oral fluid,  fingerstick or anticoagulated whole blood specimens 
for testing with OraQuick (on both oral fluid and whole blood). Though it was found that 
the OraQuick test demonstrated high sensitivity and specificity for HIV antibody with both 
whole blood and oral fluid specimens, OraQuick sensitivity (99.1% vs. 99.6%) and specificity 
(99.6% vs. 99.7%) were lower with oral fluid than with whole blood. This small amount of 
difference becomes important with dealing with large populations tested.  
A study published in Morbidity and Mortality Weekly Report (CDC, 2008) was published that 
focused on an increase in false-positives in New York clinics using oral fluid rapid tests. 
There were two periods of significant increases in false-positive test results over a four year 
span. Several months after the first increase in false-positive test results during late 2005, 
oral fluid testing in clinics was suspended (3 weeks) and replaced with finger-stick whole-
blood rapid testing, which produced no false-positive test results.  After the second increase 
in November 2007, the New York City Department of Health and Mental Hygiene halted all 
oral fluid testing in favor of finger-stick whole blood specimens. However ultimately, the 
performance of oral fluid rapid tests still exceeded the Food and Drug Administration’s 
minimum threshold of 98.0% specificity and, the authors that use of oral rapid tests makes 
HIV testing possible in many venues where performing phlebotomy or finger sticks is 
impractical for screening.  
1.8 Impact of cultural differences on HIV rapid testing 
It is reasonable to assume that the knowledge, beliefs, and attitudes about HIV testing are 
similar among all cultures. Persons living with HIV are stigmatized, ostracized, stereotyped, 
and shunned, regardless of the culture. The attitudes toward HIV testing appear to be 
slightly different. The failure to use HIV testing services by significant numbers of 
individuals at risk for HIV can be attributed to a number of factors, both on an individual as 
well as a societal level. Research has shown that the reasons high-risk Americans avoid HIV 
testing include fear of learning they are HIV-positive, belief that they are unlikely to have 
been exposed to HIV, belief that they are HIV-negative, the possibility of being HIV-
positive, the assumption that there is little they can do about being HIV-positive, perceived 
stigma, and fear (Galvin, 2000; Samet, 1997). 
It appears that the aforementioned reasons are not necessarily the same for other countries. 
Peltzer et al. (2004) sought to determine the attitudes of HIV testing and determinants of 
attitudes toward persons living with HIV (PLWH) among 600 first-year university students 
from South India, South Africa and America--vis-à-vis a self-administered questionnaire. It 
was found that American students had much more positive attitudes toward HIV testing 
than South African and Indian students. Statistical analyses showed that attitudes toward 
HIV testing were correlated, for instance, with contact readiness, which refers to the degree 
to which a person is ready to be within close proximity of a person living with HIV 
(PLWHs). Positive HIV testing attitudes were positively correlated with contact readiness 
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In the Caribbean, culture has played and continues to play a large role in HIV testing 
acceptance, including rapid HIV testing (Coggins, 2007). One particular aspect is that of 
conspiracy beliefs among African Americans and Caribbean residents alike. Many members 
of these populations believe that HIV/AIDS is a form of genocide against Blacks, while 
others feel that a cure for AIDS exists, but is being withheld from the poor. Also, a 
significant proportion subscribes to the beliefs that HIV/AIDS treatment professionals use 
people (especially minority and poor persons) as guinea pigs for the government and lastly, 
that AIDS is a man-made virus developed specifically targeting minority persons. These 
views are especially prominent within the Black community.  
In sum, there are notable individual and social cultural differences in the implementation 
and acceptability of HIV rapid testing. Across all cultures, it is undeniable that HIV rapid 
testing has expanded testing opportunities in both developed and underdeveloped 
countries. Even as some countries continue to struggle with meager resources, feeble 
laboratory infrastructure, a dearth of skilled phlebotomists and technicians, and weak 
courier networks, HIV rapid testing is becoming more routine for high risk individuals 
(Scott et al., 2009). 
1.9 New approaches in HIV rapid testing 
Over the past decade, three landmark events have impacted the landscape of HIV rapid 
testing: the licensing of the first HIV rapid test approved for use with finger-stick whole 
blood specimens (which occurred in March 2004), the CDC's HIV prevention initiative to 
increase opportunities for HIV testing; and, publication of the CDC recommendations for 
routine screening for HIV in medical care settings. During the past few years, advances in 
HIV testing have resulted in the development of new strategies to increase the number of 
persons getting tested for HIV. These advances include the integration of HIV rapid testing 
in emergency departments, implementation of computer-assisted HIV rapid testing, and the 
use of electronic media to introduce HIV rapid testing to adolescents (CDC, 2007; Merchant 
et al., 2011; Calderon et al., 2011). Emergency departments (EDs) have been one of the 
leading venues for implementing innovative strategies to increase the uptake, feasibility and 
cost per outcome in HIV testing (Prabhu et al., 2011; Hutchinson et al., 2011). Despite the 
CDC’s efforts to promote opt-out HIV screening in all EDs, it remains unavailable in several 
states. Psychosocial, behavioral and structural supports must be added to the HIV testing 
process to improve the chances of getting people tested. Merchant et al. (2011) made an 
unsuccessful attempt to use an audio computer-delivered tailored feedback intervention to 
determine if there were increases in ED patient uptake of opt-in, non-targeted rapid HIV 
screening. Though the intervention was not found to increase uptake in HIV testing, it 
showed that the belief of not being at risk for HIV (37.1%) was the most common reason for 
declining HIV screening, and the most common reason for accepting HIV screening was the 
convenience of being tested in the ED (36.8%). Moreover, it was determined that uptake is 
greater among patients who report more HIV risk and among those whose self-perceived 
HIV risk increases from baseline after completion of an HIV risk assessment.  
With Apple surging past Exxon in August 2011 as the world’s most valuable company, it 
has become clear that the most rewarding innovation is now social innovation and 
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production that takes place on the internet. Most of what has been explored to date in HIV 
prevention research is limited to the use of mobile technologies as mediums for information 
dissemination, social marketing, or medication adherence. While there is some emerging 
evidence of efficacy for mobile-based HIV interventions (Swendeman & Rotheram-Borus, 
2010), the new media of Web 2.0 is just beginning to be explored by HIV behavioral 
researchers (Bull et al., 2011; Gilliam et al., 2011). New media is defined on the AIDS.gov 
gateway as internet-based communication that is interactive, involving content that may be 
co-created and information that may be collaboratively produced on an array of digital 
devices. New media tools include blogs, social network sites like Facebook and Twitter, 
mashups, video sharing sites like Youtube, virtual worlds like Second Life, webcasts and 
webinars, RSS feeds and social bookmarking, wikis, podcasts, texting and mobile 
communication, and photo sharing sites like Flickr (see http://aids.gov/using-new-
media/tools/).  There are indications that social networking media could be an effective 
modality to removing barriers to HIV testing and reducing stigma. Calderon et al. (2011) 
compared the effectiveness of a youth-friendly HIV video with in-person counseling in 
conveying HIV knowledge and obtaining consent for HIV testing among adolescent patients 
of an urban ED using a convenience sample of 200 stable, sexually active people aged 15 to 21 
years in an urban EDs. The results indicate that a youth-friendly HIV educational video 
improved adolescents' HIV knowledge and increased their participation in HIV testing more 
than in-person counseling. This finding is consistent with other research, including a recent 
meta-analysis showing that effect sizes on HIV risk indicators are similar to human-delivered 
interventions among 12 randomized controlled trials of internet or computer-based HIV risk 
reduction interventions (Noar,  et. al., 2009; Swendeman & Rotheram-Borus, 2010).  
An ongoing study funded by the National Institute of Nursing Research may be the first of 
its kind to investigate the efficacy of social media as a delivery portal for HIV prevention 
(Bull et al., 2011; Gilliam et al., 2011). Entitled the Just/Us study, the project involves a 
randomized trial of a Facebook intervention for youth of color. The visualization of HIV-
related metrics using the internet has the potential to engage individuals outside the 
boundaries of traditional health care delivery and social services. The MIT Media Lab 
recently instituted a new research group, New Media Medicine, to discover and implement 
new approaches in this area. One innovation involves internet-delivered visualization of 
antiretroviral drug activity at the cellular level based on an individual’s lab monitoring 
(Moss, 2011). This technology is designed to be an HIV medication adherence tool, shared 
between the patient and his provider.  
Initiatives to increase uptake of HIV testing across various settings are continuing to be 
implemented by local, state, and the federal government. In 2007, the CDC expanded 
funding to 25 health departments in the Expanded HIV Testing Initiative, to enhance the 
obtainability and accessibility of HIV testing services, facilitate adoption of HIV screening in 
health-care settings, and increase identification of undiagnosed HIV infection in populations 
disproportionately affected by HIV (Vaill, et. al., 2011). This initiative has been enhanced to 
reflect key aspects of the new White House National HIV/AIDS HIV Prevention Strategy. 
Pivotal to the national strategy is to view HIV testing as the first step in what is frequently 
described as a treatment or engagement cascade. This cascade is a series of activities that are 
developed to make persons aware of their HIV status to linking them with care as well as 
adhering to their medication regime. They must be followed in sequential order to be 
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1.10 The role of rapid HIV testing in addressing HIV-related health disparities 
The Department of Health and Human Services’ Healthy People 2020 defines a health 
disparity as a particular type of health difference that is closely linked with social or 
economic disadvantage. Health disparities adversely affect groups of people who have 
experienced greater social or economic obstacles to health based on their racial or ethnic 
group, religion, socioeconomic status, ender, mental health, cognitive, sensory, or physical 
disability, sexual orientation, geography, or other characteristics historically linked to 
discrimination or exclusion. as the differences that occur by gender, race or ethnicity, 
education or income, disability, geographic location, or sexual orientation (U.S. Department 
of Health and Human Services, 2011). 
In 2002, Smedley, Smith, and Nelson published a report entitled, “Unequal Treatment: 
Confronting Racial and Ethnic Disparities in Healthcare”. The purpose of the report was to 
examine how bias, prejudice, and stereotyping contribute to unequal health care treatment. 
Among numerous findings, it was determined that there two sets of factors that contributed 
to disparities in health care. The first set of factors includes the operation of the healthcare 
systems and the legal and regulatory climate, in which they operate are significant. The 
second set of factors is the result of a confluence of three mechanisms: (1) bias (or prejudice) 
against minorities; (2) greater clinical uncertainty when interacting with minority patients; 
and (3) beliefs (or stereotypes) held by the provider about the behavior or health of 
minorities. 
Minority populations typically experience higher rates of morbidity and mortality for 
conditions such as diabetes, cardiovascular disease, some forms of cancer and HIV/AIDS 
(CDC, 2005). In communities of lower socioeconomic status, the residents (i.e., gay men, 
drug users, prisoners and formerly incarcerated persons, the homeless, and those who suffer 
from a variety of mental health disabilities) are further marginalized by higher rates of HIV-
related morbidity and mortality (NMAC, 2006). 
CDC and other federal agencies have made tremendous strides to address health disparities 
in the incidence of HIV/AIDS. This has been done by prioritizing several issues: 1) 
enhancing and improving partnerships; 2) increasing screening and testing for diseases in 
populations with known health disparities; 3) adopting an integrated service model to 
improve health care delivery; 4) improving monitoring through the enhancement of current 
data systems and the development of new systems; and, 5) adopting new diagnostic, 
treatment, and prevention technologies (Steele et al., 2007).  
CDC’s 2003 “Advancing HIV Prevention” initiative focused on HIV prevention by 
emphasizing increased HIV testing. A number of years later, the revised recommendations 
for HIV testing incorporated routine opt-out HIV screening guidelines for all patients ages 
13–64 in medical settings, regardless of their HIV risk. This was a considerable effort to 
reduce barriers to testing by eliminating previous requirements to accompany each HIV test 
with pretest counseling and separate written informed consent (CDC, 2006).  
This initiative expanded rapid HIV testing efforts considerably. There are barriers (i.e., 
conflicting guidelines among federal agencies, problems with insurance coverage of routine 
testing, low reimbursement rates for HIV testing, and lack of programs that support 
clinician education and training in HIV testing) that impact the expansion of HIV testing. 
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However, as technology advances, new strategies are being developed that will promote 
expanded HIV testing,  Expanding programs to notify partners of HIV-positive individuals, 
linking HIV testing with other health care and social services, and mounting media and 
social network outreach efforts are all facilitators to HIV testing, as outlined by Institute of 
Medicine (2011). Particularly, rapid HIV tests continue to be the preferred modality of 
testing by participants because the results are immediate and help reduce the number of 
people who fail to receive their test results.  Rapid testing affords the opportunity of 
underserved individuals, including racial/ethnic minorities) to receive HIV testing at their 
home or outside of a clinic setting. Increasing the HIV testing among members of this 
disproportionately affected population addresses one of the top 20 priorities as outlined in 
Healthy People 2020 (U.S. Department of Health and Human Services, 2011). Identifying 
persons who are HIV-infected and unaware of their status can lead to increasing access to 
care and improving health outcomes for people living with HIV, which includes a decrease 
in HIV-related morbidity and mortality and a better quality of life in general. This, in turns, 
decreases HIV-related health disparities that currently exist among members of this 
population.  
2. A discussion of Proyecto MUCHAS, an HIV-testing outreach project 
2.1 The inception of Proyecto MUCHAS 
This part of the chapter will describe the development of the HIV testing outreach project 
targeting impoverished female residents living in public housing developments (PuHD) in 
Ponce, Puerto Rico (PR) entitled Proyecto MUCHAS. The idea for working with women 
unfolded in 2005, when the principal investigator (LR Norman) relocated to Ponce, PR and 
assumed her post at the Ponce School of Medicine and Health Sciences. In reviewing the 
literature of HIV preventions that had been implemented with certain sub-populations in PR, 
it was determined that heterosexual women, especially those impoverished, had been basically 
ignored. Only one study that targeted this population was found and it was conducted close to 
20 years ago (Hunt, et. al., 1993). Therefore, based on previous knowledge of the increased 
risks that exist among members of this population documented in published research with 
U.S. samples, it was decided to target this population for research.  
Seed money came from the Puerto Rico Comprehensive Center for HIV Disparities (PR-
CCHD, NCRR Grant # U54RR19507) to conduct a two-year formative research project, 
which did not include HIV testing. It was started by going to the PuHD administration and 
getting permission and their support for research. The research team then met with the 
individual administrative staff at each of the PuHD we targeted during this phase (n=23 out 
of 25 that are managed by Machuca and Associates).  
The team also decided it was important to come up with a name and a logo for the project, 
which would be recognizable to residents of PuHDs. The project’s name became Proyecto 
MUCHAS, which stands for Proyecto – Mujeres United Combatiendo – Alerta Social. This 
translates into the English phrase: “Women Fighting HIV: Social Alert.”  Along with it, a 
logo was devised so that when residents see this acronym and the logo, they know it is 
associated with this research project (see Figure 1 below). 
In addition, the research team also developed a web-page on the school’s website  
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Fig. 1. Proyecto MUCHAS Logo 
http://www.psm.edu/MUCHAS/index.htm. Lastly, the project colors are pink (both light 
and dark) and the logo embossed onto t-shirts, which are worn by the research team 
housing on the days that HIV/STI testing is being conducted. 
Eligibility criteria included being female and a resident of the PuHD. A non-probability 
sampling approach was employed for the study (which is explained in detail below). Once a 
PuHD was selected, posters were placed up to announce that the project would be coming 
to the PuHD on a certain date and that all women were invited to come to the community 
center and participate in the study (See Figure 2 for Illustration of Flyer).  
 
Fig. 2. Flyer Posted at PuHD to Invite Residents to Participate in Proyecto MUCHAS. 
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All eligible women were invited to participate. Data were gathered between April and 
August 2006 from 1138 women in 23 various PuHDs across the city of Ponce. 
The research team then conducted four focus groups with 39 various members of the 
population at two of the large public housing developments (PuHD) (Lopez Nussa and Dr. 
Pila) to gather the formative data on their knowledge, perceived risks, attitudes, and 
behaviors related to HIV prevention. These focus groups revealed some very important 
information and the results were used to inform the development of a quantitative 
instrument. The results of the focus group have been published (Abreu, et. al., 2010). The 
instrument was piloted with a sample of 30 women in order to assess the ease of completing 
the assessment tool, to determine if the questions were easily understood, and to ensure that 
the instrument could be completed in a timely fashion. On the basis of the first piloting 
phase, revisions were made. In addition, focus groups were used to validate the instrument, 
with 10 female residents participating to review the quantitative assessment tool for 
appropriate language and content. Following the final revision, one focus group was 
conducted as a method to validate the survey instrument. It went over every question to 
make sure they were understandable and culturally appropriate. After this focus group was 
conducted some changes were made to the questionnaire and the version was finalized and 
duplicated and administered to the female residents of PuHDs. After the research team 
went through this time-consuming but very necessary protocol, the survey instrument was 
implemented to 1138 residents in the 23 PuHDs, between April and August 2006.  
Women completed the assessments in the community center room within each housing 
development. Informed consent was received from every respondent. Because of the nature 
of the questions and the possible perceived threat of addressing issues related to sexual and 
drug-using behaviors, the instrument was self-administered with no identifiers, providing 
anonymity to the respondents. Research assistants provided support for those women who 
were unable to read the questionnaire or who needed other assistance by reading the survey 
to them or completing the survey on their behalf. Each woman received $10 as 
compensation for completing the survey. All surveys were administered in Spanish. This 
survey was a baseline, formative survey, occurring before any intervention or HIV-related 
activities were provided for the residents.   
2.2 Development of Proyecto MUCHAS testing project 
2.2.1 Prevalence of HIV among women living in Puerto Rico 
Using these results and the population of Puerto Rico, as presented above, along with the 
self-reported HIV prevalence among female residents living in PuHDs, the research team 
concluded that this population was disproportionately affected by HIV.  As the percentage 
of AIDS cases among women continues to increase in Puerto Rico, it becomes imperative 
that research and prevention efforts target additional groups of women who may be at 
increased risk of HIV. 
2.2.2 Rationale for developing and implementing HIV testing out-research project 
It was self-reported data that drew the research team’s attention to the immediate necessity 
of implementing HIV testing to women who live in PuHDs (Norman, et. al., 2008). Again, as 
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prevalence among all adolescent and adult women living in Puerto Rico, according to the 
data provided by the Centers for Disease Control (CDC, 2010). As such, Pfizer 
Pharmaceuticals was approached with the data findings and they supported the project, 
awarding a two year contract to test 375 female residents of PuHDs. 
 Fortunately, by this time, the women knew who the research team was and no problems 
recruiting participants emerged. The team only had to visit four randomly selected PuHDs 
to recruit 386 women. Due to the logistics of the testing and the inability to go to the 
women’s apartments due to safety issues, the testing had to be conducted in the community 
center. However, this did not deter the women from coming and participating. The research 
team was only able test 50 women per day, so it went to each of the four randomly selected 
PuHDs two times. At the present time, only two HIV positive women (2/386 = 0.01%) have 
been identified. The research team believes that the women who were already positive are 
choosing not to come because they don’t see the benefit of being retested, even though STI 
testing (for chlamydia and gonorrhea) is offered. Consequently, the project plans to 
distribute additional information about the importance of retesting and STI testing in the 
flyers to encourage this continued participation; plans are also in place to develop 
information for male residents. This has not been done yet, but the plan is to go testing in 
the very near future to one of the largest PuHDs here in Ponce; it is one that was not visited 
during the formative research phase of the project.  
As mentioned above, men will also be invited to participate, since 11 women tested positive 
for chlamydia and one tested positive for gonorrhea (2.9% and 0.03%, respectively) 
(Norman, et. al., 2011). It is believed that the men are the vectors of the infection for these 
women and, as such, the research team needs to get them tested and referred into treatment 
as a way to prevent further transmission to the female residents of PuHD here in Puerto 
Rico.  
At this time, the team has not tested anyone using this new protocol. However, it is believed 
that the project will be successful in the continued recruitment of women as well as men in 
our project, if the previous success record is any indication. The project is currently funded 
by the RCMI program at NIH (grant # G12RR003050 awarded to the Ponce School of 
Medicine and Health Sciences from 2009-2014) to test another 375 residents of public 
housing as well as to examine the social epidemiological factors associated with the 
increased HIV/STI risk and prevalence among members of this population. 
2.2.3 Recruitment strategies used in Proyecto MUCHAS 
Initially, the recruitment strategies were not very effective. At the PuHD first visited (Lopez 
Nussa) to collect the quantitative formative data, only 15 women showed up. The research 
team had placed flyers up at the PuHD to announce the date coming. By this time, the logo 
and name were developed, as described above. Needless to say the team was very 
disappointed. However, a research assistant suggested the idea to use the PuHD’s 
megaphone to drive around the complex and let the women know the team was there, and 
to invite them to come down and participate. This resulted in approximately an additional 
75 women coming down to the community center and completing the survey. So this is the 
strategy that was used when approaching the other PuHDs, especially the large ones. A 
megaphone was purchased rather cheaply and it was very effective in the beginning to get 
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the women to come down during the day, especially at the time the novellas (Spanish soap 
opera) are being aired on the local television channels. The research team had already been 
told that this would probably be a barrier to women’s  participation. However, the number 
of women reached in five months suggests it was not a barrier. Overall, this proved the most 
effective strategy employed to recruit women into the study during the formative phase of 
the research process. An example of the effectiveness of this strategy lies in the following: 
over 200 women showed up at Dr. Pila, the largest PuHD here in Ponce, PR. The team 
actually ran out of questionnaires and had to cut off data collection even though there were 
still women who wanted to participate. By this time, word had spread throughout the 
various PuHDs, providing information about the project so that women began to recognize 
the logo and project name. As such, this resulted in the residents accepting and trusting the 
project team, and being willing to participate. As a result, data were collected from 1138 
women on the quantitative questionnaire. Using the data collected from the quantitative 
instrument, a qualitative instrument was developed to probe a bit deeper into some of the 
findings revealed from the analysis of the data set (e.g., their perception of risk, since most 
women reported being a no risk (approximately 50%)). A convenience sample was used to 
identify 150 women from various PuHDs, to ensure that there was someone from every 
PuHD that had been previously visited was included in the sample. As such, all women 
approached agreed to participate in the face-to-face interview, which took on average 
between 60 to 120 minutes to complete. 
2.3 Obstacles faced during the implementation of Proyecto MUCHAS 
The project was not without obstacles. The major obstacle faced dealt with the safety issue of 
the project team performing the research in the PuHDs. However, inner-city, low-income 
PuHDs are an appropriate and important setting for HIV/STI formative research and 
subsequent HIV risk reduction interventions. They constitute identifiable and accessible 
communities in which women at risk for HIV/STI infection can be reached. Characteristics 
of PuHDs, such as their accessibility, the potential for multiple contacts, and the formulation 
of resident-controlled intervention components, increase the likely efficacy of such HIV-
prevention programs.  
This strength, however, is directly related to the major impediment. PuHDs are well-known 
to have high rates of crime and violence, as well as illicit drug use. Puerto Rico has the 
highest murder rate in the U.S. and its territories, and 60% of those murders are linked to 
illegal drugs (Rosa, 2005). The extreme levels of drug-related crime and violence found in 
PuHDs inevitably contribute to the elevated rates of crime and violence in the overall crime 
rate in Puerto Rico (Barcelo, 2004). As such, the administration does not allow the research 
team to go to the residents’ apartments and to do the testing and data-collection in private. 
The team has to go during the day, between the hours of 10:00 a.m. and 7:00 p.m., which are 
the hours that the administration office is open.  
However, the administrative staff has been very helpful, assisting with signing women up 
and keeping order in the method of data collection, including the testing process. They are 
also able to identify any person who is not a resident of that specific PuHD but may be 
trying to participate in the study. As such, this obstacle has weakened the research design, 
by not allowing the research team to use a random design that was originally proposed. 
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trying to participate in the study. As such, this obstacle has weakened the research design, 
by not allowing the research team to use a random design that was originally proposed. 





participate. Under the circumstances, this is the best and the strongest design that can be 
employed, given the realities of the safety issues associated with being in the PuHD.  
An example of this concern is illustrated by the following: there were two homicides (both 
drug-related) that took place last year at the next scheduled site to visit and to conduct 
HIV/STI testing. Previously, a police officer at this site had expressed his concern for the 
team’s safety and he volunteered to accompany the research team around the complex. This 
offer was respectfully declined because of concern that it would dissuade participation if 
team members were accompanied by the police because of fear about informants related to 
drug use, which is very prevalent in this particular PuHD. Also, associating with the police 
in front of residents puts the team at increased risk of becoming a victim of drug-related 
violence.  
Overall, residents have been very responsive. The PI had previously conducted some 
observational research on non-injecting drug use among the residents, to present these data 
at International Harm Reduction Association Annual Meeting in Warsaw, Poland, in April 
2007. During this seven-hour observation, men openly smoked while others bought drugs. 
Yet, they made the PI feel very comfortable and safe while she was there. One of the men 
who was there was also a dealer but he trusted the PI to not ‘’narc” on him. Unfortunately, 
he was one of the victims that got shot last year.  
This acceptance and trust is vital for the success of a project like this; this also facilitates the 
willingness of residents’ acceptance of and participation in the research project. The 
residents have been very accepting and trusting, and the team wants to maintain this 
relationship. Residents recognize the project logo and name and will come down to 
participate without further use of the megaphone. The team simply puts some 
posters/flyers up at the mailbox section of the PuHD about a week or two before the site 
visit, and then when the team arrives, there are many more women waiting to be tested than 
can be completed in one day. This has been another obstacle faced, along with the 
realization that we have to work out a way to where we can test the residents in two 
consecutive days, so they do not get discouraged and are unwilling to come back. However, 
this issue has to nothing to do directly with the research project but with the disbursement 
of money from the PI’s institution. The research team is currently working with them to 
resolve this issue. 
2.4 Lessons learned from participating in Proyecto MUCHAS 
Important lessons have been learned during the development and implementation of this 
project. The most important lesson learned is that it is imperative to treat the residents with 
respect and not to be judgmental. They respect the team and the team respects them. It was 
expressed during the focus groups, which were conducted during the formative phase of 
the research project that they didn’t want someone coming over in an “Armani suit” or 
carrying a “Gucci” handbag trying to talk to them about what it is like to live in a PuHD, 
because they could not even begin to understand what these residents face and what it is 
like to be impoverished, with very limited opportunities for betterment (Abreu, et. al., 2010). 
As such, even if the team is from the Ponce School of Medicine and Health Sciences, it tries 
to treat them as equals and never pass judgment, even in light of socially undesirable 
responses (e.g., 95% of the women are unemployed, and only 11% and 22% report using 
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condoms with their last steady and non-steady sex partner) (Norman, et. al., 2010). It is 
necessary that women feel comfortable enough to share this information, in that these are 
essential characteristics that keep them in poverty as well as continuing to engage in high 
risk sexual behaviors. These behaviors include having multiple sex partners, as well as very 
low rates of condom use reported, and anal intercourse with both steady and non-steady sex 
partners. In addition, the research team asks about drug use, both a history of and current 
drug use, which is quite stigmatized, especially among women in PR-- but again, the team 
does not pass judgment on those who admit a history or current use of illicit drugs, such as 
heroin and crack-cocaine.  
The project team has also learned that these residents want to know more about HIV 
prevention and strategies to keep them safe. The PuHD administration, based on requests 
from their residents, has asked the team to prepare and deliver a knowledge and skills-
building workshop targeting toward to the PuHD residents to improve knowledge, 
attitudes, and provide skills in assessing their personal risk of contracting HIV as well as 
negotiating condom use with their sex partners. This is a positive lesson, in that these 
women have expressed not only an interest but a desire and willingness to participate in an 
intervention--if one is developed and implemented targeting them. 
In addition, it has been learned that these women have been ignored in previous HIV-
related research efforts. As mentioned above, only one study was identified that targeted 
female residents of public housing and that was almost 20 years ago (Hunt, et. al., 1993). 
These women are in dire need of HIV prevention interventions, based on their self-reported 
HIV prevalence rates being over four times of that of the general population of women of 
the same age group as well as their rates of reported high-risk behaviors. Most HIV-related 
research has focused on injecting drug use or sex work in and around the San Juan, PR area, 
especially since injecting drug use is the major mode of HIV transmission among men. 
However, heterosexual transmission is the major mode among women, constituting 
approximately two-thirds of all cases (PR Department of Health, 2011). It is an ignominy 
that no one has recognized the need of these women to receive additional HIV prevention 
interventions, including continued testing of HIV and other STIs. Residents are highly 
appreciative of the project and have become very willing to participate. The research team 
attributes most of the success of this project to date to the participants or residents who live 
in PuHDs. Without their acceptance of the team and their willingness to participate, the 
project would not have been able to reach as many women.  
3. Recommendations based on our experiences in Proyecto MUCHAS and 
other relevant research 
A number of recommendations can be made from the research team’s experience with 
Proyecto MUCHAS. The first recommendation would to treat the study population with 
respect. This is a critical element in implementing a successful HIV-testing outreach project.  
Related to this recommendation, the researchers should never be judgmental of a 
participant’s responses, even if they do report illegal or socially irresponsible behaviors. It is 
vital that participants feel comfortable providing these type of sensitive data. A second 
recommendation is that any potential research project targeting a similar population should 
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recruitment strategies are just not as effective as they need to be. When this happens, a 
researcher has to be willing to step outside their comfort zone and try something new and 
innovative, which is what the research team of Proyecto MUCHAS did, and it proved to be 
very successful. And the researchers should never assume that participants are unwilling or 
uninterested in participating in an intervention, if they believe it will  be beneficial to them. 
However, as mentioned earlier, whomever is chosen to deliver this workshop must be 
credible but also be accepted  and trusted by the participants or they will not trust any 
information that is being presented to them. The workshop coordinator/presenter must be 
willing to speak at a level that the participants can understand, as well as show empathy for 
participants who may be facing extraordinary obstacles to practicing safer sex within their 
sexual relationships. Also, the team would recommend that each research project develop a 
logo and a name that participants can associate with the project. The Proyecto MUCHAS 
project developed the logo and name before we ever conducted any data collection 
(including both the qualitative and quantitative formative data collection). Through the 
dissemination of information, it will ultimately increase participants’ acceptance and 
willingness to take part in the research project. 
4. Implications for future research using this model (Proyecto MUCHAS)  
There are a number of implications that have arisen from the experience in the development 
and implementation of Proyecto MUCHAS. First, it is important to recognize the 
vulnerability of public housing residents or low-income and impoverished persons. 
Research with female public housing residents in the U.S. provides evidence of this 
vulnerability (Sikemma, 1996; 2000). However, this project focused on prevention of HIV by 
promoting behavior change. A new paradigm has emerged, which views treatment as a 
prevention method. This new paradigm, most aggressively led by Julio Montaner, Clinical 
Director of the BC Centre for Excellence in HIV/AIDS in Vancouver, is frequently referred 
to as the Seek-Test-Treat-Retain strategy (Volkow & Montaner, 2010). The strategy has taken 
shape as multiple ecological studies emerged, showing the effectiveness of antiretroviral 
treatment in reducing HIV transmission (Anglemyer, et. al., 2011; Montaner, 2011). In May 
2011, results of an NIH-funded trial of this approach known as HPTN 052, filled important 
gaps in the evidence on efficacy (HIV Prevention Trials Network, 2011). However, it is 
important to emphasize that HIV treatment is only one of the aspects of HIV prevention 
efforts that should be targeted toward disadvantaged women. Informing a person of his/her 
HIV status is the first step. For those who test negative, they are given informational 
brochures on how to keep from contracting HIV. For those who test positive, we refer them 
to treatment, along with providing post-test counseling. This post-test counseling includes 
information on ways they can preventing transmission on to potential sex partners as well 
as how to protect themselves from re-infections. HIV prevention programs targeting this 
population must be multi-faceted, including HIV education and skills building, along with 
HIV testing and following up for treatment for those who test positive. 
The result of these developments is that there will be renewed efforts to aggressively 
implement HIV testing and retention interventions in non-traditional settings (IRIN, 2011). 
The impetus is not only the need to address significant disparities related to the HIV 
epidemic, but also the continued lack of substantive progress in the number of people aware 
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of their HIV status, and if positive, linked, and retained into care. Across the most recent 
studies, approximately one-third to one-half of the newly diagnosed do not connect to care 
in the post six month period. One in five people who are HIV positive remain unaware of 
their status in the U.S., with worse estimates for disproportionately affected populations, 
including those in developing countries (Morin, et. al., 2011). It is important to note that a 
recent CDC study documented that, similar to the developing world, the U.S. now as a 
generalized epidemic in urban poverty areas, where four to five times more ethnic 
minorities reside compared to white (Denning & DiNenno, 2010). However, it is important 
to recognize that treatment is just one aspect of future HIV transmission. It is to be included 
in a comprehensive HIV prevention program, first by testing women and informing them of 
their status. Secondly, HIV prevention information is given to women who test negative but 
continue to engage in high-risk behaviors. For those that test positive, we refer them to 
treatment, with treatment now being considered a prevention method for reasons 
mentioned above. A comprehensive, multi-faceted HIV prevention program is needed for 
female residents of public housing. 
A paradigm of early treatment is still dependent upon early detection, placing even more 
emphasis on developing innovative strategies of seek and testing and in addressing the 
acute infection period (Powers, et. al., 20111). However, despite the CDC’s nation-wide push 
to implement routine HIV testing, less than one-third of patents are offered such testing, 
even where it has been adopted; less than 70% accepted the test (Morin, et. al., 2011).  
This is why the success of Proyecto MUCHAS, is promising in utilizing a non-traditional 
setting, removing many obstacles and barriers that persons, especially impoverished 
minority ones, face. Hopefully, this is just the beginning of an HIV-testing campaign to test 
all eligible residents of PuHD’s in Ponce, PR, and eventually to those in the Southern 
Region, where approximately 17% of all reported HIV cases exist (Puerto Rico). At this time 
there are 35,000 residents who live in 73 PuHDs in the Southern region of PR, where Ponce 
is located, including women and men, adolescents and adults. There is also potential for this 
study to be replicated in other impoverished communities in PR as well as outside of PR. 
This model could be applicable with proper cultural adaptation to other countries as well, 
since subsidized or publicly provided housing is both the norm and highly understudied 
and underutilized as a venue to HIV prevention.  
4.1 HIV engagement or treatment cascade   
Another implication is related to the HIV Treatment or Engagement Cascade, which was 
referred to earlier in the chapter. The strategy of testing and treating as many HIV-positive 
individuals as possible as a primary prevention strategy has received a great deal of recent 
attention and advocacy (Dieffenbach CW, Fauci AS, 2009; Granich, et. al., 2009). Universal, 
voluntary HIV testing has been proposed to identify persons with undetected contracted 
HIV infection as well as those who are diagnosed but not receiving treatment. Once 
identified, people diagnosed with HIV should be promptly entered into care and 
encouraged to initiate and maintain ART regimens to produce viral suppression. In addition 
to the personal health benefits derived from early HIV identification and treatment, ART 
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disease transmission from infected persons to their sexual partners (Quinn, et. al., 2000; 
Velasco-Hernandez, Gershengorn HB, Blower SM 2002). Consequently, universal and 
voluntary HIV testing and antiretroviral treatment of people with HIV is seen as a 
promising strategy for reducing infectivity and lessening the likelihood of disease 
transmission (Dieffenbach CW, Fauci AS, 2009; Granich, et. al., 2009).  Again, this highlights 
the importance of testing members of a potentially high-risk of HIV.  As such, using Proyecto 
MUCHAS as a model for developing a research project for reaching these impoverished 
persons may provide the data needed to move HIV-positive participants through the stages 
of the engagement cascade (Gardner, et. al., 2011). See Figure 3 below for a graphic 







Fig. 3. HIV Engagement Cascade Flowchart  
If you notice, HIV testing and diagnosis is highlighted in red, as an indication of its 
importance in the cascade.  
Without HIV testing and informing persons of their status, no further progression can be 
made with respect to the cascade. HIV testing is the first and can be argued to be the most 
important step in getting HIV-infected patients linked to and retained in appropriate HIV 
care and treatment.  
- Decreased morbidity and 
mortality associated with HIV 
- Better quality of life for persons 
living with HIV 
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Fig. 3. HIV Engagement Cascade Flowchart  
If you notice, HIV testing and diagnosis is highlighted in red, as an indication of its 
importance in the cascade.  
Without HIV testing and informing persons of their status, no further progression can be 
made with respect to the cascade. HIV testing is the first and can be argued to be the most 
important step in getting HIV-infected patients linked to and retained in appropriate HIV 
care and treatment.  
- Decreased morbidity and 
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- Better quality of life for persons 
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1. Introduction 
Mother-to-child transmission (MTCT) of HIV is a global problem. Annually, MTCT accounts 
for almost two-thirds of the new infections that occur in children world-wide. Each year, at 
least 2 million women become infected with HIV, mainly as a result of heterosexual 
transmission, and approximately 750 000 children acquire HIV infection, mostly through 
MTCT. MTCT varies widely and is dependent on obstetric practices, mode of delivery, 
breastfeeding, and the mother’s level of the viral load. (Moodley and Moodley 2005; 
UNAIDS, 2004). HIV is transmitted from mother-to-child at various stages of pregnancy 
including in utero, intrapartum and during breastfeeding. Untreated 20-40% of infants born 
to HIV infected mothers will be infected as well, whereas a combination of antiretroviral 
therapy during pregnancy, elective caesarean section and bottle feeding reduce the risk of 
vertical transmission to below 2% (Newell, 2006).  
There are over 42 million people living with HIV/AIDS worldwide, 38.6 million of these are 
adults, 19.2 million are women and 3.2 million are children aged below 15. A total of over 3 
million people have already died of HIV/AIDS related illness. More than 90% of people 
living with HIV are in developing countries, with sub-Saharan Africa accounting for two 
thirds of all the HIV-infected people in the world (AMN, 2005; UNAIDS, 2004). As the virus 
is predominantly transmitted through sexual contact, equal numbers of males and females 
are infected, mainly young people of reproductive age. Hence, there is a growing number of 
HIV positive children infected during pregnancy, delivery or through breast milk. The 
interventions have therefore, been aimed at effectively providing alternatives to 
breastfeeding and limiting the risk of newborn infection. Some of the interventions that limit 
MTCT are using caesarian section as the mode of delivery and administering antiretroviral 
(ARV) drugs prepartum and peripartum. However, these approaches are not always 
possible in developing countries and the use of ARV drugs, in particular nevirapine (NVP), 
zidovudine (ZDV) and zidovudine/lamivudine, have been investigated in both developing 
and developed countries (Giaquito et al., 2006).  Although the available methods of 
interventions are widely used in the industrialized world, implementation seems difficult in 
developing countries because of political, financial, logical and societal factors. Screening of 
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and stigmatization, and has to be put in the balance of programmes aiming at reducing the 
number of infected children.  
Malawi's HIV infection rate is estimated to be at least 14% among the adult population aged 
between 15 – 49 (MDHS, 2004). Over 70% of hospital beds in Malawi are occupied by people 
with HIV/AIDS related conditions. Survey of tuberculosis (TB) patients has revealed that 
over 70% are co-infected with HIV. Life expectancy which was estimated to have been over 
55 years without AIDS has now come down to 42 for men and 41 for women with AIDS 
(UNAIDS 2006). Of the people infected with HIV virus, women and children are more 
infected than men. It is estimated that HIV prevalence among pregnant women may be 
between 19 and 30 percent (Baylor aids, 2005).  
PMTCT programmes continue to be a priority as MTCT accounts for 30 percent of all new 
infections in Malawi and is the second major mode of transmission after unprotected sex. 
Every year, an estimated 30,000 babies are born HIV positive. It was for this reason that in 
2001, Malawi initiated 3 PMTCT sites and in 2003, the launching was done. PMTCT 
programmes are being implemented by every district in Malawi and by end of 2005, PMTCT 
services were being implemented in 36 sites (Buhendwa, 2003). Relatively simple 
interventions to lower the risk of infection are available to only a small number of women 
and lag far behind the country's antiretroviral therapy (ART) programme, which now 
reaches 70,000 HIV-infected people or about 40 percent of those who need them. In 2005, 
5,054 women received NVP, an ARV drug that lowers the chances of a mother infecting her 
baby by up to 40 percent. This was almost twice the number who received the drug in 2004 
but in reality there is less total number of pregnant women in Malawi who accessed PMTCT 
services so far as more pregnant mothers continue to be infected (IRIN, 2007). 
With the introduction of opt-out strategy in the PMTCT programme, most antenatal 
mothers fail to access the services as required due to problems. Women feared 
transportation and supplementary food costs, referral hospitals’ reputation for being 
unfriendly and confusing and difficulties in sustaining long-term treatment would limit 
accessibility. Fear of stigma framed all concerns, posing challenges for contacting referrals 
who did not want their status disclosed (Mshana et al., 2006). The problems that limit 
women to access the PMTCT services can be minimized if they hold dialogue with their 
spouses before HIV testing. This is because as they accept HIV testing, some women decide 
not to inform their spouses when tested in the absence of the male spouse. Male 
involvement and couple counseling have been advocated as having a positive influence on 
the women’s accessibility to the PMTCT services (Homsy et al., 2006). 
A single dose of NVP given to the mother at the onset of labour and to the baby within 72 
hours after delivery reduces HIV transmission rates by 38-50% and is relatively cheap and 
easy to administer (Avert.org. 2005; Lallemant et al., 2004; Halkin et al., 2005, Scarlatti, 2004). 
While this is an opportunity to provide infected mothers with the ART, there is also need for 
mothers to know and accept their situation.  
Not all antenatal mothers in the Malamulo Hospital catchment area access maternal services 
at the hospital. Some of them continue to access delivery services at the traditional birth 
attendants (TBAs) despite attending antenatal services. More emphasis is put on the women 
to understand their situation and access PMTCT services but PMTCT coverage continues to 
be low. Not much is reported about the perceptions and factors of the service providers and 
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communities hindering antenatal mothers from accessing PMTCT services. Therefore, the 
study aimed at exploring barriers and promoting factors to delivery of PMTCT services as 
perceived by service providers and community members. The findings would be useful in 
providing the basis for understanding women’s situations and be able to provide them with 
the needed support in order to increase accessibility of PMTCT services and reduce MTCT.  
2. Methods 
2.1 Study design 
Qualitative study using focus group discussions (FGDs), part of wider operations of 
HIV/AIDS prevention project around local introduction and scale up of PMTCT services for 
antenatal mothers.   
2.2 Study area 
Malamulo mission hospital is owned by the Seventh Day Adventist Church and is located in 
the southern region of Malawi, 65 km south east of Blantyre City in Thyolo District. It was 
established in 1902 and remains the headquarters of the Adventist Church in Malawi. The 
hospital has 15 mobile sites with 2 health centres and collaborates with other Non- 
Governmental Organizations (NGOs) including Thyolo District Hospital. The Government 
and NGOs deliver health care in Malawi. Among the NGOs, faith based institutions ran 
health facilities but are subsidized by the Government. These faith based health facilities 
belong to an organization called Christian Health Association of Malawi (CHAM). 
Malamulo hospital has a membership to this organization and the study was done within its 
catchment area. 
Malamulo runs an Integrated HIV/AIDS Prevention Project with local and external support. 
At the time when this study was done, it was largely funded by USAID through an 
international organization called Private Partners Collaborating Together (PACT). The 
components were voluntary counseling and testing (VCT), management of sexually 
transmitted infections (STIs), home based care (HBC), youth friendly health services (YFHS), 
family planning (FP), prevention of mother to child transmission (PMTCT) of HIV, ART 
provision, nutrition, static and outreach mother and child health (MCH) services.  
Thyolo is one of the districts in Malawi that receives highest rainfall annually. Tea and 
coffee estates surround Malamulo hospital. The hospital is one of the teaching institutions in 
the country for allied health workers and has 300 beds. It serves an estimated population of 
a little over 70,000. Communication is a problem due to poor roads and worsens during 
rainy season. The people’s socio-economic status in this area is low. Many of them are 
seasonal migrant workers for the tea and coffee estates. Most people are peasant farmers 
who grow maize, beans, cassava and bananas mainly for home consumption. Crop harvest 
is usually poor since most of the people are not using modern farming methods. 
Malnutrition, communicable diseases such as malaria, worm infestation, TB, diarrhea 
diseases and STIs including HIV/AIDS are common. HIV prevalence in this population is 
16% slightly higher than the national one of 14% (MDHS, 2004). Many families have 
experienced a loss of a member due to AIDS and the number of orphans is also high. 
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2.3 Malamulo hospital PMTCT Programme  
Malamulo hospital PMTCT services began in July 2004. More antenatal care (ANC) mothers 
accessing services at Malamulo tested HIV positive. Malawi Government through its Health 
Ministry assessed the hospital and determined it legible for the ART provision in the area. 
Malamulo began full ART service provision in August 2004. Over 500 people have already 
accessed ART, 200 HIV infected antenatal mothers and 100 babies have been provided with 
NVP.   
Malamulo PMTCT programme is a PMTCT plus because it supports the provision of 
specialised care to HIV-infected women namely ART, STIs, HBC, infant feeding practices 
and nutrition. It further adopts national and international standards according to World 
Health Organisation (WHO). The strategies used are primary prevention in child bearing 
age for both men and women, prevention of unwanted pregnancy, prevention of HIV 
infection from an infected mother to the child by providing NVP to them, counsel and 
support on safe infant feeding, care continuum for mother and baby. The working areas are 
antenatal, labour and delivery, postnatal and community support. 
2.4 Sampling of informants  
The informants were purposively selected based on the theoretical assumption that there 
were variations and range of perceptions by community members and service providers 
towards the delivery of Malamulo Hospital PMTCT services. The informants were in five 
groups namely: 1) men, 2) women, 3) village headmen, 4) religious leaders and 5) health 
workers. These were community members from the 15 villages that surround the hospital 
and were in their child bearing ages and beyond. Their proximity to the hospital, 
involvement in the health services and being within 15 villages from where most service 
users come including antenatal mothers made them legible to participate in the study. On 
average, participants lived at distance ranging from 5 – 15 km away from the hospital and 
for logistic reasons; it was possible to reach them at such a distance. 
2.5 Data collection  
The audio taped FGDs were conducted from October 2006 – February 2007. Appointments 
to get permission to conduct FGDs were made to the village headmen, heads of household 
and the participants before the due dates. At the time of appointments, explanations were 
made about who the researcher was, the fact that the study would help to get deeper 
understanding of their perceptions about barriers and promoting factors on the delivery of 
PMTCT services and possible benefits. A guide was used during the FGDs in an open 
conversation. It consisted of themes namely; role in pregnancy and sickness, common 
practices and norms related to pregnancy, home or hospital deliveries, antenatal and 
PMTCT services. One FGD was postponed to a later date because it was raining heavily and 
there was a function at the venue on that day.  
Two pictures showing hospital and home deliveries were used as a starter. A total of 9 FGDs 
were conducted by the author with two assistants. Of these, 2 sessions were held with each 
of the following; women, men, village headmen, religious leaders and 1 with the health 
workers. To ensure privacy, all FGDs were done in a room as per participants’ choice. The 
local school head master permitted us to use one of his school classrooms. Participants 
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anonymously agreed to start the discussions and end with prayers. The discussions were 
conducted in the afternoon to accommodate the working schedules of the participants. As 
no new information seemed to be emerging, and given the paucity of the participants who 
were willing to share openly about their perceptions towards PMTCT services, data 
collection was deemed complete after the ninth group. The FGDs lasted from 90 to 135 
minutes. Participants were served with soft drinks before returning to their homes.  
2.6 Data analysis 
Data were analyzed qualitatively using content analysis guided by Graneheim and 
Lundman (2004). The process was facilitated by use of the open code soft ware developed at 
Umeå University, Sweden (Open Code, 2007). Texts were transcribed verbatim, open 
coding, categories, properties and dimensions were made (Tables 1, 2 and 3). Based on the 
coded data and themes were developed to explain perceptions about barriers and 
promoting factors among service providers and community members on the delivery of the 
PMTCT services. 
2.7 Ethical consideration 
Consent was obtained from Malamulo Hospital Administrative Council. Chiefs and 
respondents gave their oral informed consent as well. A further permission was obtained from 
the Health Sciences Research Council in the Ministry of Health, Malawi. All the respondents 
were assured that information given would be treated with strict confidentiality. 
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Cried for self 
Health workers  
Table 1. List of open codes 
 
Beliefs HIV testing Place of delivery Role in sickness and pregnancy Suggested solutions 
Couples counseled  
Couples to be faithful  
Sex stops before delivery  
Sex resumes after delivery 
Herbs used in pregnancy 
Fisi allowed if man infertile 
Baby covered with sperms 
Sex nourishes pregnancy 
Never eat eggs in pregnancy 
Offals uneaten in pregnancy 




Tested HIV positive 
Wife took HIV test 
Husband refused  
STIs are dangerous 
Protection 
ART-benefits  
Babies free of HIV 
No medicine at home 
Unskilled TBAs 
TBAs are attentive 
Less expensive care 
Safe hospital delivery  
Distance, sudden pains
Abandoned women 
Women deliver alone 
Decision discussed 
Decision made alone 
Supportive man 
Prayed for sickness 
Sick sent to hospital 
Preparations made 
Child care 
Pregnant lady to rest 
Husband to love wife 
Church helps in kind  
Chiefs help the sick 
Patients’ care 
Promote condom use 
H/workers as models 
Team work 
Older nurses to help 
Leadership to help 
Educate communities  
Less trainees in ward 
Behavioral change  
Empower community 
 Discuss problems  
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Promote condom use 
H/workers as models 
Team work 
Older nurses to help 
Leadership to help 
Educate communities  
Less trainees in ward 
Behavioral change  
Empower community 
 Discuss problems  





Category Properties  Dimensions 
Discrimination  Extent Less or more 
Few months Extent Less or more 
Behavioral change Degree Self or others 
Disease  Degree Self or others 
Support  Origin Felt or enacted 
Responsibility Origin  Felt or enacted 
Environment Impact Partly or fully 
Table 3. Examples of categories, properties and dimensions 
3. Results 
A total of 9 FGDs were conducted with 69 participants grouped by gender, age and 
occupation. At least one member from the 15 villages that surround the hospital participated 
in the discussions. Of the 69 participants, 47 were males and 22 were females with the mean 
age of 28.5 years. Fifty six were married and thirteen were singles. The participants’ number 
of children ranged from 1 to 8 with average to low socio-economic status. The clergy 
represented Christians and Moslems and so were the participants. The participants’ 
education ranged from primary school to tertiary levels and five had none.    
Four themes about barriers and promoting factors on PMTCT services as perceived by 
service providers and community members emerged: 1) Decision: Place of delivery, 2) 
Perceptions concerning service providers at hospital and home deliveries, 3) Perceptions of 
the role of communities during pregnancy and sickness and 4) Perceptions of community 
interventions (Table 4). Decision: Place of delivery was referred to the decision maker and 
the circumstances that surrounded the place of choice for delivery. Perceptions concerning 
service providers at hospital and home deliveries was referred to the attitude and 
knowledge of the birth attendants at community and hospital levels.  
Perceptions of the role of communities during pregnancy and sickness referred to the 
responsibilities assumed by communities at different levels in taking care of pregnant 
women and the sick. Perceptions of community interventions referred to suggested 
solutions to improve service delivery and accessibility as perceived by the participants. 
Involvement of care givers and their recipients is included in this theme.    
3.1 Decision: Place of delivery 
Men decided for their pregnant wives where to deliver and to a large extent women obeyed 
their husbands’ decisions. Some informants reported that decisions were discussed between 
partners, partners and family members and in certain rare situations women decided by 
themselves. Grandmothers, mothers and friends influenced the decisions based on their past 
delivery experiences. It was mentioned that previous experiences with the health facilities 
such as ANC information, treatment in the ANC and labour ward and family support 
influenced decisions about where to deliver. A female participant explained how her 
husband decided for her where to deliver: 
“For me it is my husband who reminds me when to begin ANC.  This is because he knows my dates 
and is very good at encouraging me to go for hospital delivery. He also keeps money to meet delivery 
expenses. He buys me a piece of cloth, basin and a plastic bag among other things”. 
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Codes Categories Themes 
My decision 
Husband’s decision 
Discussed with partner 
Mother’s decision 
Grandmother’s decision   
Relative’s decision 
Friends’ decision 
Useful ANC information 
Given money by husband 
Husband-encouraging 
Safe hospital delivery 
Unsafe home delivery 
Supportive husband 
Family support 
Supportive health care system 
Tradition 
Decision: Place of delivery  
Rude nurses in labour ward 
Delivered alone in labour ward 
Female nurses –disrespecting  
Male nurses- helpful 
Polite nurses in ANC 
Women respected in ANC 
Trainee nurses-less competent 
Trainee nurses-playful  
Hospital skilled personnel   
Home-unskilled personnel 
TBAs respect women 
TBAs’ care is good  
Health workers’ supportive attitude 
Health workers’ unsupportive attitude
Health workers’ job knowledge 
 
Perceptions concerning 
service providers at hospital 
and home deliveries  
Prepared for delivery experiences 
Material and moral support 
Couples advised on norms to follow 
TBAs-important for delivery 
Traditional healers-important for sickness 









Religious perspective  
Health personnel’s views 
Perceptions of the role of 
communities during 
pregnancy and sickness   
Trainees supervised 
Health promotion 
Labour ward-full time nurse  
Leadership-important 
Approachable male nurses 
Behavioural change 
Promote condom use 
Women’ early reporting  
Good nurses rewarded 
Rude nurses reprimanded 
Trained TBAs- important  
Traditional norms complied   
Interventions at hospital level 
Interventions at community level 
Service recipients’ role 
 
Perceptions of community 
interventions  
Table 4. Themes, categories and codes 
Participants reported that hospital delivery was better because of safety as opposed to home 
delivery. Some participants felt that although home delivery was regarded as unsafe but 
was ideal for them because they got used to certain birth attendants and needed no 
preparations to access the services. It was further cited by one male participant whose wife 
had 8 home deliveries without complications that it was relatively cheap to have home 
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Participants stated that complications with home deliveries such as maternal and  
child deaths influenced women to seek hospital deliveries. Female participants with past 
hospital and home delivery experiences described home delivery area as unhygienic which 
would predispose them to infection after delivery and such situation rarely happened with 
hospital delivery. Participants’ views on where to deliver were explained in the following 
way:   
“Women deliver at home because of negligence, beliefs and lack of transport. They say if 
grandmothers had several home deliveries without complications, why bother and have specific people 
to assist them during delivery. Home delivery women with difficulties seek hospital deliveries and 
these are good examples for women in the communities to appreciate the hospital services”.  
3.2 Perceptions concerning service providers at hospital and home deliveries 
Female participants reported that nurses in the ANC were kind, polite and willing to help 
and male participants had similar impressions from their wives. Nurses in the ANC 
provided the women with adequate information on various health issues, treated women 
with respect, and motivated them to attend ANC. It was also mentioned that traditional 
birth attendants were equally good at treating women with care and respect and this 
attracted more women to them.  
Participants reported that nurses in the labour ward did not respect them, were rude, and 
shouted at women during delivery and some of them delivered alone. This situation made 
women have their deliveries at the traditional birth attendants where respect and kindness 
were shown to them regardless of regular ANC attendance. Below is the description on how 
participants viewed service providers at ANC and labour ward:  
“The antenatal care clinic is fine but difficulties are found in labour ward. As nurses conduct 
examinations in the labour ward, the way they talk it is as if they are not willing to help. In the 
antenatal care, we are free to ask questions and the nurses explain and answer most of them and 
wherever necessary, we are referred to a doctor depending on our problems”. 
Some participants expressed that male nurses were kind, respected them during delivery 
and were full time in labour ward monitoring the women until delivery: 
“Female nurses are rude in the labour ward. They often tell pregnant woman that her time for 
delivery is not yet due while it is not true. As the woman leaves the labour ward she delivers on her 
own. My wife told me and this happened to her. Male nurses behave well and assist women to deliver 
with respect, dignity and rarely women complain of them”. 
All the participants stated that service providers at the hospital had knowledge, skills, 
medications and equipment to carry out their functions in a professional way. Therefore, 
they felt that hospital delivery was safe because if something went wrong during delivery, 
women would easily be assisted. It was mentioned that birth attendants at home had little 
or no education, limited knowledge, skills and lacked equipment to carry out the delivery 
services. Some participants stated that it was mere chance that women had successful home 
deliveries and recalled several incidences where women or infants died during delivery. 
They said that women die from preventable causes from home delivery. 
Perceptions About Barriers and Promoting Factors  
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3.3 Perceptions of the role of communities during pregnancy and sickness 
All the participants stated that pregnancy needed their attention to enable women deliver 
successfully. Couples had sole responsibilities for the care and particularly the husband was 
expected to look after his pregnant wife as determined by marriage counsels. It was 
mentioned that during pregnancy, the couples were advised to follow the norms and make 
preparations for deliveries. At family level the pregnant woman was provided with basic 
needs such as food and was advised to start ANC on time. Participants viewed both 
pregnancy and sickness as events that brought all the communities together. Below is the 
participants’ common impression on sickness:  
“I take part in pregnancy and sickness. When one of my family members gets sick, I send him to the 
hospital for treatment. I do the same with anyone within my village. We use a stretcher to carry the 
sick to the hospital. We often come together as people living in the village to help carry the sick to the 
hospital. We do not leave this task with the patients’ families only”. 
People outside the families helped pregnant women especially if their families were failing 
to fulfill certain obligations such as encouraging early antenatal attendance and material 
support. The religious leaders provided the pregnant women with moral and spiritual 
support and the participants encouraged utilization of heath services during pregnancy and 
sickness. Health personnel participants stated that some young women failed to attend 
ANC because of laziness and obedience to their older women who usually encouraged 
home delivery. They further said that they were eager to see as many women in the ANC 
and delivery suits as possible to reduce maternal and infants mortality rates. 
It was mentioned that pregnancy and sickness were associated with norms and traditional 
healers or birth attendants were consulted before going to the hospital. Some traditional 
beliefs encouraged regular intake of local herbs, home delivery and discouraged antenatal 
attendants to avoid getting instructions which were difficult to follow. Pregnant women 
were disallowed to eat offals, stand or sit at the door and husbands were not allowed to put 
on neck ties or socks because such things would lead to difficulties in delivery. They were 
further discouraged from eating eggs because this would cause chronic abdominal pains. 
Coincidentally, one of the HIV infected participants shared his experiences with others in 
stressing the importance of seeking medical treatment in sickness in the following way:  
“I got sick for a long time, eaten several herbs but did not help me until the time I went to the 
hospital. I tested HIV positive and I do not hide, I tell people about this. I tell them that if they fall 
sick, they should go to the hospital. If I did not go to the hospital, by now I should have been dead. 
Today I have life and leading the normal life. I am the living example and I tell people in my village to 
first go to the hospital. If there is no improvement after going to the hospital, then they can go to the 
traditional healers”. 
On average, the participants abstained from sexual contact between 6-8 months before 
delivery and resumed it 6 months after delivery. They followed this norm to avoid 
traumatizing the infants, delivering deformed babies covered with sperms, malnutrition or 
having unwanted pregnancies. It was also reported that participants were advised to stick to 
each other if they were married and HIV negative (practice mutual faithfulness), use 
condoms if they were HIV positive or not sure of their HIV status or practice abstinence if 
they were not married to avoid contracting sexually transmitted infections and HIV/AIDS. 
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the women on mutual agreements with their husbands. The practice was called “Fisi” but 
was being discouraged nowadays due to HIV/AIDS.   
The participants expected women to be submissive to their husbands in all matters relating 
to family life. Male participants suggested that before going for HIV testing, women should 
consult their husbands as failure to do so would cause family problems. Some participants 
felt that they would go for HIV testing if they thought of being HIV infected or if they got 
sick.  
3.4 Perceptions of community interventions 
While participants mentioned the health systems’ strengths and weaknesses, also chanted 
the way forward. Some participants reported that the improvements should involve all the 
partners who came into play. They mentioned that the health facility’s leadership should 
help the service providers’ attitudinal change into a more responsive and willingness to care 
for the recipients. The participants suggested the following; health promotion, trainee 
supervision, rewarding hard working nurses, disciplining the rude nurses and 
communicating the effected changes with the communities. All participants mentioned that 
the labour ward needed much attention as other hospital departments. Participants felt that 
it was the right time to express their problems:  
“The problem is with us because we hide. When the woman is in labour, the nurses are usually not 
present. The woman delivers alone and this is the report that we often get. Here we need to correct the 
situation. We request that nurses should be able to monitor the woman who goes into labour until 
delivery”.   
The ages of the trainee nurses and how they handled women in labour ward raised concerns: 
“The problem is that some of the nurses are very young, never delivered before but have to conduct 
deliveries. They disrespect the pregnant mothers due to lack of experience. It is important that a 
qualified nurse should always guide trainee nurses so that what is done should be of high quality and 
standard”. 
The participants requested training of the traditional birth attendants (TBAs) to assist 
women who may access their services due to unavoidable circumstances such as sudden 
labour pains. Some participants felt that empowerment of local communities would help 
them to be responsible for their health issues. Participants reported that individual families 
and the women should understand the importance of accessing health care services on time. 
It was mentioned that early reporting in sickness and regular ANC attendance, hospital 
delivery and discouraging norms that were detrimental to their health would be the way 
forward. 
All participants were responsible for the sick in their communities and needed them to 
access health facility treatment on time. They further reported that they discouraged the 
tendency of seeking traditional remedy before the modern medical treatment. Health 
personnel participants felt that they needed to be role models and be able to treat their 
service users with respect and dignity. Below is their expression on this:  
“We need to be role models. Pregnant women should be given time to explain their side of the story 
and do as they wish. They should be told properly about HIV testing and allowed to decide to take the 
test or not. They should never be shouted at since pregnancy and delivery are stressful”.  
Perceptions About Barriers and Promoting Factors  




The study revealed that men largely decided for their pregnant wives where to access health 
care and delivery services. This is consistent with the conversional wisdom that men are 
dominant decision makers in matters relating to fertility (Maharaj and Cleland, 2005). This 
has several implications; it may be a male dominant society where men are decision makers 
for their families leading to women’s limitations in making independent choices for their 
lives as is the case in other societies (Santelli et al, 2006). Further, if men were unsupportive 
then their wives may be negatively affected and in certain situations, family support, 
positive health care reputations and discussions with wives influenced decisions. Women 
verified their decisions with husbands, relatives or friends and were inclined to seek home 
delivery which showed that traditional beliefs were deep rooted in this society. This may 
also suggest that women in this study were less empowered to pose as powerful predictor 
of where they would wish to deliver.  
The study showed that service providers at health facility and local levels influenced the 
community’s acceptability and accessibility of the health services including PMTCT services. 
This is an important finding and it may imply that utilization of the health service is 
dependent on how well the recipients are treated, the trust the service users have in the 
service providers and the job knowledge. However, attitude and ability to treat patients 
with dignity and respect have a great role in influencing people’s willingness to access the 
services (Mathole et al., 2005; Owens, 2005; Hilget and Gill, 2007). This may suggest that 
people seek traditional health care than modern health so long they feel welcomed and seen 
not as nuisance preventing others from resting. Interestingly, male nurses were more 
preferred than female nurses by women in the labour ward because of their dedication and 
respect they showed to the women in caring for them to deliver. This further implies that 
the long traditional culture that disregarded male nurses in delivery places is changing. 
Males are therefore equally accepted to conduct deliveries in labour ward as female nurses 
given the job knowledge and eagerness to utilize it in a dignified manner.  
Pregnancy and sickness in general seemed to be community unifying events in this study. 
Families and communities at various levels took part in alleviating human suffering. This is 
congruent with what was obtained before (Mant et. al., 2005). This has several implications; 
families prepared for pregnant outcome and this extend to the community at large where 
responsible individuals were indoctrinated with traditional ideologies coupled with modern 
health care. Primarily, pregnant women and the sick sought remedies for their ailments from 
the traditional birth attendants or traditional healers and if encountered no problems, it 
became the habit at the expense of the modern health care. This suggests an opportunity to 
instill long lasting modern health care messages which are likely to be well taken up as is the 
case with traditional beliefs provided the messages are linked with live examples of health 
benefits. Communities followed traditional norms that had no health benefits and to some 
were detrimental to their health (Banda et al., 2007; Kamatenesi-Mugisha and Oryem-Origa, 
2006). Interestingly, customs such as wife inheritance and temporal allowance of fertile men to 
sleep with women whose men were infertile through mutual agreement is dying away due to 
HIV/AIDS. This is an indication that communities understand the dangers HIV/AIDS inflicts 
upon them, hence take active roles in fighting against HIV/AIDS. 
The study has revealed that the interventions deemed important for the acceptability, 
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community’s acceptability and accessibility of the health services including PMTCT services. 
This is an important finding and it may imply that utilization of the health service is 
dependent on how well the recipients are treated, the trust the service users have in the 
service providers and the job knowledge. However, attitude and ability to treat patients 
with dignity and respect have a great role in influencing people’s willingness to access the 
services (Mathole et al., 2005; Owens, 2005; Hilget and Gill, 2007). This may suggest that 
people seek traditional health care than modern health so long they feel welcomed and seen 
not as nuisance preventing others from resting. Interestingly, male nurses were more 
preferred than female nurses by women in the labour ward because of their dedication and 
respect they showed to the women in caring for them to deliver. This further implies that 
the long traditional culture that disregarded male nurses in delivery places is changing. 
Males are therefore equally accepted to conduct deliveries in labour ward as female nurses 
given the job knowledge and eagerness to utilize it in a dignified manner.  
Pregnancy and sickness in general seemed to be community unifying events in this study. 
Families and communities at various levels took part in alleviating human suffering. This is 
congruent with what was obtained before (Mant et. al., 2005). This has several implications; 
families prepared for pregnant outcome and this extend to the community at large where 
responsible individuals were indoctrinated with traditional ideologies coupled with modern 
health care. Primarily, pregnant women and the sick sought remedies for their ailments from 
the traditional birth attendants or traditional healers and if encountered no problems, it 
became the habit at the expense of the modern health care. This suggests an opportunity to 
instill long lasting modern health care messages which are likely to be well taken up as is the 
case with traditional beliefs provided the messages are linked with live examples of health 
benefits. Communities followed traditional norms that had no health benefits and to some 
were detrimental to their health (Banda et al., 2007; Kamatenesi-Mugisha and Oryem-Origa, 
2006). Interestingly, customs such as wife inheritance and temporal allowance of fertile men to 
sleep with women whose men were infertile through mutual agreement is dying away due to 
HIV/AIDS. This is an indication that communities understand the dangers HIV/AIDS inflicts 
upon them, hence take active roles in fighting against HIV/AIDS. 
The study has revealed that the interventions deemed important for the acceptability, 





This concurs with what was found before that community involvement and participation 
are known as key elements in any given successful community projects (Loss et al., 2007; 
Bhuyan, 2004). This may be explained in that the communities see the project as “our 
project” and not “their project”. The health facility’s leadership needed to look into its 
staffing problems particularly in labour ward where women complained of the nurses. This 
implies that the hospital needs to intensify its service delivery strategies, by hiring 
competent and dedicated health workers or motivating the existing members of staff to do 
the right thing for the women and the sick at large. However, the changes made at the 
hospital should contain improved communication of the services provided to the 
community. 
The community’s willingness to step up their efforts in utilizing health care services seems 
to be dependent on their relationship with the health service providers and the 
understanding health implications. This implies that there should be a trigular type of 
relationship involving the service providers at community and health facility levels and the 
communities themselves. It was evident in this study that various stakeholders experienced 
weaknesses in themselves and health workers in particular, pledged to be role models and 
would give a different face value in their health delivery involvement. This suggests that 
there was a reflection of what actually happens in each of the key players and there is a 
possibility of a change for the better.   
It was further revealed that women should consult their husbands before undergoing HIV 
testing. This is important in that the adoption of such practice would spare women from 
experiencing problems within their families and has been supported by studies before 
(Kakimoto et al., 2007; Homsy et al., 2006). This implies that women would not fear 
disclosing their HIV status hence not bullied or beaten up by their husbands and can pave 
ways for more men to access HIV testing. This may as well facilitate family unification and 
creation of positive living within couples’ relationships while living with HIV/AIDS.    
Financial constraints, author’s hospital representation and distance to find the study 
participants were the study limitations. The study has the strength of exploring barriers and 
promoting factors to delivery of PMTCT services as perceived by service providers and 
community members. Further, inclusion of participants at various levels poses a fair 
representation of the study findings useful for service delivery improvements.   
Men were decision makers in matters relating to pregnancy and where their wives should 
deliver, service providers’ attitude and knowledge affected health care service delivery, 
pregnancy and sickness were seen as unifying events by the communities. Improved 
communication between service providers and service users were the suggested 
intervention measures. Based on these findings, we recommend training of the TBAs and 
women’s empowerment to make independent choices in matters relating to pregnancy and 
child births.   
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1. Introduction  
HIV infection remains a major public health concern in Europe, with evidence of continuing 
transmission of HIV. Surveillance data published by the European Centre for Disease 
Prevention and Control and the World Health Organization Regional Office for Europe 
indicate that, in 2009, 53 427 cases of HIV were diagnosed and reported by 49 of the 53 
countries in the WHO European Region; the rate of HIV cases diagnosed was 8.5 per 100 000 
population in this region (European Centre for Disease Prevention and Control/World 
Health Organization Regional Office for Europe [ECDC/WHO Regional Office for Europe], 
2010). Migration has been acknowledged as a factor influencing the epidemiology of HIV in 
Europe (ECDC, 2010a). In 2005, 46% of all cases of heterosexually acquired HIV infection in 
Western Europe involved migrants from high prevalence countries (ECDC, 2009). 
Portugal is one of the western European countries with the highest burden of HIV infection 
(European Centre for the Epidemiological Monitoring of AIDS [EuroHIV], 2007). Recent 
data estimates that, in 2007, Portugal presented one of the highest rates of new HIV 
diagnosis in the European Region (ECDC/WHO Regional Office for Europe, 2008). The 
epidemic has been mainly driven by injecting drug users, but recently sexually transmitted 
cases are on the rise.  
The Portuguese epidemic is of the concentrated type, i.e. prevalence within the general 
Portuguese is inferior to 1% but specific groups present a high prevalence of HIV infection 
(National Coordination for HIV/AIDS Infection, 2007). The groups considered most 
vulnerable, characterized by a more intensive and frequent exposure and by a more difficult 
access to means of prevention, include the migrants (National Coordination for HIV/AIDS 
Infection, 2007). In fact, estimates indicate that immigrants represent approximately 20% of 
Portugal’s diagnosed HIV cases, accounting for a disproportionate number of new 
heterosexually acquired infections (ECDC, 2010a).  
In the last decades, immigrants’ inflows have increased across most OECD countries 
(Organisation for Economic Co-operation and Development [OECD], 2011). Statistics on 
international migration in the European Union (EU) estimate that, in 2008, the total number 
of non-nationals (people who are not citizens of their country of residence) living on the 
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international migration in the European Union (EU) estimate that, in 2008, the total number 
of non-nationals (people who are not citizens of their country of residence) living on the 





population (Eurostat, 2010). Around two thirds of all non-nationals living in the EU were 
citizens of a third country (non-EU Member State). 
The proportion of immigrants in Portugal has also continuously increasing. According to 
recent data, the total stock of foreign population (with a valid residence permit) reached 457 
000 in 2009 (4.3% of the total population) (OECD, 2011). Most of these immigrants have 
come from Brazil, Ukraine and Cape Verde (OECD, 2011). 
Migration places populations in situations of greater risk for poor health in general and HIV in 
particular (ECDC, 2010a; WHO, 2010). The linkages between migration and HIV/Aids are 
largely related to the conditions and structures of the migration process itself, as in the 
countries of origin, transit and destination (International Organization for Migration [IOM], 
2006). In host countries specifically, factors like poverty, exploitation, lack of legal protection, 
social exclusion and discrimination may increase the risk of exposure to HIV and may reduce 
the individual's ability to protect him- or herself from infection (Fenton, 2001; Soskolne & 
Shtarkshall, 2002). Other potential risk factors for migrants include separation from families 
and partners, besides separation from the socio-cultural norms that guide behaviours in more 
stable communities. These circumstances may reinforce the adoption of risk behaviours such 
as consumption of injection drugs and sexual risk practices (Albarrán & Nyamathi, 2011). 
Additionally, immigration policies that make integration of migrants in host countries more 
difficult may have a negative impact on their health (Grove, 2006). In fact, health vulnerability 
of migrants has been associated to poor access to health care (Derose et al., 2009; Politzer et al., 
2001; Stronks et al., 2001). Barriers to health services, including legal, socioeconomic, linguistic 
and cultural constraints, may result in a reduced utilization of services, in particular for 
HIV/Aids prevention and care, which makes these groups more vulnerable to HIV and their 
related complications (Dias et al., 2004; Salama & Dondero, 2001).  
Increasing the uptake of HIV testing has been acknowledgedly an important component of 
primary and secondary prevention strategies (Burns et al., 2005; ECDC, 2010b). Timely HIV 
testing may lead to improved clinical outcomes through early diagnosis and access to 
treatment as antiretroviral therapy makes individuals less infectious (Levy et al., 2007; 
Saracino et al., 2005). Moreover, awareness of positive serostatus may prevent ongoing 
transmission of disease as it enhances individual behavioural change toward reduced risky 
sexual behaviour (Ehrlich et al., 2007; Schwarcz et al., 2006).  
Given the epidemiological situation in Portugal, national HIV prevention and control efforts 
targeted to groups most-at-risk as the migrant population have been a priority. During the 
last decade, one of the main strategies undertaken has been generalizing access to early 
detection of the infection and promotion of voluntary testing and counselling (National 
Coordination for HIV/AIDS Infection, 2007). Presently, HIV testing in Portugal is non-
mandatory and can be done anonymously, confidentially and for free at the HIV Early 
Detection and Counselling Centres.  
Despite the benefits of HIV testing upon the individual and the community, and the 
continued efforts to guarantee access to diagnosis and promote the uptake of HIV testing in 
Portugal, a high proportion of adults in this country remain so far untested (National 
Coordination for HIV/AIDS Infection, 2007). Since 2001, immigrants in Portugal are entitled 
to health care regardless of legal status, including free health care to pregnant women and 
recent mothers, users of family planning programmes and individuals with transmissible 
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diseases. Nevertheless, evidence on access and utilization of health services among migrants 
in Portugal suggests that barriers related to legal issues, economic constraints, lack of 
information of migrants on their health rights and negative attitudes of health professionals 
remain (Dias et al., 2008, 2010a). 
Knowledge on HIV testing among immigrants is limited; nevertheless, the literature 
indicates that a proportion of these groups remain undiagnosed and tend to utilize HIV 
health services at a later stage of disease (Burns et al., 2007; Delpierre et al., 2007). A growing 
body of literature indicates that factors such as socio-demographic (sex, age, country of 
origin, education, immigration status), behavioural (perceived risk for HIV, risk behaviours) 
and structural (utilization of health services) are associated with HIV testing (Bond et al., 
2005; Stein & Nyamathi, 2000; Stolte et al., 2003; Wang et al., 2010).  
Understanding such factors among immigrants may contribute to developing strategies 
designed to effectively promote HIV testing and reduce undiagnosed infection. This paper 
aims to describe the proportion of HIV testing among an immigrant population in Portugal 
and identify demographic, socioeconomic, behavioural and structural factors. 
2. Methods 
Based on a participatory approach, a cross-sectional study was conducted with a sample of 
1282 immigrants (35.7% from Portuguese-speaking African countries, 33.2% from Eastern 
European countries and 31.1% from Brazil) living in the Lisbon Metropolitan Area. This area 
has currently the highest concentration of immigrant population in the country. Official data 
indicate that, in 2010, 43% of the immigrant population in Portugal (around 189 220 
immigrants) resided in the Lisbon region (Serviço de Estrangeiros e Fronteiras, 2011).  
2.1 Sampling and data collection 
Participants were selected through snowball sampling. This sampling method was used as 
the information available on immigrant population in Portugal does not allow constructing 
sampling frames for representative population based surveys.  
Representatives of non-governmental organisations (NGOs) and associations of African, 
Brazilian and eastern European immigrants were contacted by the research team and 
invited to collaborate in the study. The investigators carried out several meetings with 
NGOs members to present the research’ main objectives and procedures and ask their 
collaboration in publicising the study within the immigrant community and in identifying 
and recruiting potential participants. The inclusion criteria were being an immigrant, 
defined as a non-national person who migrated for settlement purposes (IOM, 2004) and 
being 18 years old or older. These potential participants were personally approached and 
invited to participate by the research team. After respondents finished filling the 
questionnaire they were asked to identify and recruit within their social networks other 
possible participants who met the study criteria. 
Data was collected between May 2010 and January 2011 through a questionnaire applied in 
community based associations, governmental and non-governmental organizations working 
with immigrant populations. Data collection days were scheduled with these entities based 
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Additionally, immigration policies that make integration of migrants in host countries more 
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testing may lead to improved clinical outcomes through early diagnosis and access to 
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Coordination for HIV/AIDS Infection, 2007). Since 2001, immigrants in Portugal are entitled 
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recent mothers, users of family planning programmes and individuals with transmissible 
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diseases. Nevertheless, evidence on access and utilization of health services among migrants 
in Portugal suggests that barriers related to legal issues, economic constraints, lack of 
information of migrants on their health rights and negative attitudes of health professionals 
remain (Dias et al., 2008, 2010a). 
Knowledge on HIV testing among immigrants is limited; nevertheless, the literature 
indicates that a proportion of these groups remain undiagnosed and tend to utilize HIV 
health services at a later stage of disease (Burns et al., 2007; Delpierre et al., 2007). A growing 
body of literature indicates that factors such as socio-demographic (sex, age, country of 
origin, education, immigration status), behavioural (perceived risk for HIV, risk behaviours) 
and structural (utilization of health services) are associated with HIV testing (Bond et al., 
2005; Stein & Nyamathi, 2000; Stolte et al., 2003; Wang et al., 2010).  
Understanding such factors among immigrants may contribute to developing strategies 
designed to effectively promote HIV testing and reduce undiagnosed infection. This paper 
aims to describe the proportion of HIV testing among an immigrant population in Portugal 
and identify demographic, socioeconomic, behavioural and structural factors. 
2. Methods 
Based on a participatory approach, a cross-sectional study was conducted with a sample of 
1282 immigrants (35.7% from Portuguese-speaking African countries, 33.2% from Eastern 
European countries and 31.1% from Brazil) living in the Lisbon Metropolitan Area. This area 
has currently the highest concentration of immigrant population in the country. Official data 
indicate that, in 2010, 43% of the immigrant population in Portugal (around 189 220 
immigrants) resided in the Lisbon region (Serviço de Estrangeiros e Fronteiras, 2011).  
2.1 Sampling and data collection 
Participants were selected through snowball sampling. This sampling method was used as 
the information available on immigrant population in Portugal does not allow constructing 
sampling frames for representative population based surveys.  
Representatives of non-governmental organisations (NGOs) and associations of African, 
Brazilian and eastern European immigrants were contacted by the research team and 
invited to collaborate in the study. The investigators carried out several meetings with 
NGOs members to present the research’ main objectives and procedures and ask their 
collaboration in publicising the study within the immigrant community and in identifying 
and recruiting potential participants. The inclusion criteria were being an immigrant, 
defined as a non-national person who migrated for settlement purposes (IOM, 2004) and 
being 18 years old or older. These potential participants were personally approached and 
invited to participate by the research team. After respondents finished filling the 
questionnaire they were asked to identify and recruit within their social networks other 
possible participants who met the study criteria. 
Data was collected between May 2010 and January 2011 through a questionnaire applied in 
community based associations, governmental and non-governmental organizations working 
with immigrant populations. Data collection days were scheduled with these entities based 





under investigation, the questionnaires were administered in a quiet room, in isolation, to 
ensure privacy and comfort of participants. 
Questionnaires were applied by trained interviewers from immigrant communities, 
recruited and selected in collaboration with NGOs and immigrant associations. The 
interviewers training included information about the questionnaire, the data collection 
procedures and general interview techniques. A training manual was elaborated and 
provided to support interviewers in the field. 
The questionnaire comprised closed-ended questions on sociodemographics, self-perception 
of HIV risk, knowing someone infected, number of sexual partners in Portugal in the last 12 
months, having had a consultation on sexual and reproductive health, and HIV testing. The 
instrument of data collection was constructed along with feedback provided by partners of 
the study - community based associations, governmental and non-governmental 
organizations. After the questionnaire was developed, a pre-test was conducted with 
members of immigrant communities; few amendments were made to improve clarity of the 
questions and to make it better adapted to the study populations. 
Anonymous participation and confidentiality of data was guaranteed. Informed consent 
was obtained. The study was approved by the Ethical Committee of the Institute of Hygiene 
and Tropical Medicine, New University of Lisbon.  
2.2 Measures  
Sociodemographic characteristics included sex, age (continuous variable), origin (‘African’, 
‘Brazilian’, ‘Eastern European’), educational level (‘elementary education’, ‘secondary 
education’, ‘higher education’), immigration status (‘legal status’, ‘irregular status’). Length 
of stay was a continuous variable measured in years. 
Self-perception of HIV risk was measured using a dichotomous question on fearing to 
become infected with HIV (‘yes’/’no’). Knowing someone infected (friend or relative) had 
also two response options: ‘yes’/’no’. The number of sexual partners in Portugal in the last 
12 months was a continuous variable; for descriptive analysis, this variable was recoded into 
a three-category variable: ‘1 sexual partner’, ‘2-4 sexual partners’ and ‘≥ 5 sexual partners’. 
Having had a consultation on sexual and reproductive health, having ever been tested for 
HIV, having been tested in Portugal and having been tested in the last year were measured 
as dichotomous variables (‘yes’/’no’). 
2.3 Data analysis 
Descriptive analysis was conducted for background characteristics of participants; 
continuous variables are presented as mean ± standard deviation. The associations between 
socio-demographic characteristics, fear of becoming infected, knowing someone infected, 
number of sexual partners, having had a consultation on sexual and reproductive health, 
HIV testing and the three immigrant groups were analysed using the Chi-Square test (for 
categorical variables) and the Kruskal-Wallis test (for continuous variables).  
A logistic regression analysis was performed to identify factors associated with having ever 
been HIV tested. In the final model, all the variables that were found to be significantly 
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associated with HIV testing were included: age, sex, origin, educational level, fear of 
becoming infected, knowing someone infected, number of sexual partners and having had a 
consultation on sexual and reproductive health. The magnitude of the associations was 
estimated by means of odds ratios (OR) with 95% confidence intervals. The software SPSS 
18.0 was used for all the data analysis. 
3. Results 
3.1 Socio-demographic characteristics of participants 
Of the total sample, more than a half was female (Table 1). Eastern Europeans were 
significantly older than Africans and Brazilians. Differences on educational level were found 
across origin. Most participants reported to have legal status, more frequently Eastern 
Europeans than Brazilians and Africans. The mean length of stay was higher among 
Africans, compared to Eastern Europeans and Brazilians (Table 1). 
 
 Total African Brazilian Eastern European 
P 
value 
 n % n % n % n %  
Sex   
  Female 715 55.8 265 57.9 235 55.2 215 54.0 0.504   Male 567 44.2 193 42.1 191 44.8 183 46.0 
Educational level   
  Elementary education 356 27.9 269 58.7 61 14.3 26 6.6  
  Secondary education 480 37.6 116 25.3 258 60.6 106 27.0 <0.001 
  Higher education 441 34.5 73 15.9 107 25.1 261 66.4  
Immigration status   
  Legal 1088 86.0 372 82.5 356 84.4 360 91.8 <0.001   Irregular 177 14.0 79 17.5 66 15.6 32 8.2 
 Mean SD Mean SD Mean SD Mean SD  
Age (years) 35.4 10.6 35.5 11.0 33.8 9.8 37.1 10.8 <0.001 
Length of stay (years) 7.9 10.2 11.6 10.2 4.1 6.1 7.8 11.9 <0.001 
Table 1. Socio-demographic characteristics of participants 
3.2 HIV risk perception, knowing someone infected and number of sexual partners 
Most participants (59.6%) referred to fear becoming infected with HIV, more frequently 
Brazilians (69.7%) and Africans (65.8%) compared to Eastern Europeans (41.6%) (p<0.001) 
(Table 2). Differences were found across sex: a higher proportion of women feared becoming 
infected compared to men (63.2% vs. 55.0%, respectively) (p=0.003). Origin differences 
across sexes remained: Brazilian and African women reported more often to fear becoming 
infected compared to Eastern European women (73.1% and 68.1% vs. 46.2%) (p<0.001), as 
Brazilian and African men reported more often fearing to become infected than Eastern 
European men (65.6% and 62.6% vs. 36.1%) (p<0.001). 
Almost 28% of participants had a friend or relative infected with HIV, more frequently 
Brazilians (35.7%) and Africans (25.9%) than Eastern Europeans (19.1%) (p<0.001) (Table 2). 
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Almost 28% of participants had a friend or relative infected with HIV, more frequently 
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The mean number of sexual partners in Portugal in the last 12 months was 1.6 ± 4.2; 70% of 
participants referred having had one sexual partner, 19% had between two and four and 
11% had five or more sexual partners (Table 2). Brazilians reported more frequently to have 
had one sexual partner in the last 12 months (73.4% vs. 68.7% Africans and 67.4% Eastern 
Europeans); Africans reported more frequently having had between two and four partners 
(22.2% vs. 20.1% Brazilians and 14.5% Eastern Europeans); Eastern Europeans reported 
more frequently to having had five or more sexual partners (18.1% vs. 9.1% Africans and 
6.5% Brazilians) (p<0.001) (Table 2). Differences by sex were also found, with women 
reporting more often to have one sexual partner than men (80.6% vs. 57.9%) and men 
reporting more frequently higher number of sexual partners than women (2-4 partners: 
28.7% vs. 10.6%; ≥ 5 partners: 13.4% vs. 8.9%) (p<0.001). In each sex group, the number of 
sexual partners in Portugal in the last year differed across origins. Among women, more 
frequently Africans and Brazilians referred having one sexual partner (84.9% and 83.3%, 
respectively, vs. 71.9% Eastern Europeans), Brazilians having between two and four (13.1% 
vs. 9.8% Eastern Europeans and 8.4% Africans) and Eastern Europeans having more than 
four partners (18.3% vs. 6.7% Africans and 3.5% Brazilians) (p<0.001). In contrast, among 
men, more frequently Eastern Europeans and Brazilians reported having one sexual partner 
(63.1% and 60.9%, respectively, vs. 49.3% Africans), Africans having between two and four 
(38.7% vs. 28.8% Brazilians and 19.1% Eastern Europeans) and Eastern Europeans having 
more than four (17.8% vs. 12% Africans and 10.3% Brazilians) (p=0.002). 
 
 Total African Brazilian Eastern European P value 
 n % n % n % n %  
Fear of becoming infected 
with HIV          
  Yes 752 59.6 294 65.8 295 69.7 163 41.6 <0.001   No 510 40.4 153 34.2 128 30.3 229 58.4 
Knowing someone infected 
with HIV          
  Yes 322 27.5 113 25.9 148 35.7 61 19.1 <0.001   No 850 72.5 324 74.1 267 64.3 259 80.9 
 Mean SD Mean SD Mean SD Mean SD  
Number of sexual partners in 
Portugal in the last 12 months 1.6 4.2 1.9 6.0 1.5 2.4 1.2 2.8 0.094 
Table 2. HIV risk perception, knowing someone infected and number of sexual partners 
3.3 Consultation on sexual and reproductive health and HIV testing 
Of the total sample, having been tested for HIV at least once was reported by 60%; more 
frequently among Brazilians (73.2%) and Africans (63.5%) than Eastern Europeans (41.9%) 
(p<0.001) (Table 3). Across sex, a significantly higher proportion of women had been HIV 
tested compared to men (63.4% vs. 55.8%) (p=0.006). Differences on having ever been tested 
for HIV across origins remained among women and men (women: 72.6% Brazilians and 
70.2% Africans vs. 44.9% Eastern Europeans; p<0.001) (men: 73.8% Brazilians and 54.4% 
Africans vs. 38.5% Eastern Europeans; p<0.001). No differences were observed across 
immigration status. 
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Having ever been HIV tested was mainly due to routine medical screening (31.2%), 
pregnancy/partners’ pregnancy (20.2%), curiosity (12.6%), requirement for mortgage or 
life/health insurance application (6.4%) and having engaged in risk behaviours (6%). Of 
those participants who were never tested, the main reasons were having never had risk 
behaviours (28.6%), not thinking about it (19.6%), not perceiving to be at risk (16.3%), feeling 
well (11.7%), not knowing where to do the test (9.3%) and not considering it important 
(6.9%). 
Among those who have ever been tested for HIV, 54.6% had a test in Portugal; 77.4% of 
Africans versus 42.3% Eastern Europeans and 39.7% Brazilians (p<0.001) (Table 3). Having 
been tested in Portugal did not differ significantly between women and men.  
Of participants who have ever been tested, 36.8% had their last test in the previous year 
(Table 3). Having been tested in the last year was more frequent among Africans (41.2% vs. 
36.5% Brazilians and 29.7% Eastern Europeans) (p=0.048). Also, HIV testing was more 
frequent among women (39.7% vs. 32.7%) (p=0.048). In both sex groups, origin differences 
were not found regarding having been tested in the last year. 
Approximately 23% of participants referred having had a consultation on sexual and 
reproductive health; no differences were found across origin (Table 3). According to sex, a 
higher proportion of women had a sexual and reproductive health consultation compared to 
men (32% vs. 12.4%) (p<0.001). 
 
 Total African Brazilian Eastern European 
P 
value 
 n % n % n % n %  
Having ever been tested for 
HIV          
  Yes 768 60.0 291 63.5 311 73.2 166 41.9 
<0.001 
  No 511 40.0 167 36.5 114 26.8 230 58.1 
Having been tested in 
Portugal          
  Yes 412 54.6 223 77.4 123 39.7 66 42.3 
<0.001 
  No 342 45.4 65 22.6 187 60.3 90 57.7 
Having been tested in the 
last year          
  Yes 282 36.8 120 41.2 113 36.5 49 29.7 
0.048 
  No 484 63.2 171 58.8 197 63.5 116 70.3 
Having ever had a 
consultation on sexual and 
reproductive health 
         
  Yes 295 23.3 105 23.1 90 21.2 100 25.9 
0.288 
  No 969 76.7 349 76.9 334 78.8 286 74.1 
Table 3. HIV testing (ever, in Portugal and in the last year) and consultation on sexual and 





The mean number of sexual partners in Portugal in the last 12 months was 1.6 ± 4.2; 70% of 
participants referred having had one sexual partner, 19% had between two and four and 
11% had five or more sexual partners (Table 2). Brazilians reported more frequently to have 
had one sexual partner in the last 12 months (73.4% vs. 68.7% Africans and 67.4% Eastern 
Europeans); Africans reported more frequently having had between two and four partners 
(22.2% vs. 20.1% Brazilians and 14.5% Eastern Europeans); Eastern Europeans reported 
more frequently to having had five or more sexual partners (18.1% vs. 9.1% Africans and 
6.5% Brazilians) (p<0.001) (Table 2). Differences by sex were also found, with women 
reporting more often to have one sexual partner than men (80.6% vs. 57.9%) and men 
reporting more frequently higher number of sexual partners than women (2-4 partners: 
28.7% vs. 10.6%; ≥ 5 partners: 13.4% vs. 8.9%) (p<0.001). In each sex group, the number of 
sexual partners in Portugal in the last year differed across origins. Among women, more 
frequently Africans and Brazilians referred having one sexual partner (84.9% and 83.3%, 
respectively, vs. 71.9% Eastern Europeans), Brazilians having between two and four (13.1% 
vs. 9.8% Eastern Europeans and 8.4% Africans) and Eastern Europeans having more than 
four partners (18.3% vs. 6.7% Africans and 3.5% Brazilians) (p<0.001). In contrast, among 
men, more frequently Eastern Europeans and Brazilians reported having one sexual partner 
(63.1% and 60.9%, respectively, vs. 49.3% Africans), Africans having between two and four 
(38.7% vs. 28.8% Brazilians and 19.1% Eastern Europeans) and Eastern Europeans having 
more than four (17.8% vs. 12% Africans and 10.3% Brazilians) (p=0.002). 
 
 Total African Brazilian Eastern European P value 
 n % n % n % n %  
Fear of becoming infected 
with HIV          
  Yes 752 59.6 294 65.8 295 69.7 163 41.6 <0.001   No 510 40.4 153 34.2 128 30.3 229 58.4 
Knowing someone infected 
with HIV          
  Yes 322 27.5 113 25.9 148 35.7 61 19.1 <0.001   No 850 72.5 324 74.1 267 64.3 259 80.9 
 Mean SD Mean SD Mean SD Mean SD  
Number of sexual partners in 
Portugal in the last 12 months 1.6 4.2 1.9 6.0 1.5 2.4 1.2 2.8 0.094 
Table 2. HIV risk perception, knowing someone infected and number of sexual partners 
3.3 Consultation on sexual and reproductive health and HIV testing 
Of the total sample, having been tested for HIV at least once was reported by 60%; more 
frequently among Brazilians (73.2%) and Africans (63.5%) than Eastern Europeans (41.9%) 
(p<0.001) (Table 3). Across sex, a significantly higher proportion of women had been HIV 
tested compared to men (63.4% vs. 55.8%) (p=0.006). Differences on having ever been tested 
for HIV across origins remained among women and men (women: 72.6% Brazilians and 
70.2% Africans vs. 44.9% Eastern Europeans; p<0.001) (men: 73.8% Brazilians and 54.4% 
Africans vs. 38.5% Eastern Europeans; p<0.001). No differences were observed across 
immigration status. 
HIV/AIDS Among Immigrants in Portugal:  
Socio-Demographic and Behavioural Correlates of Preventive Practices 
 
93 
Having ever been HIV tested was mainly due to routine medical screening (31.2%), 
pregnancy/partners’ pregnancy (20.2%), curiosity (12.6%), requirement for mortgage or 
life/health insurance application (6.4%) and having engaged in risk behaviours (6%). Of 
those participants who were never tested, the main reasons were having never had risk 
behaviours (28.6%), not thinking about it (19.6%), not perceiving to be at risk (16.3%), feeling 
well (11.7%), not knowing where to do the test (9.3%) and not considering it important 
(6.9%). 
Among those who have ever been tested for HIV, 54.6% had a test in Portugal; 77.4% of 
Africans versus 42.3% Eastern Europeans and 39.7% Brazilians (p<0.001) (Table 3). Having 
been tested in Portugal did not differ significantly between women and men.  
Of participants who have ever been tested, 36.8% had their last test in the previous year 
(Table 3). Having been tested in the last year was more frequent among Africans (41.2% vs. 
36.5% Brazilians and 29.7% Eastern Europeans) (p=0.048). Also, HIV testing was more 
frequent among women (39.7% vs. 32.7%) (p=0.048). In both sex groups, origin differences 
were not found regarding having been tested in the last year. 
Approximately 23% of participants referred having had a consultation on sexual and 
reproductive health; no differences were found across origin (Table 3). According to sex, a 
higher proportion of women had a sexual and reproductive health consultation compared to 
men (32% vs. 12.4%) (p<0.001). 
 
 Total African Brazilian Eastern European 
P 
value 
 n % n % n % n %  
Having ever been tested for 
HIV          
  Yes 768 60.0 291 63.5 311 73.2 166 41.9 
<0.001 
  No 511 40.0 167 36.5 114 26.8 230 58.1 
Having been tested in 
Portugal          
  Yes 412 54.6 223 77.4 123 39.7 66 42.3 
<0.001 
  No 342 45.4 65 22.6 187 60.3 90 57.7 
Having been tested in the 
last year          
  Yes 282 36.8 120 41.2 113 36.5 49 29.7 
0.048 
  No 484 63.2 171 58.8 197 63.5 116 70.3 
Having ever had a 
consultation on sexual and 
reproductive health 
         
  Yes 295 23.3 105 23.1 90 21.2 100 25.9 
0.288 
  No 969 76.7 349 76.9 334 78.8 286 74.1 
Table 3. HIV testing (ever, in Portugal and in the last year) and consultation on sexual and 





3.4 Factors associated with HIV testing 
The logistic regression analysis allowed the identification of sex, origin, fear of becoming 
infected with HIV, knowing someone infected, number of sexual partners and having ever 
had a consultation on sexual and reproductive health as positively associated with having 
been tested for HIV. 
After adjusting for potential confounding factors, having ever been tested was positively 
associated with being older (OR = 1.02, CI 95% = [1.01-1.03]), female (OR = 1.39, CI 95% = 
[1.05-1.84]), Brazilian (OR = 3.75, CI 95% = [2.56-5.50]) and African (OR = 2.60, CI 95% = 
[1.75-3.86]) compared to Eastern European, and having higher education (OR = 1.55, CI 95% 
= [1.04-2.31]) compared to elementary education (Table 4). HIV testing was also more likely 
among those reporting fear to become infected with HIV (OR = 1.28, CI 95% = [0.97-1.70]; 
p<0.10), knowing someone infected (OR = 1.97, CI 95% = [1.43-2.71]), having higher number  
 
 Crude OR  
(CI 95%) P value
Adjusted OR  
(CI 95%) P value 
Age 1.00 (0.99-1.01) 0.806 1.02 (1.01-1.03) 0.005* 
Sex     
  Male 1  1  
  Female 1.37 (1.09-1.72) 0.006* 1.39 (1.05-1.84) 0.022* 
Origin     
  Eastern European 1  1  
  African 2.41 (1.83-3.18) <0.001* 2.60 (1.75-3.86) <0.001* 
  Brazilian 3.78 (2.82-5.07) <0.001* 3.75 (2.56-5.50) <0.001* 
Educational level     
  Elementary education 1  1  
  Secondary education 0.98 (0.74-1.30) 0.903 1.06 (0.74-1.52) 0.763 
  Higher education 0.80 (0.60-1.06) 0.120 1.55 (1.04-2.31) 0.033* 
Immigration status     
  Non regular 1  1  
  Regular 0.97 (0.70-1.35) 0.870 1.29 (0.89-1.87) 0.183 
Fear of becoming infected with HIV     
  No 1  1  
  Yes 1.96 (1.56-2.47) <0.001* 1.28 (0.97-1.70) 0.084** 
Knowing someone infected with HIV     
  No 1  1  
  Yes 2.35 (1.76-3.13) <0.001* 1.97 (1.43-2.71) <0.001* 
Number of sexual partners 1.15 (1.06-1.25) 0.001* 1.12 (1.03-1.22) 0.008* 
Having ever had a consultation on 
sexual and reproductive health     
  No 1  1  
  Yes 2.37 (1.77-3.18) <0.001* 2.52 (1.78-3.58) <0.001* 
*Statistically significant at p<0.05 
**Statistically significant at p<0.10 
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of sexual partners (OR = 1.12, CI 95% = [1.03-1.22]) and having ever had a consultation on 
sexual and reproductive health (OR = 2.52, CI 95% = [1.78-3.58]). No significant association 
was found between HIV testing and immigration status. 
4. Conclusion 
In this study, the prevalence of having ever been tested for HIV was 58.6%, higher than the 
one (51.2%) estimated in a previous study conducted in 2007 with a sample of immigrants 
residing in Lisbon (Dias et al., 2010b). The prevalence of HIV testing obtained in the present 
study was also higher compared to the one estimated in the National Survey of Sexual 
Behaviour conducted in 2009 - 44% of a representative sample of the general Portuguese 
population aged 16–64 years old reported having been tested for HIV (National 
Coordination for HIV/AIDS Infection). The findings of the present study may indicate that 
the national efforts undertaken during the last years to promote HIV testing among most-at-
risk groups as migrants have been positive.  
The most commonly reported motivations for having been tested were event-driven 
(routine medical screening, pregnancy or partners’ pregnancy). Also, approximately a fifth 
of participants were tested based on person-driven reasons (i.e., having the desire to know 
one’s own HIV serostatus, having engaged in risk behaviours). This result may reflect the 
positive outcomes of prevention strategies population-wide focused on increasing 
awareness of the importance of doing the test. Nevertheless, reported reasons for having 
never been tested included low self-risk perception and lack of information on where HIV 
test can be done. These findings reinforce that continuing efforts are needed to encourage 
HIV testing among immigrant population.  
In this study, demographic, socioeconomic, behavioural and structural factors were 
identified as predictors of HIV testing.  
Differences observed across sex are consistent with previous research reporting higher 
prevalence of HIV testing among women (Fakoya et al., 2008; Lopez-Quintero et al., 2005). 
This may be due to the fact that migrant women are commonly of reproductive age and 
therefore tend to use more health services than men (Bond et al., 2005; Dias et al., 2008). 
Indeed, in this study, having had a consultation on sexual and reproductive health was 
more often reported by women. Currently, universal prenatal care in Portugal includes HIV 
counselling and testing. This may result in more opportunities to get information on HIV 
prevention and to uptake the test among female migrants.  
Accordingly, having had a sexual and reproductive health consultation was also positively 
associated with HIV testing. Although reasons for having never been consulted were not 
explored, the results suggest that access to health services is important in linking individuals 
with HIV testing services. In previous studies, utilization of health services has been found 
to increase the likelihood of HIV detection as these services are a useful setting in which to 
provide HIV preventive counselling and promote HIV testing (Bond et al., 2005; Wang et al., 
2010). The findings may also suggest that health professionals may be influential in 
encouraging individuals to receive HIV testing. In fact, previous studies have shown that 
HIV testing is more likely when health care providers initiate discussion, emphasize its 
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= [1.04-2.31]) compared to elementary education (Table 4). HIV testing was also more likely 
among those reporting fear to become infected with HIV (OR = 1.28, CI 95% = [0.97-1.70]; 
p<0.10), knowing someone infected (OR = 1.97, CI 95% = [1.43-2.71]), having higher number  
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  Regular 0.97 (0.70-1.35) 0.870 1.29 (0.89-1.87) 0.183 
Fear of becoming infected with HIV     
  No 1  1  
  Yes 1.96 (1.56-2.47) <0.001* 1.28 (0.97-1.70) 0.084** 
Knowing someone infected with HIV     
  No 1  1  
  Yes 2.35 (1.76-3.13) <0.001* 1.97 (1.43-2.71) <0.001* 
Number of sexual partners 1.15 (1.06-1.25) 0.001* 1.12 (1.03-1.22) 0.008* 
Having ever had a consultation on 
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  No 1  1  
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of sexual partners (OR = 1.12, CI 95% = [1.03-1.22]) and having ever had a consultation on 
sexual and reproductive health (OR = 2.52, CI 95% = [1.78-3.58]). No significant association 
was found between HIV testing and immigration status. 
4. Conclusion 
In this study, the prevalence of having ever been tested for HIV was 58.6%, higher than the 
one (51.2%) estimated in a previous study conducted in 2007 with a sample of immigrants 
residing in Lisbon (Dias et al., 2010b). The prevalence of HIV testing obtained in the present 
study was also higher compared to the one estimated in the National Survey of Sexual 
Behaviour conducted in 2009 - 44% of a representative sample of the general Portuguese 
population aged 16–64 years old reported having been tested for HIV (National 
Coordination for HIV/AIDS Infection). The findings of the present study may indicate that 
the national efforts undertaken during the last years to promote HIV testing among most-at-
risk groups as migrants have been positive.  
The most commonly reported motivations for having been tested were event-driven 
(routine medical screening, pregnancy or partners’ pregnancy). Also, approximately a fifth 
of participants were tested based on person-driven reasons (i.e., having the desire to know 
one’s own HIV serostatus, having engaged in risk behaviours). This result may reflect the 
positive outcomes of prevention strategies population-wide focused on increasing 
awareness of the importance of doing the test. Nevertheless, reported reasons for having 
never been tested included low self-risk perception and lack of information on where HIV 
test can be done. These findings reinforce that continuing efforts are needed to encourage 
HIV testing among immigrant population.  
In this study, demographic, socioeconomic, behavioural and structural factors were 
identified as predictors of HIV testing.  
Differences observed across sex are consistent with previous research reporting higher 
prevalence of HIV testing among women (Fakoya et al., 2008; Lopez-Quintero et al., 2005). 
This may be due to the fact that migrant women are commonly of reproductive age and 
therefore tend to use more health services than men (Bond et al., 2005; Dias et al., 2008). 
Indeed, in this study, having had a consultation on sexual and reproductive health was 
more often reported by women. Currently, universal prenatal care in Portugal includes HIV 
counselling and testing. This may result in more opportunities to get information on HIV 
prevention and to uptake the test among female migrants.  
Accordingly, having had a sexual and reproductive health consultation was also positively 
associated with HIV testing. Although reasons for having never been consulted were not 
explored, the results suggest that access to health services is important in linking individuals 
with HIV testing services. In previous studies, utilization of health services has been found 
to increase the likelihood of HIV detection as these services are a useful setting in which to 
provide HIV preventive counselling and promote HIV testing (Bond et al., 2005; Wang et al., 
2010). The findings may also suggest that health professionals may be influential in 
encouraging individuals to receive HIV testing. In fact, previous studies have shown that 
HIV testing is more likely when health care providers initiate discussion, emphasize its 





Age and educational level were also significant socioeconomic factors of HIV testing, 
similarly to other studies (Fernández et al., 2005; Haile et al., 2007). Higher education has 
been positively associated with HIV knowledge, awareness of availability of health services 
and HIV testing (Burns et al., 2005; Dias et al., 2004; Stolte et al., 2003; Wong et al., 2004).  
The results show a significant variation across origins, with Brazilian and African 
participants reporting more often to have been tested for HIV. A similar result was obtained 
in a previous study (Dias et al., 2010b). In the countries of origin of these participants, 
Portuguese is the official language. This may reinforce the idea that having a common 
language may be a facilitator of utilization of health services, and in particular for HIV 
testing. In several other investigations, linguistic differences have been mentioned as 
predictive of underutilization of HIV-related health services and having never been tested 
for HIV among immigrants (Burns et al., 2007; Dias et al., 2004; Prost et al., 2008).  
In this study, having been tested for HIV appeared to be independent of immigration status, 
which may reflect the efforts undertaken to promote voluntary, anonymous and 
confidential HIV testing, free of charge and regardless of legal status (National Coordination 
for HIV/AIDS Infection, 2007).  
Two thirds of participants feared becoming HIV infected; this variable was associated with 
higher odds of having been tested for HIV. Perception of individual HIV risk has been 
associated with knowledge of HIV risk factors, fewer risk-taking practices and HIV testing 
(Bardem-O’Fallon et al., 2004; Maman et al., 2001; Stein & Nyamathi, 2000). It is possible that 
individuals who perceive to be at risk for HIV infection are more likely to consider the 
disease as a personal danger, to recognize its consequences and to acknowledge the 
importance of adopting HIV-related protective measures (Norman & Gebre, 2005; 
Worthington & Myers, 2003). Differences by origin revealed that Brazilians and Africans 
report a higher perception of HIV risk, compared to Eastern Europeans. These findings are 
consistent with research suggesting that migrants from high prevalence countries tend to 
show high levels of knowledge and awareness of HIV risk factors (Burns et al., 2007). These 
migrants may therefore be more likely to perceive themselves at risk of HIV infection. 
Women also reported higher perception of individual risk compared to men. Although 
reasons for fearing to become infected with HIV were not explored in this study, in previous 
investigations the lack of trust in a male partner and a partner’s promiscuity are the most 
common reasons given for perceived high personal risk (Dias et al., 2004, 2010c; Sarker et al., 
2005; Ventura-Filipe et al., 2000). Additional research is needed to deepen understanding of 
the ways in which issues of gender and origin underpin HIV risk perception. 
The results show a significant association between knowing someone infected and HIV 
testing. Studies have pointed out that knowing someone with HIV/AIDS appears to be an 
important contributor to knowledge of HIV and may result in more positive attitudes 
toward HIV protective measures (Barden-O’Fallon et al., 2004; Kalichman & Simbayi, 2003). 
Increased knowledge and more positive attitudes may help individuals to recognize the 
benefits of the HIV test (Norman & Gebre, 2005). The differences observed by origin support 
the hypothesis that country of origin’s background plays an important role in HIV-related 
perceptions and experiences, thus influencing willingness to test for HIV. 
In this study, risky sexual behaviour as having multiple sexual partners was a predictor of 
HIV testing. This result confirms the findings of surveys conducted in other countries 
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showing that increasing number of sexual partners is associated with progressively higher 
prevalence of testing (Song et al., 2011; Wang et al., 2010). When individuals experience 
sexual risk behaviours, they may be aware of their increased risk for HIV infection and, in 
turn, they may be more likely to test for HIV. The findings indicate a variation on sexual 
behaviour patterns across origin and sex. Further investigation on sexual behaviours must 
take into account the cultural and gender-related influences.  
This study points out interesting challenges for HIV prevention among immigrants and may 
help in the design of tailored interventions focused on promotion of HIV testing among 
these populations. The findings highlight that strategies should be targeted to specific 
subgroups including men, Eastern Europeans, those younger, with lower educational level 
and in stable relationships. 
In view of the missed opportunities for HIV testing in outpatient care, this study reinforces 
that the sexual and reproductive health services may be a useful setting in which to provide 
HIV preventive counselling and testing. These services are considered to greatly contribute 
to HIV prevention given their potential outreach to diverse groups of the population 
through primary health care (Berer, 2004). Voluntary counselling in primary care is 
increasingly recognized as an appropriate way to encourage early diagnosis of HIV among 
immigrants, many of whom often do not suspect to be infected (Askew & Berer, 2003). 
Interventions might therefore focus on improving the provision of HIV information, 
counselling and testing in primary care. 
Further efforts to improve HIV testing among immigrants should focus on increasing 
individuals’ awareness of HIV self-risk and benefits of doing the test, as well as on 
promoting utilization of health services and providing access to timely, culturally competent 
and appropriate HIV testing and counselling. 
Studies have consistently pointed toward the need for creating further innovative and 
effective pathways to HIV testing of immigrant populations (Burns et al., 2001; Delpierre et 
al., 2007; Erwin et al., 2002). The provision of HIV detection services in non-traditional 
health settings such as mobile units may be important to facilitate HIV testing and 
dissemination of HIV information within immigrant communities. Also, the role of 
community based organizations in HIV prevention among ‘hard-to-reach’ populations as 
immigrants has been increasingly recognized (Fakoya et al., 2008; Solorio et al., 2004). 
Community-based organizations may provide counselling and testing services to migrants 
and may link those testing positive with health care services, increasing timely access to 
treatment and care. These organizations may also provide culturally relevant information on 
HIV risks, protective measures and health services available. Communities’ involvement 
and participation in the planning and development of HIV prevention interventions should 
be supported. 
A deeper understanding of the individual, behavioural and structural factors that underpin 
HIV testing among immigrant populations is needed. Cultural and gender-related issues 
should be taken into account as contributors for variation in sexual behaviour patterns, 
adoption of protective measures and HIV testing across immigrant groups. This knowledge 
is relevant to support the design of interventions aimed to increase access to diagnosis and 
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consistent with research suggesting that migrants from high prevalence countries tend to 
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migrants may therefore be more likely to perceive themselves at risk of HIV infection. 
Women also reported higher perception of individual risk compared to men. Although 
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investigations the lack of trust in a male partner and a partner’s promiscuity are the most 
common reasons given for perceived high personal risk (Dias et al., 2004, 2010c; Sarker et al., 
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the ways in which issues of gender and origin underpin HIV risk perception. 
The results show a significant association between knowing someone infected and HIV 
testing. Studies have pointed out that knowing someone with HIV/AIDS appears to be an 
important contributor to knowledge of HIV and may result in more positive attitudes 
toward HIV protective measures (Barden-O’Fallon et al., 2004; Kalichman & Simbayi, 2003). 
Increased knowledge and more positive attitudes may help individuals to recognize the 
benefits of the HIV test (Norman & Gebre, 2005). The differences observed by origin support 
the hypothesis that country of origin’s background plays an important role in HIV-related 
perceptions and experiences, thus influencing willingness to test for HIV. 
In this study, risky sexual behaviour as having multiple sexual partners was a predictor of 
HIV testing. This result confirms the findings of surveys conducted in other countries 
HIV/AIDS Among Immigrants in Portugal:  
Socio-Demographic and Behavioural Correlates of Preventive Practices 
 
97 
showing that increasing number of sexual partners is associated with progressively higher 
prevalence of testing (Song et al., 2011; Wang et al., 2010). When individuals experience 
sexual risk behaviours, they may be aware of their increased risk for HIV infection and, in 
turn, they may be more likely to test for HIV. The findings indicate a variation on sexual 
behaviour patterns across origin and sex. Further investigation on sexual behaviours must 
take into account the cultural and gender-related influences.  
This study points out interesting challenges for HIV prevention among immigrants and may 
help in the design of tailored interventions focused on promotion of HIV testing among 
these populations. The findings highlight that strategies should be targeted to specific 
subgroups including men, Eastern Europeans, those younger, with lower educational level 
and in stable relationships. 
In view of the missed opportunities for HIV testing in outpatient care, this study reinforces 
that the sexual and reproductive health services may be a useful setting in which to provide 
HIV preventive counselling and testing. These services are considered to greatly contribute 
to HIV prevention given their potential outreach to diverse groups of the population 
through primary health care (Berer, 2004). Voluntary counselling in primary care is 
increasingly recognized as an appropriate way to encourage early diagnosis of HIV among 
immigrants, many of whom often do not suspect to be infected (Askew & Berer, 2003). 
Interventions might therefore focus on improving the provision of HIV information, 
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individuals’ awareness of HIV self-risk and benefits of doing the test, as well as on 
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Studies have consistently pointed toward the need for creating further innovative and 
effective pathways to HIV testing of immigrant populations (Burns et al., 2001; Delpierre et 
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health settings such as mobile units may be important to facilitate HIV testing and 
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immigrants has been increasingly recognized (Fakoya et al., 2008; Solorio et al., 2004). 
Community-based organizations may provide counselling and testing services to migrants 
and may link those testing positive with health care services, increasing timely access to 
treatment and care. These organizations may also provide culturally relevant information on 
HIV risks, protective measures and health services available. Communities’ involvement 
and participation in the planning and development of HIV prevention interventions should 
be supported. 
A deeper understanding of the individual, behavioural and structural factors that underpin 
HIV testing among immigrant populations is needed. Cultural and gender-related issues 
should be taken into account as contributors for variation in sexual behaviour patterns, 
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1. Introduction 
According to UNAIDS, the joint United Nations Program on HIV/AIDS, 2.5 million 
children younger than 15 years are living with HIV, and during 2008  nearly half a million 
children were infected with HIV. Most of these children (67%) were from sub-Saharan 
Africa, and mother to child transmission was the major route of infection (91%) (Vermund 
2004). HIV is one of the major causes of infant mortality in developing countries (Marston et 
al., 2005; Rashid et al., 2005). Prevention of mother to child transmission (PMTCT) of HIV 
has become an important cornerstone to reduce child mortality in sub-Saharan Africa. The 
research achievements in PMTCT are remarkable. Unfortunately, it has proved much more 
difficult to translate these findings into practice in resource-poor settings. 
Virology tests are expensive and require sophisticated laboratory facilities. The expense of 
creating a laboratory with appropriate quality control and assurance to perform virology 
testing is significant, as well as the recurrent costs of test reagents. Laboratory technicians 
and scientists are in short supply in many resource-limited countries, and highly trained 
technicians may have high turnover because they are often sought by researchers and other 
countries. Venipuncture of infants requires training and supplies that are often unavailable 
outside large cities. Transport difficulties and distances may prohibit whole blood samples 
from reaching high-level laboratories in adequate time and condition for testing. Difficulties 
in returning results quickly to clinical sites may reduce acceptability of testing and cause 
results to go unclaimed. Effective infant diagnosis programs require a combination of 
clinical, serologic, and virologic approaches to the question of infant HIV status (Creek et al., 
2007). 
Diagnosis is an important aspect of providing treatment and care to those children infected. 
The earlier the diagnosis is made the better the outcome for patients. High mortality in the 
first few months of life has been reported particularly in resource limited settings (Zijenah et 
al., 1998, 2004). Approximately 20% can die by 6 months of life, 35-40% by 1 year of age and 
50-60% by 2 years (Newell at al., 2004; Obimbo et al., 2004). Currently early detection is very 
possible with virologic assays which are sensitive and specific. Serologic methods such as 
HIV- Enzyme Linked Immunosorbent Assay (ELISA), Western blot, and 
Immunofluorescence Assay can be used to diagnose HIV infection in children older than 18 
months. Cheaper rapid diagnostic tests have been introduced which can be used at the point 
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1. Introduction 
According to UNAIDS, the joint United Nations Program on HIV/AIDS, 2.5 million 
children younger than 15 years are living with HIV, and during 2008  nearly half a million 
children were infected with HIV. Most of these children (67%) were from sub-Saharan 
Africa, and mother to child transmission was the major route of infection (91%) (Vermund 
2004). HIV is one of the major causes of infant mortality in developing countries (Marston et 
al., 2005; Rashid et al., 2005). Prevention of mother to child transmission (PMTCT) of HIV 
has become an important cornerstone to reduce child mortality in sub-Saharan Africa. The 
research achievements in PMTCT are remarkable. Unfortunately, it has proved much more 
difficult to translate these findings into practice in resource-poor settings. 
Virology tests are expensive and require sophisticated laboratory facilities. The expense of 
creating a laboratory with appropriate quality control and assurance to perform virology 
testing is significant, as well as the recurrent costs of test reagents. Laboratory technicians 
and scientists are in short supply in many resource-limited countries, and highly trained 
technicians may have high turnover because they are often sought by researchers and other 
countries. Venipuncture of infants requires training and supplies that are often unavailable 
outside large cities. Transport difficulties and distances may prohibit whole blood samples 
from reaching high-level laboratories in adequate time and condition for testing. Difficulties 
in returning results quickly to clinical sites may reduce acceptability of testing and cause 
results to go unclaimed. Effective infant diagnosis programs require a combination of 
clinical, serologic, and virologic approaches to the question of infant HIV status (Creek et al., 
2007). 
Diagnosis is an important aspect of providing treatment and care to those children infected. 
The earlier the diagnosis is made the better the outcome for patients. High mortality in the 
first few months of life has been reported particularly in resource limited settings (Zijenah et 
al., 1998, 2004). Approximately 20% can die by 6 months of life, 35-40% by 1 year of age and 
50-60% by 2 years (Newell at al., 2004; Obimbo et al., 2004). Currently early detection is very 
possible with virologic assays which are sensitive and specific. Serologic methods such as 
HIV- Enzyme Linked Immunosorbent Assay (ELISA), Western blot, and 
Immunofluorescence Assay can be used to diagnose HIV infection in children older than 18 
months. Cheaper rapid diagnostic tests have been introduced which can be used at the point 





2. HIV serology 
Serology which is appropriate for diagnosing HIV infection in older children can not be 
used in young infants who are less than 18 months of age, particularly those breast feeding 
because of interference with maternal antibodies. Maternal antibodies cross the placenta so 
they can give false positive results in HIV uninfected children.  The test does not distinguish 
maternal from infant antibodies (Lujan-Zilbermann et al., 2006). However when HIV 
antibodies are not present in HIV exposed  children younger than 18 months but older than 
one year who are not breast feeding or in the window period, a diagnosis of HIV negative 
status can be made (Alecdort et al., as cited in Creek et al., 2007). Current assays have both a 
sensitivity and specificity greater than 99% in children older than 18 months.  (Palasanthiran 
et al., 1994). If the initial serologic test is positive, a second ELISA or EIA is performed on the 
same specimen. If the second test is positive a confirmatory test is indicated, commonly an 
HIV-1 Western blot or an HIV-1 indirect immunofluorescence antibody assay (Brambillia et 
al., 2003). These gold standard tests are expensive and require a long waiting period before 
results can be obtained by clinicians in charge mainly because of the batching of specimens 
to save reagents. 
Rapid tests have become important in resource limited settings mainly because of use by 
personnel with limited skills, ability to give out results immediately at site which makes 
counseling easier. Specificity and sensitivity is reasonable and comparable to those of EIAs 
used for screening (Mylonakis et al., 2000). 
In young infants HIV rapid antibody tests can have a role if the maternal HIV infection 
status is unknown. HIV exposure can be confirmed with a positive result and excluded with 
a negative one. Infants lose maternal antibodies at different times, as a result young infants 
who have lost maternal antibodies can be presumed HIV negative at a younger age with 
rapid tests if they are not breast feeding and not in the window period. This is a reasonable 
low cost approach of ruling out HIV infection in HIV exposed infants. A large proportion of 
HIV uninfected children are seronegative by 9 months of age and some as early as 4 months 
(Blackburn et al., 2006). Errors have been found with some rapid test kits reporting false 
negative results particularly in severe illness which is associated with 
hypogammaglobulinaemia hence clinical judgment and appropriate physical examination is 
necessary at the diagnostic stage. 
 The testing of saliva for HIV antibody may be useful in infants because oral fluid contains 
lower concentrations of all antibodies in comparison with blood. Diminishing maternal HIV 
antibodies in HIV-exposed but uninfected infants likely become undetectable earlier in oral 
fluids than in blood. Laboratory-based or rapid HIV tests performed on oral fluid can 
potentially exclude HIV infection earlier in life, and sample collection is less traumatic for 
the infant and caregiver. Further validation of oral fluid assays is needed to establish the 
youngest age at which seroreversion can be detected and to determine the sensitivity and 
specificity of the test at different ages (Sherman et al 2005). 
3. Virologic testing 
Nucleic acid testing methods include HIV-1 Deoxyribonucleic acid polymerase chain 
reaction (DNA PCR), HIV Ribonucleic acid polymerase chain reaction ( RNA PCR) and 
HIV-1 p24 Antigen. Polymerase chain reaction (PCR) assays detect HIV-1 DNA within 
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peripheral blood mononuclear cells (PBMC). Proper specimen collection procedures and 
processing are important for the validity of the results. Whole blood should be collected in 
tubes containing edentate calcium disodium (EDTA) or acid citrate dextrose as 
anticoagulants (Brambilla et al., 2003). Major challenges faced here include the cost of 
bleeding the patient, namely syringes, needles and appropriate blood tubes. Transportation 
of specimens and storage are also important where frequent power cuts compromise the 
quality of results. 
3.1 HIV deoxyribonucleic acid (DNA) PCR 
HIV DNA PCR is the standard method for virologic diagnosis of HIV in infants in the 
developed world. It has been used for many years, is the diagnostic test of choice 
recommended by the WHO, and has acceptable sensitivity and specificity (Bremer et al., 
1996; Sherman et al., 2005). For HIV -1 subtype B, the sensitivity and specificity of HIV-1 
DNA PCR assays approach 96% and 99% respectively, by 28 days of age. They are less 
sensitive for detection of non-B subtype infection (Lujan-Zilbermann et al, 2006). HIV 
infection can often be detected at birth, and essentially all perinatal infections are detectable 
by 4 weeks of age (Sherman et al., 2004).  Infections acquired postpartum (i.e., through 
breast-feeding) can be detected by 4-6 weeks after the last exposure. Different PCR tests exist 
world wide and not all tests are equally accurate with all HIV subtypes. The cost can range 
from $8 USD to $16USD per test (Creek et al., 2007). 
3.2 Ribonucleic acid (RNA) PCR 
An HIV RNA PCR, quantitative or qualitative, is also an accurate method of diagnosing HIV 
in young infants, with sensitivity and specificity comparable with DNA PCR testing. 
However, this test is more expensive and requires the use of plasma, which is difficult to 
obtain from infants and transport intact. HIV RNA PCR is routinely used to monitor disease 
progression and response to HAART. Whole blood specimens collected should be processed 
within 6 hours for accurate results which poses a challenge in resource poor settings 
(Brambilla et al 2003). 
3.3 Real-time PCR  
Real-time PCR allows the technician to view the increase in the amount of DNA or RNA 
when it is amplified. Real-time PCR as a new approach is gaining acceptability because of its 
improved rapidity, sensitivity, reproducibility, and the reduced risk of carry-over 
contamination, and it may reduce the cost of nucleic acid testing (Katsoulidou et al., 2006 & 
Zhao et al., 2002 as cited in Creek et al., 2007).This method is in use in numerous research 
settings and performs very well. However, at present the only commercial kits available are 
for quantitative and not qualitative detection of HIV, and large-scale use of these assays for 
public health programs has not been attempted (Creek et al., 2007).  
3.4 Ultrasensitive (US) p24 antigen assay 
The US p24 antigen assay is slightly less sensitive than HIV PCR in identifying HIV 
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3.4 Ultrasensitive (US) p24 antigen assay 
The US p24 antigen assay is slightly less sensitive than HIV PCR in identifying HIV 





(Patton et al., 2006; Sherman et al., 2004;) quantitative viral protein detection assay utilizes 
simpler technology than is required for detection of viral nucleic acids, but it is still 
relatively complex with multiple processing steps. US p24 is not in general use because 
studies validating it for infant diagnosis are recent, and achieving valid results in field 
settings has been challenging. US p24 may provide a useful alternative where PCR is not 
available. It can be used as a marker of disease progression and therapeutic response 
(Keenan et al., 2005). 
3.5 Dried blood spots (DBS) 
 The HIV-1-DNA PCR on dried blood spots have made a significant difference in giving 
young HIV infected infants a chance for survival by early diagnosis. Spotting of whole 
blood onto filter paper offers technical and economic advantages over conventional 
venipuncture methods since it simplifies sample collection and transport to reference 
laboratories for diagnostic testing and viral load quantification (Zhang et al., 2002). Because 
infant blood for testing can be taken by simply pricking a heel, toe, or finger and dried cards 
are stable for relatively long periods without refrigeration; many logistical barriers to infant 
testing can be overcome using this simple technique. However proper training of staff is 
required to improve validity of results. PCR performed on DBS is as accurate as PCR 
performed on whole blood but has higher reagent cost and some increase in processing 
time. DNA and RNA PCR, both standard and real time, have been successfully performed 
on DBS in many settings and HIV subtypes with no loss of accuracy (Cassol et al., 1996; 
Lyamuya et al., 2000; Sherman et al., 2004; 19, 26-27).  Routine collection of DBS for early 
infant diagnosis is being implemented in many countries. Dried blood spots have been 
successfully used to measure HIV-1 RNA in patients and to diagnose perinatal HIV 
infection.  Some studies have reported low stability of nucleic acids in dried blood spots 
particularly when stored under inappropriate conditions.  
Dried blood spots may also be used for HIV-1 sub typing and genotypic resistance testing 
(Fiscus et al., 2006). Although HIV-1 viral load can be successfully enumerated using dried 
blood spots there are limitations posed by volume of blood or plasma especially if sensitive 
nucleic acid testing is done or multiple tests are done on the same sample. The Vivest 
(formerly referred to as SampleTanker) is an economical dried specimen storage 
transportation system where significantly increased plasma volumes can be shipped at 
optimum temperatures (Zanoni et al., 2010). Its use was validated in Brazil, it was 
demonstrated that DNA HIV-1 viral load results from dried plasma eluted from Vivest are 
generally comparable to that of fresh plasma. Its use present a cost effective way of 
transporting specimens in resource poor settings where the logistics associated with 
shipping frozen plasma are expensive(Zanoni et al., 2010).  
4. Conclusion 
Clinicians looking after children should be aware of the different tests available to diagnose 
HIV infection in children which are useful in resource limited settings. All the different tests 
have different applications in these settings and accuracy should not be compromised so 
that the goal of reducing child mortality is met. 
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compensatory mutations also arise secondarily to restore fitness in the mutants harbouring 
costly escape (Gandhi, et al. 2003, Stanford University 2011). 
Furthermore, intra-subtype and inter-subtype differences in HIV genetic sequences evoke 
different pathways leading to escape (Pieniazek, et al. 2000). Therefore, concerted efforts, 
surveillance programs and comprehensive databases have been set up to describe subtype-
specific drug resistance mutations and their accessory mutations (which may either have 
predisposing, compensating or augmenting effects to drug concurrent resistance mutations) 
(Bennett, et al. 2009, Gifford, et al. 2007, Stanford University 2011).  
2.1 HIV, HAART and drug resistance in sub-Saharan Africa 
In sub-Saharan Africa, 22.5 million people (5% of adult population) are infected with HIV, 
effectively harbouring over two thirds of the world prevalence (33.3 million) 
(UNAIDS/WHO 2011). Furthermore, in 2009, HIV infected over 1.8 million adults and 
children in the sub-Saharan region, and caused 1.3 million deaths through AIDS. This 
represents public health emergency, requiring immediate effective intervention. However, 
resource limitation, escalating disease burden and established stigmata remain major 
challenges to effective intervention. In particular, poverty and resource limitations 
undermine HIV control by constraining the access, availability and affordability of HIV 
testing, anti-retroviral therapy (ARV), follow up, and skilled staff (UNAIDS/WHO 2011).  
Similarly, sub-Saharan African nations lacked the resources to research and develop their own 
ARV and HAART. Fortunately, although the ARV and HAART regimens were originally 
designed to inhibit subtype B HIV-1, they are also efficacious against other subtypes, including 
C - the dominant subtype infecting sub-Saharan Africa (Frater, et al. 2001, Gordon, et al. 2003, 
Kantor, et al. 2005). In the pol gene subtype C varies from subtype B by 10-12% at the 
nucleotide level, yet these genotypic differences do not appear to confer major pre-therapy 
drug resistance, although may be associated with more accessory resistance mutations and 
different molecular pathways to resistance (Frater, et al. 2002, Gordon, et al. 2003, Pieniazek, et 
al. 2000, Robertson, et al. 2000, Sanches, et al. 2007, Velazquez-Campoy, et al. 2001).  
As HAART became available, many sub-Saharan Africa states initiated large scale primary 
care dispensing of HAART to qualifying patients according to the CDC and WHO guidelines 
(Department of Health 2003). However, the regional circulating strains of HIV remain poorly 
characterised in their molecular epidemiology and genotypic profiles. In addition, various 
mono- and dual-ARV are also indicated in the prevention of mother-to-child transmission 
(PMTCT) program of different sub-Saharan regions, exposing patients to potential resistance 
development (Jourdain, et al. 2004). Therefore, ahead of the mass dispensing of HAART, it is 
important to study the molecular characterisation and baseline pre-therapy drug resistance 
profiles of subtype C HIV-1 in South Africa (Department of Health 2003, Gilks, et al. 2006). 
This will also contribute to the long-term follow up of resistance development.  
2.2 Characterising drug resistance 
There are three types of ARV resistance (DHHS-Panel 2011): 
 Clinical resistance: occurs when viral replication continues despite HAART institution, 
and carries direct clinical impact. Clinical criteria exist to define virological (increase 
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viral load, VL) and immunological failure (poor increase or decreasing of CD4 cell 
count and development of opportunistic infection) during HAART. 
 Phenotypic resistance: can assess viral growth in the presence of ARV in vitro. This test 
is highly specialized (requiring recombination of HIV pol gene with a laboratory viral 
backbone) and is time consuming (viral culture and measurements take three to four 
weeks). The test is more expensive, and has no proven advantage over genotypic 
resistance testing, and may suffer reduced sensitivity in the detection of minority 
resistant mutant isolates (when the mutants are present at less than 20% of circulating 
viral population). 
 Genotypic resistance: is conducted to sequence the RT and protease genes for the 
detection of known resistance mutations (Integrase sequencing can also be done, on 
request). The test is considerably less expensive, time consuming and more widely 
available when compared to the phenotypic resistance assay (although the level of 
expertise required is still very high and not common to routine diagnostic laboratories). 
Furthermore, different sequencing assay techniques could be employed to improve 
sensitivity of detecting minority resistant mutants. A ‘virtual phenotype’ can also be 
imputed to measure the phenotypic impact of a mutation using laboratory strain 
manipulation. To date, global databases including Stanford HIV drug resistance 
database (Stanford HIV db) have collated, analysed and summarised considerable 
amounts of different genotype-treatment, genotype-clinical, and genotype-phenotype 
evidence based academic publications. 
The identification of drug resistance in sub-Saharan Africa has become a major issue in 
patients receiving HAART and in drug-naïve individuals (Shekelle, et al. 2007). Guidelines 
exist for the surveillance of both - the World Health Organisation (WHO) and Stanford HIV 
db publish a list of mutations for use in surveillance of transmitted drug resistance (TDRM) 
and the International AIDS Society (IAS) produce a list for use in the monitoring of treated 
populations (HRDS-Team 2003, Johnson, et al. 2008, Stanford University 2011). The WHO, 
Stanford HIV db and IAS committees regularly update the definitions and clinical 
significance (phenotypic resistance, clinical association and outcome meta-analyses) of drug 
resistance mutations and drug associated polymorphisms (Bennett, et al. 2009, Shafer, et al. 
2007). However, authorities disagree on the classification of naturally occurring non-clade B 
polymorphisms, drug-associated polymorphisms not associated with direct measurable 
drug resistances, and polymorphisms associated with reversion of previous drug-resistance 
mutation (Stanford University 2011). Therefore, many of the Stanford db’s ‘potentially low 
grade’ and ‘low grade’ resistance mutations are excluded from the IAS and WHO 
surveillance lists, showing there are discrepancies between the key opinion leaders. 
Recently, the updated TDRM list from the Stanford HIV db has become unified with the 
WHO guidelines (Gilks, et al. 2006, HRDS-Team 2003). The mutations in the TDRM 
surveillance list are selected on the basis that they are non-polymorphic, clinically 
significant and applicable across all subtypes. The implementation of such a standard 
should facilitate a specific method to assess changes in drug resistance prevalence in 
populations over time (Garcia-Diaz, et al. 2008, HRDS-Team 2003, Seebregts, et al. 5-8 June 
2007). It is clearly ideal to have a single mutations list to screen all populations, however the 
possibility exists that for South Africa where the dynamics of therapy provision and the 
more recent introduction of universal access to HAART makes for a unique situation, a 
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3. Molecular epidemiology and genotypic drug resistance in treatment-naïve 
HIV population of South Africa 
In South Africa (SA, Figure 1), 5.5 million people are infected with HIV (ASSA 2007, 
UNAIDS/WHO 2011, Venter 2005). Since 2004, the SA government has made antiretroviral 
therapy (ARV) available to HIV positive individuals through public sector ARV programs - 
an initiative with significant clinical, public health and economic impact (Department of 
Health 2003, Egger, et al. 1997, Frater 2002, Palella, et al. 1998, Sow, et al. 2007, Venter 2005).  
Until recently, only a few small to medium-sized South African cohorts have reported the 
molecular characterisation and baseline pre-therapy resistance profiles of HIV infection, 
predominantly amongst the KwaZulu Natal, Gauteng and Limpopo provinces (Bessong, et 
al. 2006, Gordon, et al. 2003, Pillay, et al. 2002, Shekelle, et al. 2007). There are also emerging 
data on drug resistance from other major cities of sub-Saharan countries such as Uganda, 
Tanzania, Botswana, Zimbabwe, Zambia, Malawi and Kenya (Bussmann, et al. 2005, 
Eshleman, et al. 2009, Gordon, et al. 2003, Hamers, et al. 2010, Kamoto and Aberle-Grasse 
2008, Lihana, et al. 2009, Mosha, et al. 2011, SATuRN-Database, et al. 2011, Shekelle, et al. 
2007, Tshabalala, et al. 2011). There is currently no similar information available from other 
less urbanised regions of South Africa, such as Free State Province (Figure 1) with a 
population of approximately 3 million, an antenatal clinic HIV prevalence of 33.9%, and the 
life expectancy estimate of 46.5 years (ASSA 2007). Under the Free State Comprehensive 
Care, Management and Treatment of HIV and AIDS program, highly active antiretroviral 
therapy (HAART) has been available since 2004 as a combination stavudine and lamivudine 
with either nevirapine or Kaletra, and has significantly reduced the number of HIV-related 
deaths (hazard ratio 0.14) (Fairall, et al. 2008).  
In patients who report that they are drug-naive, resistance mutations might either reveal 
transmitted variants or might indicate that patients are not, in fact, drug-naive or are 
unaware of previous ARV exposure (Garcia-Diaz, et al. 2008). The extent to which 
unrecognized access contributes to the level of resistance in patients enrolling onto public 
sector ARV is unknown in South Africa, and very difficult to measure. Prior to the 
introduction of the public sector ARV treatment programme, ARV drugs were available for 
the PMTCT through private clinics and other unregulated routes, although previous studies 
suggest a low prevalence of baseline drug resistance in South Africa (Bessong, et al. 2006, 
Gordon, et al. 2003, Pillay, et al. 2002, Shekelle, et al. 2007).  
Here, the discussion on molecular epidemiology and pre-therapy drug resistance will be 
applied to a South African clinical cohort study (Huang, et al. 2009). In the Free State 
province of South Africa, 425 HIV type-1 (HIV-1)-positive patients newly recruited to the 
public sector ARV treatment programme and reporting to be drug-naïve were studied. The 
molecular epidemiology of HIV-1 infection within this region were characterised, and the 
prevalence of drug resistance and other polymorphisms associated with drug exposure 
were measured. A correlation existed between low CD4 T cell counts and drug-selected 
polymorphisms, suggesting that many mutations in drug-naive individuals are not 
transmitted, but are the result of acquired resistance through unrecognised ARV access.  
The aims of this study were: to describe the viral molecular epidemiology of Free State 
Province, South Africa (Figure 1), to investigate the prevalence of drug-resistance associated 
mutations, and resistance to HAART in the pre-therapy cohort and to model the impact of 
ART availability on baseline antiretroviral resistance.   
 




Left panel: South Africa (in red) at the south of Sub-Saharan Africa (boxed and enlarged from the world 
map in left lower corner).  
Right panel: Free State province (in blue, capital: Bloemfontein) and KwaZulu Natal province (in 
purple, capital: Durban) are two of the nine provinces in central east region of South Africa. 
Fig. 1. Map of South Africa and its provinces, figure modified from original (Wikimedia-
Commons 2010) 
4. Experimental approach to the Free State cohort 
In total, 884 adult patients were recruited at their first visit to government antiretroviral 
therapy (ART) clinics in the Free State province of South Africa between February and 
September 2006. Informed consent for additional sampling of plasma for viral sequencing 
was obtained. All patients had been diagnosed with HIV infection at local primary care 
clinics, and then referred to district or regional HIV clinics to be assessed for suitability for 
HAART. On attending the clinic, patients were counseled by trained HIV nurses and asked 
directly whether they had previously received PMTCT, mono-, dual- or triple antiretroviral 
therapy. Patients who admitted previous drug exposure were excluded from this analysis. 
Demographic details, routine CD4 T cell counts and an additional 10ml of peripheral venous 
blood were collected from each individual patient. The ethics and study design were 
approved by the regional university and department of health.  
The 884 patients were stratified according to their CD4 cell count into 5 groups as follows: 
<100 cells/l (n = 195, 22.1%); 100-199 cells/l (n= 212, 24%); 200-349 cells/l (n=244, 
27.6%); 350-499 cells/l (n=123, 13.9%) and >500 cells/l (n=110, 12.4%) (Table 1). From this 
cohort of 884, viral sequences were analysed from 425 patients to form the ‘low’ (<100 CD4 
cells/l; n=195), ‘intermediate’ (200-349 CD4 cells/l; n=120) and ‘high’ (>500 CD4 cells/l; 
n=110) CD4 cell count stratification groups. 
For sequencing, RNA was extracted from plasma, converted to cDNA and then amplified by 
polymerase chain reaction before sequencing using ABI Big Dye terminator kits (Applied 
Biosystems). The primers used for the PCR and sequencing are described elsewhere (Frater, 
et al. 2007). From the 425 patients, complete protease sequences (99 amino acids) and amino 
acids 1-530 of reverse transcriptase (RT) were successfully. The pol gene sequences were 
submitted to the BioAfrica database and REGA HIV-1 subtype tool for subtype 





3. Molecular epidemiology and genotypic drug resistance in treatment-naïve 
HIV population of South Africa 
In South Africa (SA, Figure 1), 5.5 million people are infected with HIV (ASSA 2007, 
UNAIDS/WHO 2011, Venter 2005). Since 2004, the SA government has made antiretroviral 
therapy (ARV) available to HIV positive individuals through public sector ARV programs - 
an initiative with significant clinical, public health and economic impact (Department of 
Health 2003, Egger, et al. 1997, Frater 2002, Palella, et al. 1998, Sow, et al. 2007, Venter 2005).  
Until recently, only a few small to medium-sized South African cohorts have reported the 
molecular characterisation and baseline pre-therapy resistance profiles of HIV infection, 
predominantly amongst the KwaZulu Natal, Gauteng and Limpopo provinces (Bessong, et 
al. 2006, Gordon, et al. 2003, Pillay, et al. 2002, Shekelle, et al. 2007). There are also emerging 
data on drug resistance from other major cities of sub-Saharan countries such as Uganda, 
Tanzania, Botswana, Zimbabwe, Zambia, Malawi and Kenya (Bussmann, et al. 2005, 
Eshleman, et al. 2009, Gordon, et al. 2003, Hamers, et al. 2010, Kamoto and Aberle-Grasse 
2008, Lihana, et al. 2009, Mosha, et al. 2011, SATuRN-Database, et al. 2011, Shekelle, et al. 
2007, Tshabalala, et al. 2011). There is currently no similar information available from other 
less urbanised regions of South Africa, such as Free State Province (Figure 1) with a 
population of approximately 3 million, an antenatal clinic HIV prevalence of 33.9%, and the 
life expectancy estimate of 46.5 years (ASSA 2007). Under the Free State Comprehensive 
Care, Management and Treatment of HIV and AIDS program, highly active antiretroviral 
therapy (HAART) has been available since 2004 as a combination stavudine and lamivudine 
with either nevirapine or Kaletra, and has significantly reduced the number of HIV-related 
deaths (hazard ratio 0.14) (Fairall, et al. 2008).  
In patients who report that they are drug-naive, resistance mutations might either reveal 
transmitted variants or might indicate that patients are not, in fact, drug-naive or are 
unaware of previous ARV exposure (Garcia-Diaz, et al. 2008). The extent to which 
unrecognized access contributes to the level of resistance in patients enrolling onto public 
sector ARV is unknown in South Africa, and very difficult to measure. Prior to the 
introduction of the public sector ARV treatment programme, ARV drugs were available for 
the PMTCT through private clinics and other unregulated routes, although previous studies 
suggest a low prevalence of baseline drug resistance in South Africa (Bessong, et al. 2006, 
Gordon, et al. 2003, Pillay, et al. 2002, Shekelle, et al. 2007).  
Here, the discussion on molecular epidemiology and pre-therapy drug resistance will be 
applied to a South African clinical cohort study (Huang, et al. 2009). In the Free State 
province of South Africa, 425 HIV type-1 (HIV-1)-positive patients newly recruited to the 
public sector ARV treatment programme and reporting to be drug-naïve were studied. The 
molecular epidemiology of HIV-1 infection within this region were characterised, and the 
prevalence of drug resistance and other polymorphisms associated with drug exposure 
were measured. A correlation existed between low CD4 T cell counts and drug-selected 
polymorphisms, suggesting that many mutations in drug-naive individuals are not 
transmitted, but are the result of acquired resistance through unrecognised ARV access.  
The aims of this study were: to describe the viral molecular epidemiology of Free State 
Province, South Africa (Figure 1), to investigate the prevalence of drug-resistance associated 
mutations, and resistance to HAART in the pre-therapy cohort and to model the impact of 
ART availability on baseline antiretroviral resistance.   
 




Left panel: South Africa (in red) at the south of Sub-Saharan Africa (boxed and enlarged from the world 
map in left lower corner).  
Right panel: Free State province (in blue, capital: Bloemfontein) and KwaZulu Natal province (in 
purple, capital: Durban) are two of the nine provinces in central east region of South Africa. 
Fig. 1. Map of South Africa and its provinces, figure modified from original (Wikimedia-
Commons 2010) 
4. Experimental approach to the Free State cohort 
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cells/l; n=195), ‘intermediate’ (200-349 CD4 cells/l; n=120) and ‘high’ (>500 CD4 cells/l; 
n=110) CD4 cell count stratification groups. 
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2011, de Oliveira, et al. 2005). Phylogenetic analysis and maximum likelihood trees were 
constructed using the General Time Reversible substitution model with optimised 
proportions of invariable sites and gamma distribution (GTR+G+I) using PAUP* (version 
4.0 beta) and PhyML (version 2.4.4) software. The pol sequences of the cohort were 
compared to 986 well-characterised isolates from the BioAfrica database and those available 
on the Los Alamos database (www.hiv.lanl.gov) to determine subtype and lineage 
relationships (Guindon and Gascuel 2003, Los Alamos National Laboratory 2011). The 
Slatkin and Maddison test was used to assess clustering between the Free State Province 
sequences and other South African sequences, using MacClade (version 4) (Gifford, et al. 
2007). 
The protease and RT sequences were submitted to the Stanford drug resistance database 
(version 4.3.1, http://hivdb.stanford.edu/pages/algs/HIVdb.html) to identify subtype-
associated polymorphisms and drug resistance mutations (Bennett, et al. 2008). The Stanford 
mutation scoring system (Table 1) was used to distinguish accessory mutations (mutation 
score 0-9) from clinically significant mutations (‘potentially low level’ resistance (score 10-
14), ‘low level’ (score 15-30), ‘intermediate level’ (score 30-59) and ‘high level’ (score >=60) 
resistance) (Bennett, et al. 2008, Stanford University 2011). 
An ordinary differential equation model was devised for this study to describe the 
dynamics of resistance to a single drug, such as Nevirapine, with a simple genetic resistance 
profile. The model encapsulates four main processes: selection of drug resistance in hosts 
treated in the public sector ARV treatment program, selection of drug resistance prior to 
‘official’ treatment by other means such as private prescriptions, transmission of drug 
resistant strains to new hosts, and reversion to drug-sensitive strains in untreated hosts. 
Fisher’s exact test (two tailed) and chi-square test were used to compare pre-therapy 
resistance findings between groups with different CD4 cell counts.  
5. Molecular epidemiology and drug resistance prevalence in the Free State 
In the analysis, there were three key findings. Firstly, there was evidence of multiple 
introductions of HIV-1 into the Free State, but random distribution of drug resistance-
associated polymorphisms. Secondly, the overall prevalence of pre-therapy drug resistance 
was low, but drug-selected polymorphisms were concentrated among patients with low 
CD4 T cell counts. Thirdly, mathematical modelling suggested that baseline drug resistance 
may be driven by exposure to ARVs available through non-governmental routes and that, 
unless drug availability is controlled, resistance prevalence is likely to rise. In the section 
below, each of the findings will be described and discussed in more details.  
5.1 Characterisation of the Free State province cohort in South African 
Table 1 summarises the cohort demography and division for sub-studies. Patients attending 
antiretroviral clinics in Free State province during 2006 demonstrated a mean CD4 T cell 
count of 271 cells/l, with 44.8% of patients possessing a CD4 cell counts of less than 200 
cells/l, significantly lower than other published chronic HIV cohorts (Kiepiela, et al. 2004). 
In an earlier study of 2777 chronically HIV infected individuals in the Pelonomi Hospital, 
Bloemfontein recruited between 1991 and 1997 (van der Ryst, et al. 1998), the mean CD4 T cell 
counts was 421 cells/l. The low mean CD4 T cell counts seen in the Free State Cohort is likely  
 





Table 1. Details of HIV-1 positive patients recruited to three subgroups according to CD4 T 
cell count 






2011, de Oliveira, et al. 2005). Phylogenetic analysis and maximum likelihood trees were 
constructed using the General Time Reversible substitution model with optimised 
proportions of invariable sites and gamma distribution (GTR+G+I) using PAUP* (version 
4.0 beta) and PhyML (version 2.4.4) software. The pol sequences of the cohort were 
compared to 986 well-characterised isolates from the BioAfrica database and those available 
on the Los Alamos database (www.hiv.lanl.gov) to determine subtype and lineage 
relationships (Guindon and Gascuel 2003, Los Alamos National Laboratory 2011). The 
Slatkin and Maddison test was used to assess clustering between the Free State Province 
sequences and other South African sequences, using MacClade (version 4) (Gifford, et al. 
2007). 
The protease and RT sequences were submitted to the Stanford drug resistance database 
(version 4.3.1, http://hivdb.stanford.edu/pages/algs/HIVdb.html) to identify subtype-
associated polymorphisms and drug resistance mutations (Bennett, et al. 2008). The Stanford 
mutation scoring system (Table 1) was used to distinguish accessory mutations (mutation 
score 0-9) from clinically significant mutations (‘potentially low level’ resistance (score 10-
14), ‘low level’ (score 15-30), ‘intermediate level’ (score 30-59) and ‘high level’ (score >=60) 
resistance) (Bennett, et al. 2008, Stanford University 2011). 
An ordinary differential equation model was devised for this study to describe the 
dynamics of resistance to a single drug, such as Nevirapine, with a simple genetic resistance 
profile. The model encapsulates four main processes: selection of drug resistance in hosts 
treated in the public sector ARV treatment program, selection of drug resistance prior to 
‘official’ treatment by other means such as private prescriptions, transmission of drug 
resistant strains to new hosts, and reversion to drug-sensitive strains in untreated hosts. 
Fisher’s exact test (two tailed) and chi-square test were used to compare pre-therapy 
resistance findings between groups with different CD4 cell counts.  
5. Molecular epidemiology and drug resistance prevalence in the Free State 
In the analysis, there were three key findings. Firstly, there was evidence of multiple 
introductions of HIV-1 into the Free State, but random distribution of drug resistance-
associated polymorphisms. Secondly, the overall prevalence of pre-therapy drug resistance 
was low, but drug-selected polymorphisms were concentrated among patients with low 
CD4 T cell counts. Thirdly, mathematical modelling suggested that baseline drug resistance 
may be driven by exposure to ARVs available through non-governmental routes and that, 
unless drug availability is controlled, resistance prevalence is likely to rise. In the section 
below, each of the findings will be described and discussed in more details.  
5.1 Characterisation of the Free State province cohort in South African 
Table 1 summarises the cohort demography and division for sub-studies. Patients attending 
antiretroviral clinics in Free State province during 2006 demonstrated a mean CD4 T cell 
count of 271 cells/l, with 44.8% of patients possessing a CD4 cell counts of less than 200 
cells/l, significantly lower than other published chronic HIV cohorts (Kiepiela, et al. 2004). 
In an earlier study of 2777 chronically HIV infected individuals in the Pelonomi Hospital, 
Bloemfontein recruited between 1991 and 1997 (van der Ryst, et al. 1998), the mean CD4 T cell 
counts was 421 cells/l. The low mean CD4 T cell counts seen in the Free State Cohort is likely  
 





Table 1. Details of HIV-1 positive patients recruited to three subgroups according to CD4 T 
cell count 






a result of the cohort studied – ARV clinics tend to be enriched with patients presented 
during symptomatic phase of late HIV. There was no public ARV program available during 
1990s. The availability of HAART from the government is expected to improve quality of 
life and reverse this population-wide fall in CD4 cell counts (Venter 2005). 
The 884 patients were stratified according to CD4 T cell count, and viral sequences were 
analysed from 425 patients to form the low (<100 cells/µl; n=195), intermediate (200–349 
cells/µl; n=120) and high (>500 cells/µl; n=110) CD4 T cell counts stratification groups. The 
mean CD4 T cell counts for all patients within the low, intermediate and high groups were 
45.4, 270.0 and 651.8 cells/µl, respectively. The mean age of the cohort was 36.1 years (Table 
1). Complete protease gene sequences (99 amino acids) and amino acids 1–530 of the RT gene 
were successfully amplified from 390 and 397 patients, respectively. The REGA subtyping 
tool revealed all isolates to be subtype C. All sequences were combined with reference 
sequences from the BioAfrica database and their phylogeny analysed using maximal 
likelihood trees (de Oliveira and Cassol 2011, de Oliveira, et al. 2005).  
5.2 Molecular epidemiology studies revealed dynamic relationships between the local 
circulating viral isolates and the Southern Africa strains  
The Free State is located in central South Africa and is relatively isolated from other South 
African centres. The phylogenetic analysis confirmed that Free State province is dominated 
by HIV-1 subtype C infection, much like the rest of South Africa (Table 1). There were 
multiple small but distinct clusters within the Free State, which suggests the mixing of HIV-
1 strains from across South Africa, with migration into and through the Free State, possibly 
a result of the mining industry, transport routes and other economic reasons (Figure 2 and 
3). However, despite these clusters, viruses with drug-resistance associated mutations are 
distributed randomly, suggesting that they have evolved recently as a result of individual 
drug exposure rather than being a transmission cluster.  
In Figure 2, the maximum likelihood tree shows 390 HIV-1 pol sequences from the Free State 
in the context of local and global HIV-1 subtype C viruses from the BioAfrica database. The 
Free State strains (n=390) are in red, the South African strains (n=428) are in green, and 
remaining global subtype C strains (n=551) are in black. In Figure 3, the tree shows the 
phylogeny of the Free State patients (n=390) in the context of local HIV-1 subtype C virus 
strains from other provinces within SA (n=428). The Free State strains are highlighted in red, 
the drug resistant strains are highlighted in blue, whilst the SA reference strains (mainly 
from Gauteng, Kwa-Zulu Natal and Western Cape Province) are highlighted in green. 
The Free State sequences appear to be distributed randomly amongst both Southern African 
(Figure 2) and South African (Figure 3) reference sequences. Quantitative analysis of 
clustering showed that 52.5% of sequences occurred in 61 clusters of between 2 and 18 
sequences (mean 3.4 patients per cluster: 27 clusters of two, 10 clusters of three, 8 clusters of 
four, 3 clusters of five, 1 clusters of six, 2 clusters of seven, and 3 individual clusters of eight, 
nine and eighteen sequences). The analysis also shows that 70.6% of the Free State sequences 
(in isolation or in clusters) have a South African reference sequence as the nearest neighbour, 
but there is also clustering of sequences sampled from the Free State compared with other 
major South African centres (Slatkins and Maddison test, P<0.001). In addition, 96.1% of  
Free State strains are most closely related to a Southern African sequence and 97.2%  
 





The pol gene of HIV-1 isolates sampled from Free State patients (red) are shown in the context of 
published South African (green) and non-South African (black) HIV-1 subtype C reference sequences. 
Resistant isolates defined by International AIDS Society (IAS)–USA and other drug-associated 
mutations defined by the Stanford Drug Resistance Database are shown (blue dotted arrows, ending in 
“o” and “*”, respectively). This maximal likelihood tree was constructed using the general time 
reversible substitution model with optimised proportions of invariable sites and gamma distribution 
(GTR+G+I) using PAUP* (version 4.0 beta) and PhyML (version 2.4.4) software. 
Fig. 2. Phylogenetic tree of the HIV-1 molecular epidemiology in the Free State, South Africa 
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The pol gene of HIV isolates sampled from the Free State patients (in red) are shown in the context of 
published South African HIV-1 Subtype C database (in green). The two HIV population sequences 
showed remarkable homology, sharing common internal nodes. Only 1 group of 18 Free State isolates 
clustered with more than 10 sequences. The drug resistant isolates from Free State patients (blue stars) 
distribute sporadically across the tree. This maximal likelihood tree was constructed using the general 
time reversible substitution model with optimised proportions of invariable sites and gamma 
distribution (GTR+G+I) using PAUP* (version 4.0 beta) and PhyML (version 2.4.4) software. 
Fig. 3. Phylogenetic tree describing HIV molecular epidemiology of the Free State Province 
and its drug resistant subjects in the context of South African HIV-1 subtype C reference 
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of Free State strains are most closely related to an African sequence. Only 2.8% of the Free 
State sequences are closely related to a non-African sequence.  
Sequences that contained any drug-associated polymorphism or a mutation from the IAS–
USA surveillance list are indicated and are randomly distributed (Johnson, et al. 2008). The 
absence of linkage of these variant sequences does not support significant transmission of 
drug resistance within this cohort (Slatkins and Maddison test, P=0.85).  
It is also important to note that in contrast to the developed nations, HIV molecular 
epidemiology remains poorly characterised in the sub-Saharan Africa. In an effort to fight 
the pandemic in its epicentre, initiatives have begun to enhance the understanding of 
molecular epidemiology of HIV infection in sub-Saharan African. Consortiums such as 
Southern African Treatment and Resistance Network (SATuRN) were established as a 
regional mirror of the Stanford HIV db in sub-Saharan region (SATuRN-Database, et al. 
2011). In 2009, only 428 RT sequences were enlisted, with the active contribution from the 
likes of this cohort (n=390), the sample size of SATuRN is expanding rapidly. 
5.3 Low prevalence of pre-therapy drug resistance in the Free State  
All available pre-therapy pol gene sequences (n=390 for PR; n=397 for RT amino acids 1-530) 
from the Free State cohort were submitted to the Stanford HIV Resistance Database for 
identification of polymorphic sites associated with drug resistance. Although all potential 
resistance mutations were identified, specific attention was paid to the mutations from three 
drug classes currently being provided as part of the Free State public HAART regimen, 
namely protease inhibitor (PI), nucleoside reverse transcriptase inhibitor (NRTI), and non-
nucleoside reverse transcriptase inhibitor (NNRTI). 
According to the Stanford Drug Resistance Database list, the prevalence of non-accessory 
mutations was 4.1%, comprising 16 patients carrying a total of 19 non-accessory mutations 
(Table 1, Accessory mutations are defined as “atypical mutations or subtype-associated 
polymorphisms possibly related to secondary drug resistance” (Stanford University 2011)). 
The overall prevalence of clinically significant drug resistance mutations (according to the 
IAS–USA classification) was low (2.3%, Table 1), in concordence with the findings of 
previous smaller studies from South Africa (Bessong, et al. 2006, Gordon, et al. 2003, 
Johnson, et al. 2008, Pillay, et al. 2002, Shekelle, et al. 2007). A total of 64 (16.4%) patients 
sampled had a mutation at any of the drug resistance amino acid sites, including those that 
have been found to be naturally occurring polymorphisms (Table 1).  
The 16 patients with non-accessory mutations – according to the Stanford definition – are 
detailed in Table 2. Of these, nine had clinically significant mutations according to the IAS–
USA list. These were Y181C (n=2), K103N (n=3), Y188L (n=1), V106M (n=1), V108I (n=1) and 
K219E (n=1) in the RT gene, and M46L (n=1) and N88S (n=1) in the protease gene. The referral 
centres and local clinics where these patients had been recruited were either visited or 
contacted; however, in all but five cases the patients had been lost to follow-up. Of the four 
who had maintained undetectable viral loads on therapy, none had clinically significant IAS–
USA defined mutations at baseline (V179D, M46L, A98G and T69N). The one patient identified 
with a detectable viral load on ARVs (13,000 RNA copies/ml after 5 months) had V179D at 
baseline, although no sequence data was available from subsequent samples to determine the 
development of resistance (Table 2). Of the 16 patients with significant resistance, 6 were male. 
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The non-accessory mutations identified in the cohort are explored in more detail in Table 3. 
For each mutation, the number in each CD4 T cell counts stratification is shown and 
compared with the reported prevalence in databases of drug-naive subtype B and C 
populations and in drug-experienced subtype C populations. To determine the clinical 
implications of these identified mutations, the Stanford database MARVEL report for each is 
summarized and the significance of the mutations in the surveillance lists of the WHO 
(updated 2009) and IAS–USA (updated December 2008) are compared (Table 3) (Bennett, et 
al. 2009, Johnson, et al. 2008, Stanford University 2011). For all the mutations, the prevalence 
in databases of drug-experienced subtype C cohorts was higher than in drug-naive patients 
with implications that these mutations might act as markers of drug exposure, even if not 
conferring clinically relevant resistance. 
5.4 Enrichment of drug-associated mutations among patients with low CD4 T cell 
counts  
Drug-associated polymorphisms (based on the Stanford database) were concentrated among 
patients with low CD4 T cell counts – 6.8% of patients with CD4 T cell counts <100 cells/µl 
carried non-accessory mutations compared with 1.8% and 1.2% of patients with 
intermediate and high CD4 T cell counts, respectively (P=0.015; Table 1 and Figure 4). The 
prevalence of resistance according to the IAS–USA definition was 3.6%, 0.9% and 1.2% for 
low, intermediate and high CD4 T cell counts groups, respectively (Table 1). Although not 
statistically significant, there were more accessory mutations among patients with low CD4 
T cell counts (19.3%) compared with the intermediate (13.4%) and the high (14.0%) CD4 T 
cell counts groups. When using the more relaxed Stanford definition, mutations 
concentrated among patients with low CD4 T cell counts for all mutations (Figure 4; 
P=0.004). Although not statistically significant, when only considering clinically relevant 
mutations, there was a trend for enrichment of resistance among low CD4 T cell counts for 
the IAS–USA (P=0.055) and the WHO TDRM lists (P=0.086; Table 3).  
In a supposedly drug-naive cohort, the enrichment of mutations with low CD4 T cell counts 
suggests that, rather than being transmitted, these polymorphisms had been selected by 
drug exposure (Garcia-Diaz, et al. 2008, Jourdain, et al. 2004). Transmitted mutations should 
be more common in recently infected individuals as they may revert to wild type over time 
in the absence of therapy (Gandhi, et al. 2003). Chronically infected patients with low CD4 T 
cell counts would be expected to have relatively less mutations if transmission was the only 
source of drug resistance. It should also be noted that other evidences have suggested that 
many of the transmitted resistance can stably persist over prolonged period within the HIV 
recipient (Brenner, et al. 2002, Novak, et al. 2005, Smith, et al. 2007). However, in the setting 
of this chronic cohort where majority of the patients are in advanced AIDS and HIV 
acquisition more likely occurred at a longer time ago, this explanation is unlikely to explain 
the observed drug-associated polymorphism prevalence given the availability of ARV in the 
distant past of SA. In this cohort, the patients were counselled by trained local HIV-1 nurses 
regarding drug history whether through the prevention of PMTCT, ARV programmes in 
different provinces, countries and private clinics or other non-governmental sources. This 
cohort does not comply with all the WHO guidelines for the identification of transmitted 
resistance (i.e. patients with recent infection, aged <25 years and no history of pregnancy 
(Bennett, et al. 2008, Gilks, et al. 2006, HRDS-Team 2003)), and although transmission of 
mutations is documented in other cohorts (Gifford, et al. 2007, Gilks, et al. 2006, Pillay 2007, 
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Richman, et al. 2004), a combination of phylogeny and the association with lower CD4 T cell 
counts in the data suggested that transmission was unlikely to be a significant cause of 
resistance in the Free State.  
The NNRTI class, in particularly Nevirapine, was associated with significant baseline drug-
associated mutations amongst the low CD4 T cell counts patient strata (Jourdain, et al. 2004). 
The genotypes and phylogeny of the NNRTI resistance strains were heterogenous (Figure 4 
and Table 2) and were not derived from any common founder (Figure 2 and 3). Of the 
patients with low CD4 T cell counts (<100 cells/µl), 5.2% possessed non-nucleoside reverse 
transcriptase inhibitor (NNRTI)-associated mutations compared with 1.8% of patients with 
intermediate and 0.0% of patients with high CD4 T cell counts (P=0.005; Figure 4 and Table 
3). The major mutation genotypes observed for NNRTI resistance were K103N (grade 5; 3 
isolates), V106M (grade 5; 1 isolate), Y181C (grade 5; 2 isolates), and Y188L (grade 5; 1 
isolate). Other NNRTI mutations included K103R (grade 1; 3 isolates), V108I (grade 2; 1 
isolate), A98G (grade 2; 2 isolates), V179D (grade 2; 3 isolates), E138K (grade 3; 1 isolate), 
(Table 2). This association remained significant when restricted to NNRTI mutations on the 
IAS–USA list (P=0.031; Table 3). The distribution of NNRTI mutations within patients with  
 
The plot depicts all pre-therapy patients carrying drug-associated mutations to any of the highly active 
antiretroviral therapy constituents, including protease inhibitors (PIs), nucleoside reverse transcriptase 
inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs), stratified according to 
CD4 T cell count. The P-value was calculated using the χ2 test, comparing the mutations across CD4 T 
cell counts.  
Fig. 4. Distribution of drug-associated mutations in pre-therapy patients according to CD4 T 
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low CD4 T cell counts was concentrated further among the individuals with lowest CD4 T 
cell counts (Table 2), who also tended to have higher grade resistant mutations.  
In contrast, the prevalence of resistance to non-NNRTI classes of HAART was much lower 
(Table 2 and 3). Only two major PI resistance mutations in protease were observed (M46L 
(grade 3) and N88S (grade 4)) and two NRTI mutations (T69N (grade 2) and K219E (grade 3)).  
Very few individuals were identified with clusters of mutations, indicative of potential 
multi-class resistance (Table 2). One patient (OX927) had significant resistance to both NRTI 
(K219E) and NNRTI (Y181C). One patient (OX1082) possessed two significant NNRTI 
resistance mutations, V106M and Y188L. Another (OX2032) carried E138K and Y181C. 
A key route of ARV exposure is the nevirapine-only regimen initially used for PMTCT from 
2000 (Department of Health 2003, Jourdain, et al. 2004, Shekelle, et al. 2007). Those patients 
with major NNRTI mutations were predominantly women of child-bearing age. Nevirapine 
is an inexpensive and effective agent and a key constituent of HAART regimens in resource-
limited settings. In this cohort, nevirapine had the highest prevalence of drug-associated 
mutations. The drug has a long half-life, a simple mutational pathway and is prone to rapid 
resistance even with the single doses used in PMTCT (Grossman, et al. 2004, Jourdain, et al. 
2004, Shekelle, et al. 2007). Unfortunately, despite contacting or visiting the referring clinics, 
the demographic details to determine the extent of this effect were not available for this 
analysis because of loss of follow-up for most of the affected patients.  
5.5 Mathematical modelling of acquisition of drug resistance 
The presence of inducible drug-resistance mutations in a population prior to recruitment to 
the ARV program indicates either access to antiretroviral therapy from alternative routes or 
transmission of drug-resistant strains. A mathematical model was developed to address two 
questions. Firstly, how long would it take for the observed level of inducible resistance 
mutation prevalence to develop in the absence of non-governmental access to drugs? 
Secondly, if alternative routes of drug access are maintained at the current rates, what is the 
likely prevalence of drug resistance in the next ten years? 
Regarding the first question on the attributable impact on baseline inducible drug resistance 
of non-governmental access to ARVs, the model estimates that it should take between 20 
and 35 years for a treatment naïve population exposed to NNRTI as part of HAART to 
achieve the observed level of resistance in the Free State cohort (Figure 5a). This supports 
the existence of additional sources of NNRTI exposure and that the Free State population is 
not entirely treatment naïve before the government program. 
In answer to the second question, the model predicts that in patients with low CD4 T cell 
counts the prevalence of NNRTI resistance will increase to 7.1% (confidence interval (CI): 5.7 
to 8.2%) over the next 10 years, if the additional sources of NNRTI exposure are maintained 
(Figure 5b). The resistance prevalence can however be stabilised to 5.2% (CI = 3.6 to 6.2%) 
over next 10 years, if additional exposure to NNRTI causing resistance can be reduced to 1% 
(currently 4.2%, Figure 5c). If all additional NNRTI exposure could be restricted, the present 
resistance prevalence could not sustain itself and would be expect to fall. 
Therefore, according to the mathematical model, the prevalence of NNRTI resistance is 
likely to increase, if additional non-governmental ART exposure is not controlled. The 
 




Panel A: A projection of how resistance would develop in the absence of alternative, non-governmental 
sources of ARTs, if there was no initial resistance to NNRTI.  
Panel B: A projection of how NNRTI resistance will increase over the next 10 years if the percentage of 
infected hosts acquiring resistance from alternative access to therapy continues at the current level of 
4% (estimated using the model).  
Panel C: A projection of resistance emergence over the next 10 years, if the percentage of infected hosts 
acquiring resistance from alternative access to therapy reduces to 1%. 
Limited data were available to estimate the rate at which drug resistant virus reverts to drug sensitive 
virus in untreated hosts (ψ), hence all model predictions were made for three different reversion rates: 
ψ = 0.13 years-1 (dashed line), ψ  = 0.05 years-1 (solid line) and ψ  = 0.01 years-1 (dotted line). 
Fig. 5. Model predictions of how the prevalence of NNRTI resistance in hosts, prior to 
enrolment onto governmental ARTs, is expected to develop over time in the Free-State 
population 
implications of this would include reduced drug efficacy and a requirement for clinical drug 
resistance surveillance, with its inherent financial costs. Newer antiretroviral classes, such as 
integrase and CCR5 inhibitors are currently unavailable through SA government programs 
re-enforcing the need to preserve the NNRTI class (Department of Health 2003). In 
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December 2007, South Africa revised its PMTCT regimen to a combination of zidovudine 
and nevirapine. Although this measure should improve PMTCT efficacy and reduce the 
emergence of NNRTI resistance, the logistics of introducing this change might delay its 
implementation in all areas of South Africa and a proportion of mothers might still receive 
nevirapine monotherapy.  
Nonetheless, PMTCT cannot be responsible for all the observed resistance in the cohort – 6 of 
the 16 patients were men and the age of the females ranged from 25 to 56 years. These patients 
predominantly had lower grade mutations, suggestive of exposure but not clinical resistance. 
It is possible that some individuals had previously received treatment in other clinics, for 
example, contract workers travelling between provinces. In addition, patients with lower CD4 
T cell counts are more likely to be symptomatic, to use drugs prescribed to family or friends 
and might have previously sought medication through other non-government sources 
(Novak, et al. 2005, Uy, et al. Jul 2007). At the time of sampling, drugs such as nevirapine, 
lamivudine, stavudine and didanosine were also available through private practitioners in the 
Free State, although the duration for which drugs would be prescribed is dependent on the 
patient’s ability to pay (Dahab, et al. 2008, Garcia-Diaz, et al. 2008).  
6. Conclusion 
In summary, this chapter has reviewed the molecular epidemiology and the practical 
implications for HIV drug resistance testing in sub-Saharan Africa. The example study of a 
large cohort from South Africa has revealed new molecular epidemiological and drug 
resistance surveillance data. The prevalence of drug-associated mutations among patients is 
reassuringly low, but the association with low CD4 T cell counts is previously undescribed 
and warrants close monitoring of the virological response when these patients start therapy. 
In particular, with increasing access to antiretrovirals and growing evidence for the role of 
treatment as prevention, continued robust resistance surveillance mechanisms will be 
required for the foreseeable future. 
Funding and Competing Interests: K-HGH is supported by the Rhodes Scholarships and 
James Martin 21st Century School. JF is funded by the Medical Research Council. The 
funders had no role in study design, data collection and analysis, decision to publish, or 
preparation of the manuscript. The data presented here have been presented at international 
conferences and in peer-reviewed journals prior to this publication. 
Competing interests: The authors have declared that no competing interests exist. 
7. References 
[1] Aboulker, J. P., and A. M. Swart. 1993. Preliminary analysis of the Concorde trial. 
Concorde Coordinating Committee. Lancet 341:889-90. 
[2] Armstrong, K. L., T. H. Lee, and M. Essex. 2009. Replicative capacity differences of 
thymidine analog resistance mutations in subtype B and C human immunodeficiency 
virus type 1. J Virol 83:4051-9. 
[3] ASSA. 2007. ASSA 2003 Demographic Model Produced by the Actuarial Society of South 
Africa. Demographic Model. ASSA. 
 
HIV Drug Resistance in Sub-Saharan Africa – Implications for Testing and Treatment 
 
127 
[4] Barbaro, G., A. Scozzafava, A. Mastrolorenzo, and C. T. Supuran. 2005. Highly active 
antiretroviral therapy: current state of the art, new agents and their 
pharmacological interactions useful for improving therapeutic outcome. Curr 
Pharm Des 11:1805-43. 
[5] Bennett, D. E., R. J. Camacho, D. Otelea, D. R. Kuritzkes, H. Fleury, M. Kiuchi, W. 
Heneine, R. Kantor, M. R. Jordan, J. M. Schapiro, A. M. Vandamme, P. Sandstrom, 
C. A. Boucher, D. van de Vijver, S. Y. Rhee, T. F. Liu, D. Pillay, and R. W. Shafer. 
2009. Drug resistance mutations for surveillance of transmitted HIV-1 drug-
resistance: 2009 update. PLoS ONE 4:e4724. 
[6] Bennett, D. E., M. Myatt, S. Bertagnolio, D. Sutherland, and C. F. Gilks. 2008. 
Recommendations for surveillance of transmitted HIV drug resistance in countries 
scaling up antiretroviral treatment. Antivir Ther 13 Suppl 2:25-36. 
[7] Bessong, P. O., J. Mphahlele, I. A. Choge, L. C. Obi, L. Morris, M. L. Hammarskjold, and 
D. M. Rekosh. 2006. Resistance mutational analysis of HIV type 1 subtype C among 
rural South African drug-naive patients prior to large-scale availability of 
antiretrovirals. AIDS Res Hum Retroviruses 22:1306-12. 
[8] Brenner, B. G., J. P. Routy, M. Petrella, D. Moisi, M. Oliveira, M. Detorio, B. Spira, V. 
Essabag, B. Conway, R. Lalonde, R. P. Sekaly, and M. A. Wainberg. 2002. 
Persistence and fitness of multidrug-resistant human immunodeficiency virus type 
1 acquired in primary infection. J Virol 76:1753-61. 
[9] Bussmann, H., V. Novitsky, W. Wester, T. Peter, K. Masupu, L. Gabaitiri, S. Kim, S. 
Gaseitsiwe, T. Ndungu, R. Marlink, I. Thior, and M. Essex. 2005. HIV-1 subtype C 
drug-resistance background among ARV-naive adults in Botswana. Antivir Chem 
Chemother 16:103-15. 
[10] Carvajal-Rodriguez, A., K. A. Crandall, and D. Posada. 2007. Recombination favors the 
evolution of drug resistance in HIV-1 during antiretroviral therapy. Infect Genet 
Evol 7:476-83. 
[11] Dahab, M., S. Charalambous, R. Hamilton, K. Fielding, K. Kielmann, G. J. Churchyard, 
and A. D. Grant. 2008. "That is why I stopped the ART": patients' & providers' 
perspectives on barriers to and enablers of HIV treatment adherence in a South 
African workplace programme. BMC Public Health 8:63. 
[12] de Oliveira, T., and S. Cassol. 2011. The BioAfrica website, 2011 (accessible at: 
http://www.bioafrica.net). South African National Bioinformatics Institute. 
[13] de Oliveira, T., K. Deforche, S. Cassol, M. Salminen, D. Paraskevis, C. Seebregts, J. 
Snoeck, E. J. van Rensburg, A. M. Wensing, D. A. van de Vijver, C. A. Boucher, R. 
Camacho, and A. M. Vandamme. 2005. An automated genotyping system for 
analysis of HIV-1 and other microbial sequences. Bioinformatics 21:3797-800. 
[14] Department of Health, S. A. 2003. Operational Plan for Comprehensive HIV and Aids 
Care, Management and Treatment for South Africa. In S. A. Department of Health 
(ed.). 
[15] DHHS-Panel. 2011. Guidelines for the use of antiretroviral agents in HIV-1-infected 
adults and adolescents. , p. 1–166. In D. o. H. a. H. Services. (ed.). Panel on 
Antiretroviral Guidelines for Adults and Adolescents. 
[16] Egger, M., B. Hirschel, P. Francioli, P. Sudre, M. Wirz, M. Flepp, M. Rickenbach, R. 





December 2007, South Africa revised its PMTCT regimen to a combination of zidovudine 
and nevirapine. Although this measure should improve PMTCT efficacy and reduce the 
emergence of NNRTI resistance, the logistics of introducing this change might delay its 
implementation in all areas of South Africa and a proportion of mothers might still receive 
nevirapine monotherapy.  
Nonetheless, PMTCT cannot be responsible for all the observed resistance in the cohort – 6 of 
the 16 patients were men and the age of the females ranged from 25 to 56 years. These patients 
predominantly had lower grade mutations, suggestive of exposure but not clinical resistance. 
It is possible that some individuals had previously received treatment in other clinics, for 
example, contract workers travelling between provinces. In addition, patients with lower CD4 
T cell counts are more likely to be symptomatic, to use drugs prescribed to family or friends 
and might have previously sought medication through other non-government sources 
(Novak, et al. 2005, Uy, et al. Jul 2007). At the time of sampling, drugs such as nevirapine, 
lamivudine, stavudine and didanosine were also available through private practitioners in the 
Free State, although the duration for which drugs would be prescribed is dependent on the 
patient’s ability to pay (Dahab, et al. 2008, Garcia-Diaz, et al. 2008).  
6. Conclusion 
In summary, this chapter has reviewed the molecular epidemiology and the practical 
implications for HIV drug resistance testing in sub-Saharan Africa. The example study of a 
large cohort from South Africa has revealed new molecular epidemiological and drug 
resistance surveillance data. The prevalence of drug-associated mutations among patients is 
reassuringly low, but the association with low CD4 T cell counts is previously undescribed 
and warrants close monitoring of the virological response when these patients start therapy. 
In particular, with increasing access to antiretrovirals and growing evidence for the role of 
treatment as prevention, continued robust resistance surveillance mechanisms will be 
required for the foreseeable future. 
Funding and Competing Interests: K-HGH is supported by the Rhodes Scholarships and 
James Martin 21st Century School. JF is funded by the Medical Research Council. The 
funders had no role in study design, data collection and analysis, decision to publish, or 
preparation of the manuscript. The data presented here have been presented at international 
conferences and in peer-reviewed journals prior to this publication. 
Competing interests: The authors have declared that no competing interests exist. 
7. References 
[1] Aboulker, J. P., and A. M. Swart. 1993. Preliminary analysis of the Concorde trial. 
Concorde Coordinating Committee. Lancet 341:889-90. 
[2] Armstrong, K. L., T. H. Lee, and M. Essex. 2009. Replicative capacity differences of 
thymidine analog resistance mutations in subtype B and C human immunodeficiency 
virus type 1. J Virol 83:4051-9. 
[3] ASSA. 2007. ASSA 2003 Demographic Model Produced by the Actuarial Society of South 
Africa. Demographic Model. ASSA. 
 
HIV Drug Resistance in Sub-Saharan Africa – Implications for Testing and Treatment 
 
127 
[4] Barbaro, G., A. Scozzafava, A. Mastrolorenzo, and C. T. Supuran. 2005. Highly active 
antiretroviral therapy: current state of the art, new agents and their 
pharmacological interactions useful for improving therapeutic outcome. Curr 
Pharm Des 11:1805-43. 
[5] Bennett, D. E., R. J. Camacho, D. Otelea, D. R. Kuritzkes, H. Fleury, M. Kiuchi, W. 
Heneine, R. Kantor, M. R. Jordan, J. M. Schapiro, A. M. Vandamme, P. Sandstrom, 
C. A. Boucher, D. van de Vijver, S. Y. Rhee, T. F. Liu, D. Pillay, and R. W. Shafer. 
2009. Drug resistance mutations for surveillance of transmitted HIV-1 drug-
resistance: 2009 update. PLoS ONE 4:e4724. 
[6] Bennett, D. E., M. Myatt, S. Bertagnolio, D. Sutherland, and C. F. Gilks. 2008. 
Recommendations for surveillance of transmitted HIV drug resistance in countries 
scaling up antiretroviral treatment. Antivir Ther 13 Suppl 2:25-36. 
[7] Bessong, P. O., J. Mphahlele, I. A. Choge, L. C. Obi, L. Morris, M. L. Hammarskjold, and 
D. M. Rekosh. 2006. Resistance mutational analysis of HIV type 1 subtype C among 
rural South African drug-naive patients prior to large-scale availability of 
antiretrovirals. AIDS Res Hum Retroviruses 22:1306-12. 
[8] Brenner, B. G., J. P. Routy, M. Petrella, D. Moisi, M. Oliveira, M. Detorio, B. Spira, V. 
Essabag, B. Conway, R. Lalonde, R. P. Sekaly, and M. A. Wainberg. 2002. 
Persistence and fitness of multidrug-resistant human immunodeficiency virus type 
1 acquired in primary infection. J Virol 76:1753-61. 
[9] Bussmann, H., V. Novitsky, W. Wester, T. Peter, K. Masupu, L. Gabaitiri, S. Kim, S. 
Gaseitsiwe, T. Ndungu, R. Marlink, I. Thior, and M. Essex. 2005. HIV-1 subtype C 
drug-resistance background among ARV-naive adults in Botswana. Antivir Chem 
Chemother 16:103-15. 
[10] Carvajal-Rodriguez, A., K. A. Crandall, and D. Posada. 2007. Recombination favors the 
evolution of drug resistance in HIV-1 during antiretroviral therapy. Infect Genet 
Evol 7:476-83. 
[11] Dahab, M., S. Charalambous, R. Hamilton, K. Fielding, K. Kielmann, G. J. Churchyard, 
and A. D. Grant. 2008. "That is why I stopped the ART": patients' & providers' 
perspectives on barriers to and enablers of HIV treatment adherence in a South 
African workplace programme. BMC Public Health 8:63. 
[12] de Oliveira, T., and S. Cassol. 2011. The BioAfrica website, 2011 (accessible at: 
http://www.bioafrica.net). South African National Bioinformatics Institute. 
[13] de Oliveira, T., K. Deforche, S. Cassol, M. Salminen, D. Paraskevis, C. Seebregts, J. 
Snoeck, E. J. van Rensburg, A. M. Wensing, D. A. van de Vijver, C. A. Boucher, R. 
Camacho, and A. M. Vandamme. 2005. An automated genotyping system for 
analysis of HIV-1 and other microbial sequences. Bioinformatics 21:3797-800. 
[14] Department of Health, S. A. 2003. Operational Plan for Comprehensive HIV and Aids 
Care, Management and Treatment for South Africa. In S. A. Department of Health 
(ed.). 
[15] DHHS-Panel. 2011. Guidelines for the use of antiretroviral agents in HIV-1-infected 
adults and adolescents. , p. 1–166. In D. o. H. a. H. Services. (ed.). Panel on 
Antiretroviral Guidelines for Adults and Adolescents. 
[16] Egger, M., B. Hirschel, P. Francioli, P. Sudre, M. Wirz, M. Flepp, M. Rickenbach, R. 





combination therapies in HIV infected patients in Switzerland: prospective 
multicentre study. Swiss HIV Cohort Study. Bmj 315:1194-9. 
[17] Eshleman, S. H., O. Laeyendecker, N. Parkin, W. Huang, C. Chappey, A. C. Paquet, D. 
Serwadda, S. J. Reynolds, N. Kiwanuka, T. C. Quinn, R. Gray, and M. Wawer. 2009. 
Antiretroviral drug susceptibility among drug-naive adults with recent HIV 
infection in Rakai, Uganda. Aids 23:845-52. 
[18] Fairall, L. R., M. O. Bachmann, G. M. Louwagie, C. van Vuuren, P. Chikobvu, D. Steyn, 
G. H. Staniland, V. Timmerman, M. Msimanga, C. J. Seebregts, A. Boulle, R. 
Nhiwatiwa, E. D. Bateman, M. F. Zwarenstein, and R. D. Chapman. 2008. 
Effectiveness of antiretroviral treatment in a South African program: a cohort 
study. Arch Intern Med 168:86-93. 
[19] Frater, A. J., A. Beardall, K. Ariyoshi, D. Churchill, S. Galpin, J. R. Clarke, J. N. Weber, 
and M. O. McClure. 2001. Impact of baseline polymorphisms in RT and protease on 
outcome of highly active antiretroviral therapy in HIV-1-infected African patients. 
Aids 15:1493-502. 
[20] Frater, A. J., H. Brown, A. Oxenius, H. F. Gunthard, B. Hirschel, N. Robinson, A. J. 
Leslie, R. Payne, H. Crawford, A. Prendergast, C. Brander, P. Kiepiela, B. D. 
Walker, P. J. Goulder, A. McLean, and R. E. Phillips. 2007. Effective T-cell responses 
select human immunodeficiency virus mutants and slow disease progression. J 
Virol 81:6742-51. 
[21] Frater, A. J., D. T. Dunn, A. J. Beardall, K. Ariyoshi, J. R. Clarke, M. O. McClure, and J. 
N. Weber. 2002. Comparative response of African HIV-1-infected individuals to 
highly active antiretroviral therapy. Aids 16:1139-46. 
[22] Frater, J. 2002. The impact of HIV-1 subtype on the clinical response on HAART. J HIV 
Ther 7:92-6. 
[23] Gandhi, R. T., A. Wurcel, E. S. Rosenberg, M. N. Johnston, N. Hellmann, M. Bates, M. 
S. Hirsch, and B. D. Walker. 2003. Progressive reversion of human 
immunodeficiency virus type 1 resistance mutations in vivo after transmission of a 
multiply drug-resistant virus. Clin Infect Dis 37:1693-8. 
[24] Garcia-Diaz, A., C. Blok, S. Madge, C. Booth, M. Tyrer, S. Bonora, T. Mahungu, A. 
Owen, M. Johnson, and A. M. Geretti. 2008. Detection of low-frequency K103N 
mutants after unstructured discontinuation of efavirenz in the presence of the 
CYP2B6 516 TT polymorphism. J Antimicrob Chemother 62:1188-90. 
[25] Garcia-Lerma, J. G., H. MacInnes, D. Bennett, H. Weinstock, and W. Heneine. 2004. 
Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E 
mutation evolves rapidly to zidovudine resistance in vitro and shows a high 
replicative fitness in the presence of zidovudine. J Virol 78:7545-52. 
[26] Gifford, R. J., T. de Oliveira, A. Rambaut, O. G. Pybus, D. Dunn, A. M. Vandamme, P. 
Kellam, and D. Pillay. 2007. Phylogenetic surveillance of viral genetic diversity and 
the evolving molecular epidemiology of human immunodeficiency virus type 1. J 
Virol 81:13050-6. 
[27] Gilks, C. F., S. Crowley, R. Ekpini, S. Gove, J. Perriens, Y. Souteyrand, D. Sutherland, 
M. Vitoria, T. Guerma, and K. De Cock. 2006. The WHO public-health approach to 
antiretroviral treatment against HIV in resource-limited settings. Lancet 368:505-10. 
[28] Gordon, M., T. De Oliveira, K. Bishop, H. M. Coovadia, L. Madurai, S. Engelbrecht, E. 
Janse van Rensburg, A. Mosam, A. Smith, and S. Cassol. 2003. Molecular 
 
HIV Drug Resistance in Sub-Saharan Africa – Implications for Testing and Treatment 
 
129 
characteristics of human immunodeficiency virus type 1 subtype C viruses from 
KwaZulu-Natal, South Africa: implications for vaccine and antiretroviral control 
strategies. J Virol 77:2587-99. 
[29] Grossman, Z., V. Istomin, D. Averbuch, M. Lorber, K. Risenberg, I. Levi, M. Chowers, 
M. Burke, N. Bar Yaacov, and J. M. Schapiro. 2004. Genetic variation at NNRTI 
resistance-associated positions in patients infected with HIV-1 subtype C. Aids 
18:909-15. 
[30] Guindon, S., and O. Gascuel. 2003. A simple, fast, and accurate algorithm to estimate 
large phylogenies by maximum likelihood. Systematic Biology:8. 
[31] Hamers, R. L., M. Siwale, C. L. Wallis, M. Labib, R. van Hasselt, W. S. Stevens, R. 
Schuurman, A. M. Wensing, M. Van Vugt, and T. F. Rinke de Wit. 2010. HIV-1 drug 
resistance mutations are present in six percent of persons initiating antiretroviral 
therapy in Lusaka, Zambia. J Acquir Immune Defic Syndr 55:95-101. 
[32] HRDS-Team. 2003. Guidelines for Surveillance of HIV Drug Resistance. Guideline. 
WHO. 
[33] Huang, K. H., D. Goedhals, H. Fryer, C. van Vuuren, A. Katzourakis, T. De Oliveira, H. 
Brown, S. Cassol, C. Seebregts, A. McLean, P. Klenerman, R. Phillips, and J. Frater. 
2009. Prevalence of HIV type-1 drug-associated mutations in pre-therapy patients 
in the Free State, South Africa. Antivir Ther 14:975-84. 
[34] Johnson, V. A., F. Brun-Vezinet, B. Clotet, H. F. Gunthard, D. R. Kuritzkes, D. Pillay, J. 
M. Schapiro, and D. D. Richman. 2008. Update of the Drug Resistance Mutations in 
HIV-1. Top HIV Med 16:138-45. 
[35] Jourdain, G., N. Ngo-Giang-Huong, S. Le Coeur, C. Bowonwatanuwong, P. Kantipong, 
P. Leechanachai, S. Ariyadej, P. Leenasirimakul, S. Hammer, and M. Lallemant. 
2004. Intrapartum exposure to nevirapine and subsequent maternal responses to 
nevirapine-based antiretroviral therapy. N Engl J Med 351:229-40. 
[36] Kamoto, K., and J. Aberle-Grasse. 2008. Surveillance of transmitted HIV drug 
resistance with the World Health Organization threshold survey method in 
Lilongwe, Malawi. Antivir Ther 13 Suppl 2:83-7. 
[37] Kantor, R., D. A. Katzenstein, B. Efron, A. P. Carvalho, B. Wynhoven, P. Cane, J. 
Clarke, S. Sirivichayakul, M. A. Soares, J. Snoeck, C. Pillay, H. Rudich, R. 
Rodrigues, A. Holguin, K. Ariyoshi, M. B. Bouzas, P. Cahn, W. Sugiura, V. Soriano, 
L. F. Brigido, Z. Grossman, L. Morris, A. M. Vandamme, A. Tanuri, P. Phanuphak, 
J. N. Weber, D. Pillay, P. R. Harrigan, R. Camacho, J. M. Schapiro, and R. W. Shafer. 
2005. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse 
transcriptase genotype: results of a global collaboration. PLoS Med 2:e112. 
[38] Kiepiela, P., A. J. Leslie, I. Honeyborne, D. Ramduth, C. Thobakgale, S. Chetty, P. 
Rathnavalu, C. Moore, K. J. Pfafferott, L. Hilton, P. Zimbwa, S. Moore, T. Allen, C. 
Brander, M. M. Addo, M. Altfeld, I. James, S. Mallal, M. Bunce, L. D. Barber, J. 
Szinger, C. Day, P. Klenerman, J. Mullins, B. Korber, H. M. Coovadia, B. D. Walker, 
and P. J. Goulder. 2004. Dominant influence of HLA-B in mediating the potential 
co-evolution of HIV and HLA. Nature 432:769-75. 
[39] Kuritzkes, D. R. 2007. HIV resistance: frequency, testing, mechanisms. Top HIV Med 
15:150-4. 
[40] Larder, B. A., P. Kellam, and S. D. Kemp. 1993. Convergent combination therapy can 





combination therapies in HIV infected patients in Switzerland: prospective 
multicentre study. Swiss HIV Cohort Study. Bmj 315:1194-9. 
[17] Eshleman, S. H., O. Laeyendecker, N. Parkin, W. Huang, C. Chappey, A. C. Paquet, D. 
Serwadda, S. J. Reynolds, N. Kiwanuka, T. C. Quinn, R. Gray, and M. Wawer. 2009. 
Antiretroviral drug susceptibility among drug-naive adults with recent HIV 
infection in Rakai, Uganda. Aids 23:845-52. 
[18] Fairall, L. R., M. O. Bachmann, G. M. Louwagie, C. van Vuuren, P. Chikobvu, D. Steyn, 
G. H. Staniland, V. Timmerman, M. Msimanga, C. J. Seebregts, A. Boulle, R. 
Nhiwatiwa, E. D. Bateman, M. F. Zwarenstein, and R. D. Chapman. 2008. 
Effectiveness of antiretroviral treatment in a South African program: a cohort 
study. Arch Intern Med 168:86-93. 
[19] Frater, A. J., A. Beardall, K. Ariyoshi, D. Churchill, S. Galpin, J. R. Clarke, J. N. Weber, 
and M. O. McClure. 2001. Impact of baseline polymorphisms in RT and protease on 
outcome of highly active antiretroviral therapy in HIV-1-infected African patients. 
Aids 15:1493-502. 
[20] Frater, A. J., H. Brown, A. Oxenius, H. F. Gunthard, B. Hirschel, N. Robinson, A. J. 
Leslie, R. Payne, H. Crawford, A. Prendergast, C. Brander, P. Kiepiela, B. D. 
Walker, P. J. Goulder, A. McLean, and R. E. Phillips. 2007. Effective T-cell responses 
select human immunodeficiency virus mutants and slow disease progression. J 
Virol 81:6742-51. 
[21] Frater, A. J., D. T. Dunn, A. J. Beardall, K. Ariyoshi, J. R. Clarke, M. O. McClure, and J. 
N. Weber. 2002. Comparative response of African HIV-1-infected individuals to 
highly active antiretroviral therapy. Aids 16:1139-46. 
[22] Frater, J. 2002. The impact of HIV-1 subtype on the clinical response on HAART. J HIV 
Ther 7:92-6. 
[23] Gandhi, R. T., A. Wurcel, E. S. Rosenberg, M. N. Johnston, N. Hellmann, M. Bates, M. 
S. Hirsch, and B. D. Walker. 2003. Progressive reversion of human 
immunodeficiency virus type 1 resistance mutations in vivo after transmission of a 
multiply drug-resistant virus. Clin Infect Dis 37:1693-8. 
[24] Garcia-Diaz, A., C. Blok, S. Madge, C. Booth, M. Tyrer, S. Bonora, T. Mahungu, A. 
Owen, M. Johnson, and A. M. Geretti. 2008. Detection of low-frequency K103N 
mutants after unstructured discontinuation of efavirenz in the presence of the 
CYP2B6 516 TT polymorphism. J Antimicrob Chemother 62:1188-90. 
[25] Garcia-Lerma, J. G., H. MacInnes, D. Bennett, H. Weinstock, and W. Heneine. 2004. 
Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E 
mutation evolves rapidly to zidovudine resistance in vitro and shows a high 
replicative fitness in the presence of zidovudine. J Virol 78:7545-52. 
[26] Gifford, R. J., T. de Oliveira, A. Rambaut, O. G. Pybus, D. Dunn, A. M. Vandamme, P. 
Kellam, and D. Pillay. 2007. Phylogenetic surveillance of viral genetic diversity and 
the evolving molecular epidemiology of human immunodeficiency virus type 1. J 
Virol 81:13050-6. 
[27] Gilks, C. F., S. Crowley, R. Ekpini, S. Gove, J. Perriens, Y. Souteyrand, D. Sutherland, 
M. Vitoria, T. Guerma, and K. De Cock. 2006. The WHO public-health approach to 
antiretroviral treatment against HIV in resource-limited settings. Lancet 368:505-10. 
[28] Gordon, M., T. De Oliveira, K. Bishop, H. M. Coovadia, L. Madurai, S. Engelbrecht, E. 
Janse van Rensburg, A. Mosam, A. Smith, and S. Cassol. 2003. Molecular 
 
HIV Drug Resistance in Sub-Saharan Africa – Implications for Testing and Treatment 
 
129 
characteristics of human immunodeficiency virus type 1 subtype C viruses from 
KwaZulu-Natal, South Africa: implications for vaccine and antiretroviral control 
strategies. J Virol 77:2587-99. 
[29] Grossman, Z., V. Istomin, D. Averbuch, M. Lorber, K. Risenberg, I. Levi, M. Chowers, 
M. Burke, N. Bar Yaacov, and J. M. Schapiro. 2004. Genetic variation at NNRTI 
resistance-associated positions in patients infected with HIV-1 subtype C. Aids 
18:909-15. 
[30] Guindon, S., and O. Gascuel. 2003. A simple, fast, and accurate algorithm to estimate 
large phylogenies by maximum likelihood. Systematic Biology:8. 
[31] Hamers, R. L., M. Siwale, C. L. Wallis, M. Labib, R. van Hasselt, W. S. Stevens, R. 
Schuurman, A. M. Wensing, M. Van Vugt, and T. F. Rinke de Wit. 2010. HIV-1 drug 
resistance mutations are present in six percent of persons initiating antiretroviral 
therapy in Lusaka, Zambia. J Acquir Immune Defic Syndr 55:95-101. 
[32] HRDS-Team. 2003. Guidelines for Surveillance of HIV Drug Resistance. Guideline. 
WHO. 
[33] Huang, K. H., D. Goedhals, H. Fryer, C. van Vuuren, A. Katzourakis, T. De Oliveira, H. 
Brown, S. Cassol, C. Seebregts, A. McLean, P. Klenerman, R. Phillips, and J. Frater. 
2009. Prevalence of HIV type-1 drug-associated mutations in pre-therapy patients 
in the Free State, South Africa. Antivir Ther 14:975-84. 
[34] Johnson, V. A., F. Brun-Vezinet, B. Clotet, H. F. Gunthard, D. R. Kuritzkes, D. Pillay, J. 
M. Schapiro, and D. D. Richman. 2008. Update of the Drug Resistance Mutations in 
HIV-1. Top HIV Med 16:138-45. 
[35] Jourdain, G., N. Ngo-Giang-Huong, S. Le Coeur, C. Bowonwatanuwong, P. Kantipong, 
P. Leechanachai, S. Ariyadej, P. Leenasirimakul, S. Hammer, and M. Lallemant. 
2004. Intrapartum exposure to nevirapine and subsequent maternal responses to 
nevirapine-based antiretroviral therapy. N Engl J Med 351:229-40. 
[36] Kamoto, K., and J. Aberle-Grasse. 2008. Surveillance of transmitted HIV drug 
resistance with the World Health Organization threshold survey method in 
Lilongwe, Malawi. Antivir Ther 13 Suppl 2:83-7. 
[37] Kantor, R., D. A. Katzenstein, B. Efron, A. P. Carvalho, B. Wynhoven, P. Cane, J. 
Clarke, S. Sirivichayakul, M. A. Soares, J. Snoeck, C. Pillay, H. Rudich, R. 
Rodrigues, A. Holguin, K. Ariyoshi, M. B. Bouzas, P. Cahn, W. Sugiura, V. Soriano, 
L. F. Brigido, Z. Grossman, L. Morris, A. M. Vandamme, A. Tanuri, P. Phanuphak, 
J. N. Weber, D. Pillay, P. R. Harrigan, R. Camacho, J. M. Schapiro, and R. W. Shafer. 
2005. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse 
transcriptase genotype: results of a global collaboration. PLoS Med 2:e112. 
[38] Kiepiela, P., A. J. Leslie, I. Honeyborne, D. Ramduth, C. Thobakgale, S. Chetty, P. 
Rathnavalu, C. Moore, K. J. Pfafferott, L. Hilton, P. Zimbwa, S. Moore, T. Allen, C. 
Brander, M. M. Addo, M. Altfeld, I. James, S. Mallal, M. Bunce, L. D. Barber, J. 
Szinger, C. Day, P. Klenerman, J. Mullins, B. Korber, H. M. Coovadia, B. D. Walker, 
and P. J. Goulder. 2004. Dominant influence of HLA-B in mediating the potential 
co-evolution of HIV and HLA. Nature 432:769-75. 
[39] Kuritzkes, D. R. 2007. HIV resistance: frequency, testing, mechanisms. Top HIV Med 
15:150-4. 
[40] Larder, B. A., P. Kellam, and S. D. Kemp. 1993. Convergent combination therapy can 





[41] Larder, B. A., S. D. Kemp, and P. R. Harrigan. 1995. Potential mechanism for sustained 
antiretroviral efficacy of AZT-3TC combination therapy. Science 269:696-9. 
[42] Lihana, R. W., S. A. Khamadi, K. Lubano, R. Lwembe, M. K. Kiptoo, N. Lagat, J. G. 
Kinyua, F. A. Okoth, E. M. Songok, E. P. Makokha, and H. Ichimura. 2009. HIV 
type 1 subtype diversity and drug resistance among HIV type 1-infected Kenyan 
patients initiating antiretroviral therapy. AIDS Res Hum Retroviruses 25:1211-7. 
[43] Los Alamos National Laboratory, L. 2011. HIV Databases. Los Alamos National 
Security, LLC. 
[44] Mosha, F., W. Urassa, S. Aboud, E. Lyamuya, E. Sandstrom, H. Bredell, and C. 
Williamson. 2011. Prevalence of genotypic resistance to antiretroviral drugs in 
treatment-naive youths infected with diverse HIV type 1 subtypes and recombinant 
forms in Dar es Salaam, Tanzania. AIDS Res Hum Retroviruses 27:377-82. 
[45] Novak, R. M., L. Chen, R. D. MacArthur, J. D. Baxter, K. Huppler Hullsiek, G. Peng, Y. 
Xiang, C. Henely, B. Schmetter, J. Uy, M. van den Berg-Wolf, and M. Kozal. 2005. 
Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, 
treatment-naive patients: implications for routine resistance screening before 
initiation of antiretroviral therapy. Clin Infect Dis 40:468-74. 
[46] Palella, F. J., Jr., K. M. Delaney, A. C. Moorman, M. O. Loveless, J. Fuhrer, G. A. Satten, 
D. J. Aschman, and S. D. Holmberg. 1998. Declining morbidity and mortality 
among patients with advanced human immunodeficiency virus infection. HIV 
Outpatient Study Investigators. N Engl J Med 338:853-60. 
[47] Pieniazek, D., M. Rayfield, D. J. Hu, J. Nkengasong, S. Z. Wiktor, R. Downing, B. 
Biryahwaho, T. Mastro, A. Tanuri, V. Soriano, R. Lal, and T. Dondero. 2000. 
Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid 
mutation patterns associated with protease resistance in protease inhibitor-naive 
individuals worldwide. HIV Variant Working Group. Aids 14:1489-95. 
[48] Pillay, C., H. Bredell, J. McIntyre, G. Gray, and L. Morris. 2002. HIV-1 subtype C 
reverse transcriptase sequences from drug-naive pregnant women in South Africa. 
AIDS Res Hum Retroviruses 18:605-10. 
[49] Pillay, D. 2007. The priorities for antiviral drug resistance surveillance and research. J 
Antimicrob Chemother 60 Suppl 1:i57-8. 
[50] Prado, J. G., T. Wrin, J. Beauchaine, L. Ruiz, C. J. Petropoulos, S. D. Frost, B. Clotet, R. 
T. D'Aquila, and J. Martinez-Picado. 2002. Amprenavir-resistant HIV-1 exhibits 
lopinavir cross-resistance and reduced replication capacity. AIDS 16:1009-17. 
[51] Richman, D. D., S. C. Morton, T. Wrin, N. Hellmann, S. Berry, M. F. Shapiro, and S. A. 
Bozzette. 2004. The prevalence of antiretroviral drug resistance in the United States. 
Aids 18:1393-401. 
[52] Robertson, D. L., J. P. Anderson, J. A. Bradac, J. K. Carr, B. Foley, R. K. Funkhouser, F. 
Gao, B. H. Hahn, M. L. Kalish, C. Kuiken, G. H. Learn, T. Leitner, F. McCutchan, S. 
Osmanov, M. Peeters, D. Pieniazek, M. Salminen, P. M. Sharp, S. Wolinsky, and B. 
Korber. 2000. HIV-1 nomenclature proposal. Science 288:55-6. 
[53] Sanches, M., S. Krauchenco, N. H. Martins, A. Gustchina, A. Wlodawer, and I. 
Polikarpov. 2007. Structural characterization of B and non-B subtypes of HIV-
protease: insights into the natural susceptibility to drug resistance development. J 
Mol Biol 369:1029-40. 
 
HIV Drug Resistance in Sub-Saharan Africa – Implications for Testing and Treatment 
 
131 
[54] SATuRN-Database, S. Y. Rhee, T. Liu, T. de Oliveira, and R. W. Shafer. 2011. SATuRN - 
Southern African Treatment and Resistance Network and the Stanford HIV Drug 
Resistance Database ( http://www.bioafrica.net/saturn/ ). 
[55] Seebregts, C. J., C. van Vuuren, D. Goedhals, T. de Oliveira, P. Drew, P. Makhoahle, R. 
Nhiwatiwa, V. Timmerman, F. L., E. Kotze, R. Chapman, and S. Cassol. 5-8 June 
2007. Baseline Characterization and Resistance Genotyping of HIV from the Public 
Sector Antiretroviral Treatment Program in the Free State Province of South Africa, 
The Third South African AIDS Conference, Durban, South Africa. 
[56] Shafer, R. W., S. Y. Rhee, D. Pillay, V. Miller, P. Sandstrom, J. M. Schapiro, D. R. 
Kuritzkes, and D. Bennett. 2007. HIV-1 protease and reverse transcriptase 
mutations for drug resistance surveillance. Aids 21:215-23. 
[57] Shekelle, P., M. Maglione, M. B. Geotz, G. Wagner, Z. Wang, L. Hilton, J. Carter, S. 
Chen, C. Tringle, W. Mojica, and S. Newberry. 2007. Antiretroviral (ARV) drug 
resistance in the developing world. Evid Rep Technol Assess (Full Rep):1-74. 
[58] Smith, D. M., J. K. Wong, H. Shao, G. K. Hightower, S. H. Mai, J. M. Moreno, C. C. 
Ignacio, S. D. Frost, D. D. Richman, and S. J. Little. 2007. Long-term persistence of 
transmitted HIV drug resistance in male genital tract secretions: implications for 
secondary transmission. J Infect Dis 196:356-60. 
[59] Sow, P. S., L. F. Otieno, E. Bissagnene, C. Kityo, R. Bennink, P. Clevenbergh, F. W. Wit, 
E. Waalberg, T. F. Rinke de Wit, and J. M. Lange. 2007. Implementation of an 
antiretroviral access program for HIV-1-infected individuals in resource-limited 
settings: clinical results from 4 African countries. J Acquir Immune Defic Syndr 
44:262-7. 
[60] Stanford University, U. 2011. HIV Drug Resistance Database  
(http://hivdb.stanford.edu/). Stanford University. 
[61] Tshabalala, M., J. Manasa, L. S. Zijenah, S. Rusakaniko, G. Kadzirange, M. Mucheche, 
S. Kassaye, E. Johnston, and D. A. Katzenstein. 2011. Surveillance of transmitted 
antiretroviral drug resistance among HIV-1 infected women attending antenatal 
clinics in Chitungwiza, Zimbabwe. PLoS ONE 6:e21241. 
[62] UNAIDS/WHO 2011, posting date. Report on the Global HIV/AIDS Epidemic. 
www.unaids.org. UNAIDS. [Online.] 
[63] Uy, J., C. Armon, K. Buchacz, J. Brooks, and H. Investigators. Jul 2007. Initiation of 
HAART at CD4 cell counts >= 350 cells/mm3 is associated with a lower prevalence 
of antiretroviral resistance mutations at virologic failure, 4th IAS Conference on 
HIV Pathogenesis, Treatment and Prevention. Kaiser Network, Sydney, Australia. 
[64] van der Ryst, E., M. Kotze, G. Joubert, M. Steyn, H. Pieters, M. van der Westhuizen, M. 
van Staden, and C. Venter. 1998. Correlation among total lymphocyte count, 
absolute CD4+ count, and CD4+ percentage in a group of HIV-1-infected South 
African patients. J Acquir Immune Defic Syndr Hum Retrovirol 19:238-44. 
[65] Velazquez-Campoy, A., M. J. Todd, S. Vega, and E. Freire. 2001. Catalytic efficiency 
and vitality of HIV-1 proteases from African viral subtypes. Proc Natl Acad Sci U S 
A 98:6062-7. 
[66] Venter, W. D. F. 2005. A critical evaluation of the South African state antiretroviral 
programme. The Southern African Journal of HIV Medicine. 





[41] Larder, B. A., S. D. Kemp, and P. R. Harrigan. 1995. Potential mechanism for sustained 
antiretroviral efficacy of AZT-3TC combination therapy. Science 269:696-9. 
[42] Lihana, R. W., S. A. Khamadi, K. Lubano, R. Lwembe, M. K. Kiptoo, N. Lagat, J. G. 
Kinyua, F. A. Okoth, E. M. Songok, E. P. Makokha, and H. Ichimura. 2009. HIV 
type 1 subtype diversity and drug resistance among HIV type 1-infected Kenyan 
patients initiating antiretroviral therapy. AIDS Res Hum Retroviruses 25:1211-7. 
[43] Los Alamos National Laboratory, L. 2011. HIV Databases. Los Alamos National 
Security, LLC. 
[44] Mosha, F., W. Urassa, S. Aboud, E. Lyamuya, E. Sandstrom, H. Bredell, and C. 
Williamson. 2011. Prevalence of genotypic resistance to antiretroviral drugs in 
treatment-naive youths infected with diverse HIV type 1 subtypes and recombinant 
forms in Dar es Salaam, Tanzania. AIDS Res Hum Retroviruses 27:377-82. 
[45] Novak, R. M., L. Chen, R. D. MacArthur, J. D. Baxter, K. Huppler Hullsiek, G. Peng, Y. 
Xiang, C. Henely, B. Schmetter, J. Uy, M. van den Berg-Wolf, and M. Kozal. 2005. 
Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, 
treatment-naive patients: implications for routine resistance screening before 
initiation of antiretroviral therapy. Clin Infect Dis 40:468-74. 
[46] Palella, F. J., Jr., K. M. Delaney, A. C. Moorman, M. O. Loveless, J. Fuhrer, G. A. Satten, 
D. J. Aschman, and S. D. Holmberg. 1998. Declining morbidity and mortality 
among patients with advanced human immunodeficiency virus infection. HIV 
Outpatient Study Investigators. N Engl J Med 338:853-60. 
[47] Pieniazek, D., M. Rayfield, D. J. Hu, J. Nkengasong, S. Z. Wiktor, R. Downing, B. 
Biryahwaho, T. Mastro, A. Tanuri, V. Soriano, R. Lal, and T. Dondero. 2000. 
Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid 
mutation patterns associated with protease resistance in protease inhibitor-naive 
individuals worldwide. HIV Variant Working Group. Aids 14:1489-95. 
[48] Pillay, C., H. Bredell, J. McIntyre, G. Gray, and L. Morris. 2002. HIV-1 subtype C 
reverse transcriptase sequences from drug-naive pregnant women in South Africa. 
AIDS Res Hum Retroviruses 18:605-10. 
[49] Pillay, D. 2007. The priorities for antiviral drug resistance surveillance and research. J 
Antimicrob Chemother 60 Suppl 1:i57-8. 
[50] Prado, J. G., T. Wrin, J. Beauchaine, L. Ruiz, C. J. Petropoulos, S. D. Frost, B. Clotet, R. 
T. D'Aquila, and J. Martinez-Picado. 2002. Amprenavir-resistant HIV-1 exhibits 
lopinavir cross-resistance and reduced replication capacity. AIDS 16:1009-17. 
[51] Richman, D. D., S. C. Morton, T. Wrin, N. Hellmann, S. Berry, M. F. Shapiro, and S. A. 
Bozzette. 2004. The prevalence of antiretroviral drug resistance in the United States. 
Aids 18:1393-401. 
[52] Robertson, D. L., J. P. Anderson, J. A. Bradac, J. K. Carr, B. Foley, R. K. Funkhouser, F. 
Gao, B. H. Hahn, M. L. Kalish, C. Kuiken, G. H. Learn, T. Leitner, F. McCutchan, S. 
Osmanov, M. Peeters, D. Pieniazek, M. Salminen, P. M. Sharp, S. Wolinsky, and B. 
Korber. 2000. HIV-1 nomenclature proposal. Science 288:55-6. 
[53] Sanches, M., S. Krauchenco, N. H. Martins, A. Gustchina, A. Wlodawer, and I. 
Polikarpov. 2007. Structural characterization of B and non-B subtypes of HIV-
protease: insights into the natural susceptibility to drug resistance development. J 
Mol Biol 369:1029-40. 
 
HIV Drug Resistance in Sub-Saharan Africa – Implications for Testing and Treatment 
 
131 
[54] SATuRN-Database, S. Y. Rhee, T. Liu, T. de Oliveira, and R. W. Shafer. 2011. SATuRN - 
Southern African Treatment and Resistance Network and the Stanford HIV Drug 
Resistance Database ( http://www.bioafrica.net/saturn/ ). 
[55] Seebregts, C. J., C. van Vuuren, D. Goedhals, T. de Oliveira, P. Drew, P. Makhoahle, R. 
Nhiwatiwa, V. Timmerman, F. L., E. Kotze, R. Chapman, and S. Cassol. 5-8 June 
2007. Baseline Characterization and Resistance Genotyping of HIV from the Public 
Sector Antiretroviral Treatment Program in the Free State Province of South Africa, 
The Third South African AIDS Conference, Durban, South Africa. 
[56] Shafer, R. W., S. Y. Rhee, D. Pillay, V. Miller, P. Sandstrom, J. M. Schapiro, D. R. 
Kuritzkes, and D. Bennett. 2007. HIV-1 protease and reverse transcriptase 
mutations for drug resistance surveillance. Aids 21:215-23. 
[57] Shekelle, P., M. Maglione, M. B. Geotz, G. Wagner, Z. Wang, L. Hilton, J. Carter, S. 
Chen, C. Tringle, W. Mojica, and S. Newberry. 2007. Antiretroviral (ARV) drug 
resistance in the developing world. Evid Rep Technol Assess (Full Rep):1-74. 
[58] Smith, D. M., J. K. Wong, H. Shao, G. K. Hightower, S. H. Mai, J. M. Moreno, C. C. 
Ignacio, S. D. Frost, D. D. Richman, and S. J. Little. 2007. Long-term persistence of 
transmitted HIV drug resistance in male genital tract secretions: implications for 
secondary transmission. J Infect Dis 196:356-60. 
[59] Sow, P. S., L. F. Otieno, E. Bissagnene, C. Kityo, R. Bennink, P. Clevenbergh, F. W. Wit, 
E. Waalberg, T. F. Rinke de Wit, and J. M. Lange. 2007. Implementation of an 
antiretroviral access program for HIV-1-infected individuals in resource-limited 
settings: clinical results from 4 African countries. J Acquir Immune Defic Syndr 
44:262-7. 
[60] Stanford University, U. 2011. HIV Drug Resistance Database  
(http://hivdb.stanford.edu/). Stanford University. 
[61] Tshabalala, M., J. Manasa, L. S. Zijenah, S. Rusakaniko, G. Kadzirange, M. Mucheche, 
S. Kassaye, E. Johnston, and D. A. Katzenstein. 2011. Surveillance of transmitted 
antiretroviral drug resistance among HIV-1 infected women attending antenatal 
clinics in Chitungwiza, Zimbabwe. PLoS ONE 6:e21241. 
[62] UNAIDS/WHO 2011, posting date. Report on the Global HIV/AIDS Epidemic. 
www.unaids.org. UNAIDS. [Online.] 
[63] Uy, J., C. Armon, K. Buchacz, J. Brooks, and H. Investigators. Jul 2007. Initiation of 
HAART at CD4 cell counts >= 350 cells/mm3 is associated with a lower prevalence 
of antiretroviral resistance mutations at virologic failure, 4th IAS Conference on 
HIV Pathogenesis, Treatment and Prevention. Kaiser Network, Sydney, Australia. 
[64] van der Ryst, E., M. Kotze, G. Joubert, M. Steyn, H. Pieters, M. van der Westhuizen, M. 
van Staden, and C. Venter. 1998. Correlation among total lymphocyte count, 
absolute CD4+ count, and CD4+ percentage in a group of HIV-1-infected South 
African patients. J Acquir Immune Defic Syndr Hum Retrovirol 19:238-44. 
[65] Velazquez-Campoy, A., M. J. Todd, S. Vega, and E. Freire. 2001. Catalytic efficiency 
and vitality of HIV-1 proteases from African viral subtypes. Proc Natl Acad Sci U S 
A 98:6062-7. 
[66] Venter, W. D. F. 2005. A critical evaluation of the South African state antiretroviral 
programme. The Southern African Journal of HIV Medicine. 





(http://en.wikipedia.org/wiki/South_Africa). Multi-license with GFDL and 
Creative Commons CC-BY-SA-2.5 and older versions (2.0 and 1.0). [Online.] 
[68] Yarchoan, R., R. W. Klecker, K. J. Weinhold, P. D. Markham, H. K. Lyerly, D. T. 
Durack, E. Gelmann, S. N. Lehrman, R. M. Blum, D. W. Barry, and et al. 1986. 
Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV 






(http://en.wikipedia.org/wiki/South_Africa). Multi-license with GFDL and 
Creative Commons CC-BY-SA-2.5 and older versions (2.0 and 1.0). [Online.] 
[68] Yarchoan, R., R. W. Klecker, K. J. Weinhold, P. D. Markham, H. K. Lyerly, D. T. 
Durack, E. Gelmann, S. N. Lehrman, R. M. Blum, D. W. Barry, and et al. 1986. 
Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV 
replication, to patients with AIDS or AIDS-related complex. Lancet 1:575-80. 
 
HIV Testing
Edited by Ricardo Sobhie Diaz
Edited by Ricardo Sobhie Diaz
It can be said that now is the best time for everyone infected to become aware of their 
own HIV status. The state of the art in HIV management progressively reveals that 
antiretroviral treatment can prevent transmission, as well as chronic damage in the 
human body, if started early.  Unfortunately, antiretrovirals are not widely available in 
many places, especially in developing countries.  In these parts of the world, diagnosis 
of HIV infection must be kept in the agenda as a priority, in order to understand specific 
details of local epidemics and as an effort to interrupt the chain of HIV transmission.
Photo by jarun011 / iStock
ISBN 978-953-307-871-7
H
IV
 Testing
 51-6739 6
